<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in patients with low disease activity - Verhoef, LM - 2019 | Cochrane Library</title> <meta content="Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in patients with low disease activity - Verhoef, LM - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010455.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in patients with low disease activity - Verhoef, LM - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010455.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010455.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in patients with low disease activity" name="citation_title"/> <meta content="Lise M Verhoef" name="citation_author"/> <meta content="Sint Maartenskliniek" name="citation_author_institution"/> <meta content="L.Verhoef@maartenskliniek.nl" name="citation_author_email"/> <meta content="Bart JF van den Bemt" name="citation_author"/> <meta content="Aatke van der Maas" name="citation_author"/> <meta content="Sint Maartenskliniek" name="citation_author_institution"/> <meta content="Johanna E Vriezekolk" name="citation_author"/> <meta content="Sint Maartenskliniek" name="citation_author_institution"/> <meta content="Marlies E Hulscher" name="citation_author"/> <meta content="Radboud Institute for Health Sciences, Radboud University Medical Center" name="citation_author_institution"/> <meta content="Frank HJ van den Hoogen" name="citation_author"/> <meta content="Wilco CH Jacobs" name="citation_author"/> <meta content="The Health Scientist" name="citation_author_institution"/> <meta content="Noortje van Herwaarden" name="citation_author"/> <meta content="Sint Maartenskliniek" name="citation_author_institution"/> <meta content="Alfons A den Broeder" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD010455.pub3" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/05/24" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010455.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010455.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010455.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antibodies, Monoclonal, Humanized; Antirheumatic Agents [*therapeutic use]; Arthritis, Rheumatoid [*drug therapy]; Randomized Controlled Trials as Topic; Receptors, Tumor Necrosis Factor [*therapeutic use]; Recurrence; Remission Induction; Tumor Necrosis Factor-alpha [*antagonists &amp; inhibitors]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010455.pub3&amp;doi=10.1002/14651858.CD010455.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010455.pub3&amp;doi=10.1002/14651858.CD010455.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010455.pub3&amp;doi=10.1002/14651858.CD010455.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010455.pub3&amp;doi=10.1002/14651858.CD010455.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010455.pub3&amp;doi=10.1002/14651858.CD010455.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010455.pub3&amp;doi=10.1002/14651858.CD010455.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010455.pub3&amp;doi=10.1002/14651858.CD010455.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010455.pub3&amp;doi=10.1002/14651858.CD010455.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010455.pub3&amp;doi=10.1002/14651858.CD010455.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010455.pub3&amp;doi=10.1002/14651858.CD010455.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010455.pub3&amp;doi=10.1002/14651858.CD010455.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010455.pub3&amp;doi=10.1002/14651858.CD010455.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010455.pub3&amp;doi=10.1002/14651858.CD010455.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010455.pub3&amp;doi=10.1002/14651858.CD010455.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010455.pub3&amp;doi=10.1002/14651858.CD010455.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010455.pub3&amp;doi=10.1002/14651858.CD010455.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010455.pub3&amp;doi=10.1002/14651858.CD010455.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010455.pub3&amp;doi=10.1002/14651858.CD010455.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010455.pub3&amp;doi=10.1002/14651858.CD010455.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010455.pub3&amp;doi=10.1002/14651858.CD010455.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010455.pub3&amp;doi=10.1002/14651858.CD010455.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010455.pub3&amp;doi=10.1002/14651858.CD010455.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010455.pub3&amp;doi=10.1002/14651858.CD010455.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="sogqpCtr";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010455\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010455\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010455\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010455\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ms","fa","ru"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010455.pub3",title:"Down\\u2010titration and discontinuation strategies of tumour necrosis factor\\u2013blocking agents for rheumatoid arthritis in patients with low disease activity",firstPublishedDate:"May 24, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Musculoskeletal Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=sogqpCtr&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010455.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010455.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010455.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010455.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010455.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010455.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010455.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010455.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010455.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010455.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4776 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010455.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010455.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010455.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010455.pub3/full#CD010455-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010455.pub3/full#CD010455-sec-0108"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010455.pub3/full#CD010455-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010455.pub3/full#CD010455-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010455.pub3/full#CD010455-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010455.pub3/full#CD010455-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010455.pub3/full#CD010455-sec-0053"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010455.pub3/full#CD010455-sec-0096"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010455.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010455.pub3/appendices#CD010455-sec-0113"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010455.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010455.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/table_n/CD010455StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/table_n/CD010455StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010455.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010455.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010455.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010455.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010455.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010455.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in patients with low disease activity </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010455.pub3/information#CD010455-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Lise M Verhoef</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010455.pub3/information#CD010455-cr-0003">Bart JF van den Bemt</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010455.pub3/information#CD010455-cr-0004">Aatke van der Maas</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010455.pub3/information#CD010455-cr-0005">Johanna E Vriezekolk</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010455.pub3/information#CD010455-cr-0006">Marlies E Hulscher</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010455.pub3/information#CD010455-cr-0007">Frank HJ van den Hoogen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010455.pub3/information#CD010455-cr-0008">Wilco CH Jacobs</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010455.pub3/information#CD010455-cr-0009">Noortje van Herwaarden</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010455.pub3/information#CD010455-cr-0010">Alfons A den Broeder</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/information/en#CD010455-sec-0128">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 24 May 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010455.pub3">https://doi.org/10.1002/14651858.CD010455.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010455-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010455-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010455-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010455-abs-0007">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010455-abs-0001" lang="en"> <section id="CD010455-sec-0001"> <h3 class="title" id="CD010455-sec-0001">Background</h3> <p>Anti–tumour necrosis factor (TNF) agents are effective in treating people with rheumatoid arthritis (RA), but are associated with (dose‐dependent) adverse effects and high costs. To prevent overtreatment, several trials have assessed the effectiveness of down‐titration compared with continuation of the standard dose. This is an update of a Cochrane Review published in 2014. </p> </section> <section id="CD010455-sec-0002"> <h3 class="title" id="CD010455-sec-0002">Objectives</h3> <p>To evaluate the benefits and harms of down‐titration (dose reduction, discontinuation, or disease activity‐guided dose tapering) of anti‐TNF agents on disease activity, functioning, costs, safety, and radiographic damage compared with usual care in people with RA and low disease activity. </p> </section> <section id="CD010455-sec-0003"> <h3 class="title" id="CD010455-sec-0003">Search methods</h3> <p>We searched MEDLINE, Embase, Web of Science and CENTRAL (29 March 2018) and four trial registries (11 April 2018) together with reference checking, citation searching, and contact with study authors to identify additional studies. We screened conference proceedings (American College of Rheumatology and European League Against Rheumatism 2005‐2017). </p> </section> <section id="CD010455-sec-0004"> <h3 class="title" id="CD010455-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) and controlled clinical trials (CCTs) comparing down‐titration (dose reduction, discontinuation, disease activity–guided dose tapering) of anti‐TNF agents (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab) to usual care/no down‐titration in people with RA and low disease activity. </p> </section> <section id="CD010455-sec-0005"> <h3 class="title" id="CD010455-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methodology.</p> </section> <section id="CD010455-sec-0006"> <h3 class="title" id="CD010455-sec-0006">Main results</h3> <p>One previously included trial was excluded retrospectively in this update because it was not an RCT/CCT. We included eight additional trials, for a total of 14 studies (13 RCTs and one CCT, 3315 participants in total) reporting anti‐TNF down‐titration. Six studies (1148 participants) reported anti‐TNF dose reduction compared with anti‐TNF continuation. Eight studies (2111 participants) reported anti‐TNF discontinuation compared with anti‐TNF continuation (three studies assessed both anti‐TNF discontinuation and dose reduction), and three studies assessed disease activity–guided anti‐TNF dose tapering (365 participants). These studies included data on all anti‐TNF agents, but primarily adalimumab and etanercept. Thirteen studies were available in full text, one was available as abstract. We assessed the included studies generally at low to moderate risk of bias; our main concerns were bias due to open‐label treatment and unblinded outcome assessment. Clinical heterogeneity between the trials was high. The included studies were performed at clinical centres around the world and included people with early as well as established RA, the majority of whom were female with mean ages between 47 and 60. Study durations ranged from 6 months to 3.5 years. </p> <p>We found that anti‐TNF dose reduction leads to little or no difference in mean disease activity score (DAS28) after 26 to 52 weeks (high‐certainty evidence, mean difference (MD) 0.06, 95% confidence interval (CI) −0.11 to 0.24, absolute risk difference (ARD) 1%) compared with continuation. Also, anti‐TNF dose reduction does not result in an important deterioration in function after 26 to 52 weeks (Health Assessment Questionnaire Disability Index (HAQ‐DI)) (high‐certainty evidence, MD 0.09, 95% CI 0.00 to 0.19, ARD 3%). Next to this, anti‐TNF dose reduction may slightly reduce the proportion of participants switched to another biologic (low‐certainty evidence), but probably slightly increases the proportion of participants with minimal radiographic progression after 52 weeks (moderate‐certainty evidence, risk ratio (RR) 1.22, 95% CI 0.76 to 1.95, ARD 2% higher). Anti‐TNF dose reduction may cause little or no difference in serious adverse events, withdrawals due to adverse events and proportion of participants with persistent remission (low‐certainty evidence). </p> <p>Results show that anti‐TNF discontinuation probably slightly increases the mean disease activity score (DAS28) after 28 to 52 weeks (moderate‐certainty evidence, MD 0.96, 95% CI 0.67 to 1.25, ARD 14%), and that the RR of persistent remission lies between 0.16 and 0.77 (low‐certainty evidence). Anti‐TNF discontinuation increases the proportion participants with minimal radiographic progression after 52 weeks (high‐certainty evidence, RR 1.69, 95% CI 1.10 to 2.59, ARD 7%) and may lead to a slight deterioration in function (HAQ‐DI) (low‐certainty evidence). It is uncertain whether anti‐TNF discontinuation influences the number of serious adverse events (due to very low‐certainty evidence) and the number of withdrawals due to adverse events after 28 to 52 weeks probably increases slightly (moderate‐certainty evidence, RR 1.46, 95% CI 0.75 to 2.84, ARD 1% higher). </p> <p>Anti‐TNF disease activity–guided dose tapering may result in little or no difference in mean disease activity score (DAS28) after 72 to 78 weeks (low‐certainty evidence). Furthermore, anti‐TNF disease activity–guided dose tapering results in little or no difference in the proportion of participants with persistent remission after 18 months (high‐certainty evidence, RR 0.89, 95% CI 0.75 to 1.06, ARD −9%) and may result in little or no difference in switching to another biologic (low‐certainty evidence). Anti‐TNF disease activity–guided dose tapering may slightly increase proportion of participants with minimal radiographic progression (low‐certainty evidence) and probably leads to a slight deterioration of function after 18 months (moderate‐certainty evidence, MD 0.2 higher, 0.02 lower to 0.42 higher, ARD 7% higher), It is uncertain whether anti‐TNF disease activity‐guided dose tapering influences the number of serious adverse events due to very low‐certainty evidence. </p> </section> <section id="CD010455-sec-0007"> <h3 class="title" id="CD010455-sec-0007">Authors' conclusions</h3> <p>We found that fixed‐dose reduction of anti‐TNF, after at least three to 12 months of low disease activity, is comparable to continuation of the standard dose regarding disease activity and function, and may be comparable with regards to the proportion of participants with persistent remission. Discontinuation (also without disease activity–guided adaptation) of anti‐TNF is probably inferior to continuation of treatment with respect to disease activity, the proportion of participants with persistent remission, function, and minimal radiographic damage. Disease activity–guided dose tapering of anti‐TNF is comparable to continuation of treatment with respect to the proportion of participants with persistent remission and may be comparable regarding disease activity. </p> <p>Caveats of this review are that available data are mainly limited to etanercept and adalimumab, the heterogeneity between studies, and the use of superiority instead of non‐inferiority designs. </p> <p>Future research should focus on the anti‐TNF agents infliximab and golimumab; assessment of disease activity, function, and radiographic outcomes after longer follow‐up; and assessment of long‐term safety, cost‐effectiveness, and predictors for successful down‐titration. Also, use of a validated flare criterion, non‐inferiority designs, and disease activity–guided tapering instead of fixed‐dose reduction or discontinuation would allow researchers to better interpret study findings and generalise to clinical practice. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010455-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010455-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD010455-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD010455-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010455-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010455-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD010455-abs-0009">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010455-abs-0003" lang="en"> <h3>Lowering the dose of or stopping anti‐tumour necrosis factor drugs in people with rheumatoid arthritis who are doing well (low disease activity) </h3> <p>We conducted an updated review of studies in which treatment with anti‐tumour necrosis factor (anti‐TNF) drugs (adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab) was lowered or stopped in people with rheumatoid arthritis (RA) who use anti‐TNF drugs and are doing well (low disease activity). Our systematic search up to March 2018 identified 14 studies (3315 participants). The included studies were performed at clinical centres around the world and included people with early as well as established RA, the majority of whom were female with mean ages varying between 47 and 60. Study durations ranged from 6 months to 3.5 years. </p> <p><b>What is rheumatoid arthritis? What is stopping or lowering the dose of anti‐TNF drugs?</b> </p> <p>When you have RA, your immune system, which normally fights infection, attacks the lining of your joints. This makes your joints swollen, stiff, and painful. There is no cure for RA, so treatments aim to relieve pain and stiffness, improve ability to move, and prevent damage to the joints. </p> <p>Anti‐TNF agents are biological drugs for RA. They lessen complaints by reducing inflammation in the joints, and they reduce radiographic joint damage. Reducing or stopping anti‐TNF treatment when disease activity is low might reduce dose‐dependent side effects (mainly infections) and costs. </p> <p><b>Key results</b> </p> <p>Data were available for all anti‐TNF agents, but mostly for adalimumab and etanercept.</p> <p><i><b>Disease activity</b> </i> </p> <p>‐ People who lowered the dose of anti‐TNF showed little or no increase in disease activity compared with people who continued anti‐TNF (high‐certainty evidence). </p> <p>‐ People who stopped anti‐TNF had a 0.96 unit increase in disease activity on a scale from 0.9 to 8 compared with people who continued anti‐TNF (absolute difference 14%, moderate‐certainty evidence). </p> <p>‐ People who gradually lowered the dose of anti‐TNF showed little or no increase in disease activity compared with people who continued anti‐TNF (low‐certainty evidence). </p> <p><i><b>Persistent remission</b> </i> </p> <p>‐ There was little or no difference in the number of people who had persistent remission between those who lowered the dose of anti‐TNF compared with continuation of anti‐TNF (low‐certainty evidence). </p> <p>‐ Data on how stopping anti‐TNF affects persistent remission were not pooled because results were not similar across studies (low‐certainty evidence). The absolute difference varied between 15% and 68% fewer people that remained in remission when stopping anti‐TNF compared to continuation of anti‐TNF. </p> <p>‐ There was little or no difference in the number of people who had persistent remission between those who gradually lowered the dose of anti‐TNF compared with continuation of anti‐TNF (high‐certainty evidence). </p> <p><i><b>X‐ray progression</b> </i> </p> <p>‐ 24 more people per 1000 had a greater than 0.5 point progression of joint damage after a year when lowering the dose of anti‐TNF (scale 0 to 448) (absolute difference 2%, moderate‐certainty evidence). </p> <p>‐ 73 more people per 1000 who stopped anti‐TNF had a greater than 0.5 point progression of joint damage after a year than people who continued anti‐TNF (absolute difference 7%, high‐certainty evidence). </p> <p>‐ 110 more people per 1000 had greater than 0.5 or greater than 1.0 point progression of joint damage after 1.5 years when gradually lowering the dose of anti‐TNF (low‐certainty evidence). </p> <p><i><b>Function</b> </i> </p> <p>‐ People who lowered the dose of anti‐TNF had a 0.09 unit worsening of function (scale 0 to 3) compared with people who continued anti‐TNF (absolute difference 3%, high‐certainty evidence). </p> <p>‐ People stopping anti‐TNF had a 0.18 unit worsening of function compared with people who continued anti‐TNF (absolute difference 6%, low‐certainty evidence). </p> <p>‐ People gradually lowering the dose of anti‐TNF had a 0.2 unit worsening in function compared with people who continued anti‐TNF (absolute difference 7%, moderate‐certainty evidence). </p> <p><i><b>Side effects</b> </i> </p> <p>‐ There was little or no difference in number of serious adverse events in people lowering the dose of anti‐TNF compared to continuation anti‐TNF (low‐certainty evidence). </p> <p>‐ It is uncertain whether gradually lowering the dose of or stopping anti‐TNF influences the number of serious adverse events (very low‐certainty evidence). </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010455-sec-0108" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010455-sec-0108"></div> <h3 class="title" id="CD010455-sec-0109">Implications for practice</h3> <section id="CD010455-sec-0109"> <p>This review of the data has several implications for clinical practice with regard to the three different strategies studied: dose reduction, discontinuation, and disease activity‐guided tapering of anti–tumour necrosis factor (anti‐TNF). </p> <p>Firstly, fixed‐dose reduction of anti‐TNF (especially etanercept) in people with rheumatoid arthritis (RA) with at least three to 12 months of low disease activity is comparable with continuing the standard dose with regard to mean disease activity, the proportion of participants remaining in remission, and mean function. Consequently, an attempt to reduce the dose (or increase the dosage interval) in people with low disease activity with RA on full‐dose anti‐TNF seems sensible in clinical practice. It should be mentioned, however, that all treatment changes in RA should be done carefully on a background of 'treat to target', that is guided by disease activity. Dose reduction probably slightly increases the proportion of participants with minimal radiographic progression. Anti‐TNF dose reduction may cause little or no difference in number of serious adverse events and withdrawals due to adverse events, although certainty of evidence was low. This review showed that slightly fewer participants undergoing anti‐TNF dose reduction may switch to another biologic disease‐modifying antirheumatic drug (bDMARD) compared to continuation. An explanation for this might be that temporary disease flares (inherent to the disease) are treated in the dose reduction group by increasing the dose, while in the continuation group patients are switched to another biologic. </p> <p>Secondly, this review shows that anti‐TNF discontinuation (without disease activity–guided restarting of treatment) is an inferior strategy compared with continuation of anti‐TNF in terms of disease control (mean disease activity and the proportion of participants remaining in remission), minimal radiographic damage, function and the number of withdrawals due to adverse events. Although a sizeable proportion of patients can stop the anti‐TNF without deterioration, the large majority of patients who cannot discontinue the drug are harmed if the treatment is not reinstated. The effect of discontinuation on the number of serious adverse events remains uncertain. However, given the current evidence, discontinuation should not be attempted without regular assessment of disease activity, setting a treatment goal, and reinstatement of treatment when necessary. </p> <p>The abovementioned findings converge finally in the evidence on the disease activity‐guided dose tapering strategy. This review shows that disease activity‐guided tapering is comparable to continuation with regard to mean disease activity, the proportion of participants remaining in remission and the proportion of participants switched to another biologic. Tapering may result in a slight increase in the proportion of participants with radiographic progression and probably leads to a slight deterioration in function. The effect of disease activity‐guided dose tapering of anti‐TNF on the number of serious adverse events and withdrawals due to adverse events could not be determined with certainty. This evidence is similar to that for fixed‐dose reduction. Because disease activity‐guided dose tapering provides the opportunity to find the lowest effective dose for each individual patient and to discontinue treatment as the final step of the tapering process, this may be the most cost‐effective and feasible approach in clinical practice. Since uncertainty remains on several important outcome measures, more data on, for example, radiographic damage progression, function, (serious) adverse events, and costs are warranted. </p> <p>With respect to interpretation, it should be noted that the burden of proof in this case does not lie solely with dose reduction or stopping compared with continued use. To our knowledge, no controlled data are available on anti‐TNF continued use after week 52, including all registration studies. Consequently, there remains equipoise on what is the best strategy after one year of treatment with anti‐TNF. </p> </section> <h3 class="title" id="CD010455-sec-0110">Implications for research</h3> <section id="CD010455-sec-0110"> <p>Our review highlights what is already known about anti‐TNF down‐titration in people with low RA disease activity, and on the other hand identifies gaps in our knowledge. Here we would like to mention a number of aspects that could be targeted in future studies. Of note, most of these points are currently being addressed in several ongoing studies. </p> <p> <ul id="CD010455-list-0013"> <li> <p>The design selected for studies comparing an anti‐TNF down‐titration strategy versus an anti‐TNF continuation strategy should include a non‐inferiority approach instead of the classical superiority analyses, as the aim is to maintain and not improve clinical outcomes, while minimising the amount of treatment that is needed. Superiority analyses can be reserved for domains were superiority can be expected, such as drug use, infections, and costs. As guidelines for performing a systematic review on non‐inferiority studies are absent, development of such guidelines would be helpful. </p> </li> <li> <p>The intervention should include disease activity–guided dose tapering or stopping of the anti‐TNF agent using tight control/treat to target instead of fixed‐dose adaptation or stopping, as the former is more compatible with clinical practice. </p> </li> <li> <p>The domain in which an intervention should be non‐inferior is long‐term RA disease control. Although temporary flaring will inevitably be seen more often in the trial‐and‐error dose‐tapering arm, both the incidence of more severe or prolonged flaring and mean disease activity at study end should be comparable. </p> </li> <li> <p>Consequently, in addition to mean disease activity at study end, cumulative incidence of a validated RA flare criterion could be used. Use of (one of) validated Outcome Measures in Rheumatology Clinical Trials (OMERACT) disease activity score in 28 joints (DAS28)‐based flare criteria should be considered (<a href="./references#CD010455-bbs2-0100" title="van derMaasA , LieE , ChristensenR , ChoyE , deManY , vanRielP , et al. Construct and criterion validity of several proposed DAS28‐based rheumatoid arthritis flare criteria: an OMERACT cohort validation study. Annals of the Rheumatic Diseases2013;72:1800‐5. ">van der Maas 2013 Flare</a>). Use of a validated flare criterion also increases standardisation for future meta‐analyses. </p> </li> <li> <p>Other outcomes besides disease activity that should be included are cost, quality of life, cost‐effectiveness, and (long‐term) safety, because these constitute the reason why down‐titration is contemplated in the first place. </p> </li> <li> <p>The drugs that are studied should preferably also include other anti‐TNF agents like certolizumab pegol, golimumab, and infliximab. </p> </li> <li> <p>Prediction of (un)successful dose tapering would perhaps further improve outcomes of individualised disease activity–guided dose tapering, and prediction modelling should be considered, using, for example, genetics, imaging, biomarkers, and drug levels. Possible gains when using a good prediction rule include (1) prevention of unnecessary flaring in patients that cannot be dose reduced; and (2) prevention of months of slow dose tapering in patients that can be stopped directly. </p> </li> <li> <p>Finally, although outside the scope of this review, efforts should be (and already are) directed toward other non–anti‐TNF biologicals (abatacept, tocilizumab) and toward other inflammatory diseases in which biologicals are used, both within rheumatology (ankylosing spondylitis, psoriatic arthritis) and within other medical specialties (gastroenterology, dermatology). </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010455-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010455-sec-0022"></div> <div class="table" id="CD010455-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Anti‐TNF dose reduction versus anti‐TNF continuation</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Anti‐TNF dose reduction compared to anti‐TNF continuation for rheumatoid arthritis in patients with low disease activity</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents<br/> <b>Setting:</b> clinical research centres<br/> <b>Intervention:</b> anti‐TNF dose reduction<br/> <b>Comparison:</b> anti‐TNF continuation </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>What happens</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with anti‐TNF continuation</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with anti‐TNF dose reduction</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease activity score</b><br/> Assessed with: DAS28<br/> Scale from 0.9 to 8; higher scores indicate worse disease activity<br/> Follow‐up: range 26 weeks to 52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean disease activity score was 2.34</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.06 higher<br/> (0.11 lower to 0.24 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>501<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: 1% higher (95% CI 2% lower to 3% higher)</p> <p>Relative percentage change: 2% higher (95% CI 5% lower to 10% higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐TNF dose reduction results in little or no difference in disease activity score (DAS28). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with persistent remission</b><br/> Assessed with: DAS28 &lt; 2.6 (remission)<br/> Follow‐up: 52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>653 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>659 per 1000<br/> (522 to 835) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.01<br/> (0.80 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>612<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: 1% higher (95% CI 13% lower to 18% higher)</p> <p>Relative percentage change: 1% higher (95% CI 20% lower to 28% higher)</p> <p>NNTB: not applicable (not statistically significant)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐TNF dose reduction may result in little or no difference in the proportion of participants with persistent remission (DAS28 &lt; 2.6). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants switched to another biologic</b> </p> <p>Mean follow‐up of 3.5 ± 1.5 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>44 per 1000<br/> (19 to 102) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.40<br/> (0.17 to 0.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>323<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: 7% lower (95% CI 9% lower to 1% lower)</p> <p>Relative percentage change: 60% (95% CI 83% lower to 7% lower)</p> <p>NNTB: 15 (95% CI 12 to 100)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐TNF dose reduction may slightly reduce the proportion of participants switched to another biologic. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with minimal radiographic progression</b><br/> Assessed with: mSvdH score &gt; 0.5<br/> Follow‐up: 52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>129 per 1000<br/> (80 to 206) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.22<br/> (0.76 to 1.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>553<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: 2% higher (95% CI 3% lower to 10% higher)</p> <p>Relative percentage change: 22% higher (95% CI 34% lower to 95% higher)</p> <p>NNTH: not applicable (not statistically significant)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐TNF dose reduction probably slightly increases the proportion of participants with minimal radiographic progression (mSvdH &gt; 0.5) . </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function</b><br/> Assessed with: Health Assessment Questionnaire<br/> Scale from 0 to 3; higher scores indicate worse function<br/> Follow‐up: range 26 weeks to 52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean function was 0.52</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.09 higher<br/> (0 to 0.19 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>501<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: 3% higher (95% CI 0% higher to 6% higher)</p> <p>Relative percentage change: 15% higher (95% CI 0% higher to 31% higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐TNF dose reduction does not result in an important deterioration in function.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of serious adverse events</b> </p> <p>Follow‐up: range 26 weeks to 52 weeks (mean follow‐up for <a href="./references#CD010455-bbs2-0008" title="BotsiosC , FurlanA , OstuniP , SfrisoP , TodescoS , PunziL . Effects of low‐dose etanercept in maintaining DAS‐remission previously achieved with standard‐dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2007;66(Suppl II):54. RaffeinerB , BotsiosC , OmettoF , BernardiL , StramareR , TodescoS , et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology2015;33:63‐8. [PUBMED: 25535985] ">Raffeiner 2015</a> 3.5 ± 1.5 years) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1000<br/> (34 to 94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.09<br/> (0.65 to 1.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1084<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: 0% (95% CI 2% lower to 4% higher)</p> <p>Relative percentage change: 9% higher (95% CI 35% lower to 82% higher)</p> <p>NNTH: not applicable (not statistically significant)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐TNF dose reduction may cause little or no difference in the number of serious adverse events.. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> </p> <p>Follow‐up: 52 weeks (mean follow‐up for <a href="./references#CD010455-bbs2-0008" title="BotsiosC , FurlanA , OstuniP , SfrisoP , TodescoS , PunziL . Effects of low‐dose etanercept in maintaining DAS‐remission previously achieved with standard‐dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2007;66(Suppl II):54. RaffeinerB , BotsiosC , OmettoF , BernardiL , StramareR , TodescoS , et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology2015;33:63‐8. [PUBMED: 25535985] ">Raffeiner 2015</a> 3.5 ± 1.5 years) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000<br/> (16 to 70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.07<br/> (0.51 to 2.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>937<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: 0% (95% CI 2% lower to 4% higher)</p> <p>Relative percentage change: 7% higher (95% CI 49% lower to 124% higher)</p> <p>NNTH: not applicable (not statistically significant)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐TNF dose reduction may cause little or no difference in the number of withdrawals due to adverse events . </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>DAS28:</b> disease activity score in 28 joints; <b>MD:</b> mean difference; <b>mSvdH:</b> modified Sharp van der Heijde; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome; <b>RCT:</b> randomised controlled trial: <b>RR:</b> risk ratio; <b>TNF:</b> tumour necrosis factor </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup>Downgraded two levels due to heterogeneity (I<sup>2</sup>=73%)<br/> <sup>2</sup>Downgraded two levels due to concerns about study risk of bias (high risk of selection bias, performance bias, detection bias and other bias).<br/> <sup>3</sup>Downgraded one level due to imprecision (insufficient sample size/low number of events).<br/> <sup>4</sup>Downgraded one level due to concerns about study risk of bias (mainly due to high risk of attrition bias in <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a> and high risk of bias on several domains in <a href="./references#CD010455-bbs2-0008" title="BotsiosC , FurlanA , OstuniP , SfrisoP , TodescoS , PunziL . Effects of low‐dose etanercept in maintaining DAS‐remission previously achieved with standard‐dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2007;66(Suppl II):54. RaffeinerB , BotsiosC , OmettoF , BernardiL , StramareR , TodescoS , et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology2015;33:63‐8. [PUBMED: 25535985] ">Raffeiner 2015</a>). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010455-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Anti‐TNF discontinuation versus anti‐TNF continuation</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Anti‐TNF discontinuation compared to anti‐TNF continuation for rheumatoid arthritis in patients with low disease activity</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents<br/> <b>Setting:</b> clinical research centres<br/> <b>Intervention:</b> anti‐TNF discontinuation<br/> <b>Comparison:</b> anti‐TNF continuation </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>What happens</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with anti‐TNF continuation</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with anti‐TNF discontinuation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Disease activity score ‐</b> <br/> assessed with: DAS28<br/> Scale from: 0.9 to 8; higher scores indicate worse disease activity<br/> follow up: range 28 weeks to 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Discontinuation without restarting, or with restarting and LOCF analysis</b> </p> <p>Mean disease activity score was 2.82</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.96 higher<br/> (0.67 higher to 1.25 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>733<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absolute risk difference: 14% higher (95% CI 9% higher to 18% higher)</p> <p>Relative percentage change: 25% (95% CI 18% higher to 33% higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐TNF discontinuation probably increases the disease activity score slightly</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with persistent remission</b><br/> Assessed with: DAS28 &lt; 2.6 (remission)<br/> Follow‐up: range 28 weeks to 52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>RR values range from 0.16 to 0.77. Absolute risk differences range from 15% lower to 68% lower. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1188<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not pooled due to heterogeneity.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐TNF discontinuation may reduce the proportion of participants with persistent remission </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion participants that switched to another biologic due to loss of response</b> ‐ not measured </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies were found that evaluated the proportion of participants that switched to another biologic due to persistent loss of response. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion participants with minimal radiographic progression</b><br/> Assessed with: mSvdH &gt; 0.5<br/> Follow‐up: mean 52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>178 per 1000<br/> (116 to 273) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.69<br/> (1.10 to 2.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>549<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: 7% higher (95% CI 1% higher to 17% higher)</p> <p>Relative percentage change: 69% higher (95% CI 10% higher to 159% higher)</p> <p>NNTH: 15 (95% CI 6 to 100)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐TNF discontinuation increases the proportion participants with minimal radiographic progression &gt; 0.5 mSvdH point. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function</b><br/> Assessed with: Health Assessment Questionnaire<br/> Scale from 0 to 3; higher scores indicate worse functioning<br/> Follow‐up: range 28 weeks to 52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean function was 0.52</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.18 higher<br/> (0.05 higher to 0.31 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1498<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: 6% higher (95% CI 2% higher to 17% higher)</p> <p>Relative percentage change: 26% higher (95% CI 7% higher to 44% higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐TNF discontinuation may lead to a slight deterioration in function.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of serious adverse events</b> </p> <p>Follow‐up: range 28 weeks to 52 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>57 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000<br/> (47 to 116) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.29<br/> (0.82 to 2.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2095<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: 2% higher (95% CI 1% lower to 6% higher)</p> <p>Relative percentage change: 29% higher (95% CI 18% lower to 103% higher)</p> <p>NNTH: not applicable (not statistically significant)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It is uncertain whether anti‐TNF discontinuation influences the number of serious adverse events because the certainty of the evidence is very low and because of imprecision. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> </p> <p>Follow‐up: range 28 weeks to 52 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 1000<br/> (20 to 76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.46<br/> (0.75 to 2.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1116<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: 1% higher (95% CI 1% lower to 5% higher)</p> <p>Relative percentage change: 46% (95% CI 25% lower to 184% higher)</p> <p>NNTH: not applicable (not statistically significant)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐TNF discontinuation probably slightly increases the number of withdrawals due to adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>DAS28:</b> disease activity score in 28 joints; <b>LOCF:</b> last observation carried forward; <b>MD:</b> mean difference; <b>mSvdH:</b> modified Sharp van der Heijde; <b>NNTH:</b> number needed to treat for an additional harmful outcome; <b>RCT:</b> randomised controlled trial: <b>RR:</b> risk ratio; <b>TNF:</b> tumour necrosis factor </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level due to heterogeneity (I<sup>2</sup>=61% for disease activity score and I<sup>2</sup>=31% for number of serious adverse events).<br/> <sup>2</sup>Downgraded two levels due to heterogeneity (I<sup>2</sup>=80% for proportion of participants with remission and I<sup>2</sup>=79% for function).<br/> <sup>3</sup>Downgraded one level due to imprecision (low number of events).<br/> <sup>4</sup>Downgraded one level due to concerns about study risk of bias (high risk of selection bias, detection bias, attrition bias and other bias). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010455-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Anti‐TNF disease activity–guided dose tapering versus anti‐TNF continuation</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Anti‐TNF disease activity–guided dose tapering compared to anti‐TNF continuation for rheumatoid arthritis in patients with low disease activity</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents<br/> <b>Setting:</b> clinical research centres<br/> <b>Intervention:</b> anti‐TNF disease activity–guided dose tapering<br/> <b>Comparison:</b> anti‐TNF continuation </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>What happens</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with anti‐TNF continuation</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with anti‐TNF disease activity–guided dose tapering</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease activity score</b><br/> Assessed with: DAS28<br/> Scale from 0.9 to 8; higher scores indicate worse disease activity<br/> Follow‐up: range 72 weeks to 78 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean disease activity score was 2.34</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.25 higher<br/> (0.17 lower to 0.67 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>357<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: 4% higher (95% CI 2% lower to 9% higher)</p> <p>Relative percentage change: 10% higher (95% CI 7% lower to 26% higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐TNF disease activity–guided dose tapering may result in little or no difference in disease activity score. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with persistent remission</b><br/> Assessed with: DAS28 &lt; 2.6 (remission)<br/> Follow‐up: 18 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>797 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>709 per 1000<br/> (597 to 844) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.89<br/> (0.75 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: 9% lower (95% CI 20% lower to 5% higher)</p> <p>Relative percentage change: 10% higher (95% CI 7% lower to 26% higher)</p> <p>NNTH: not applicable (not statistically significant)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐TNF disease activity–guided dose tapering results in little or no difference in the proportion of participants with persistent remission. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants switched to another biologic due to loss of response</b><br/> Follow‐up: 18 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>76 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47 per 1000<br/> (19 to 117) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.62<br/> (0.25 to 1.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>317<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: 3% lower (95% CI 6% lower to 4% higher)</p> <p>Relative percentage change: 38% higher (95% CI 75% lower to 54% higher)</p> <p>NNTH: not applicable (not statistically significant)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐TNF disease activity–guided dose tapering may result in little or no difference in the proportion of participants that switch to another biologic. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with minimal radiographic progression</b><br/> Assessed with: mSvdH score &gt; 0.5 or &gt; 1.0<br/> Follow‐up: mean 18 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>242 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>352 per 1000<br/> (187 to 662) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.45<br/> (0.77 to 2.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>312<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: 11% higher (95% CI 6% lower to 42% higher)</p> <p>Relative percentage change: 45% higher (95% CI 23% lower to 173% higher)</p> <p>NNTH: not applicable (not statistically significant)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐TNF disease activity–guided dose tapering may slightly increase the proportion of participants with minimal radiographic progression (mSvdH &gt; 0.5 or &gt; 1.0). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function</b><br/> Assessed with: Health Assessment Questionnaire<br/> Scale from 0 to 3; higher scores indicate worse function<br/> Follow‐up: mean 18 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean function was 0.4</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.2 higher<br/> (0.02 lower to 0.42 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: 7% higher (95% CI 1% lower to 14% higher)</p> <p>Relative percentage change: 33% higher (95% CI 3% lower to 70% higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐TNF disease activity–guided dose tapering probably leads to a slight deterioration of function. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of serious adverse events</b> </p> <p>Follow‐up: 18 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>129 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>160 per 1000<br/> (54 to 477) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.24<br/> (0.42 to 3.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>317<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: 3% higher (95% CI 8% lower to 35% higher)</p> <p>Relative percentage change: 24% higher (95% CI 58% lower to 270% higher)</p> <p>NNTH: not applicable (not statistically significant)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It is uncertain whether anti‐TNF disease activity‐guided dose tapering influences the number of serious adverse events because the certainty of the evidence is very low and because of imprecision. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> ‐ not measured </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies were found that evaluated the number of withdrawals due to adverse events.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>DAS28:</b> disease activity score in 28 joints; <b>MD:</b> mean difference; <b>mSvdH:</b> modified Sharp van der Heijde; <b>NNTH:</b> number needed to treat for an additional harmful outcome; <b>RCT:</b> randomised controlled trial: <b>RR:</b> risk ratio; <b>TNF:</b> tumour necrosis factor </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup>Downgraded two levels due to heterogeneity (I<sup>2</sup>=70% for disease activity score and I<sup>2</sup>=69% for number of serious adverse events).<br/> <sup>2</sup>Downgraded two levels due to imprecision (insufficient sample size/low number of events).<br/> <sup>3</sup>Downgraded one level due to heterogeneity (I<sup>2</sup>=59%).<br/> <sup>4</sup>Downgraded one level due to imprecision (insufficient sample size). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010455-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010455-sec-0023"></div> <section id="CD010455-sec-0024"> <h3 class="title" id="CD010455-sec-0024">Description of the condition</h3> <p>Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterised by symmetrical joint inflammation that often leads to joint damage. Tumour necrosis factor–blocking (anti‐TNF) agents have proved effective as therapies for RA (<a href="./references#CD010455-bbs2-0055" title="BlumenauerBBTB , JuddM , WellsGA , BurlsA , CranneyA , HochbergMC , et al. Infliximab for the treatment of rheumatoid arthritis. Cochrane Database of Systematic Reviews2002, Issue 3. [DOI: 10.1002/14651858.CD003785] ">Blumenauer 2002</a>; <a href="./references#CD010455-bbs2-0056" title="BlumenauerBBTB , CranneyA , BurlsA , CoyleD , HochbergMC , TugwellP , et al. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database of Systematic Reviews2003, Issue 3. [DOI: 10.1002/14651858.CD004525] ">Blumenauer 2003</a>; <a href="./references#CD010455-bbs2-0076" title="Navarro‐SarabiaF , Ariza‐ArizaR , Hernandez‐CruzB , VillanuevaI . Adalimumab for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews2005, Issue 3. [DOI: 10.1002/14651858.CD005113.pub2] ">Navarro‐Sarabia 2005</a>; <a href="./references#CD010455-bbs2-0081" title="Ruiz GarciaV , JobanputraP , BurlsA , CabelloJB , Gálvez MuñozJG , Saiz CuencaESC , et al. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD007649.pub3] ">Ruiz Garcia 2014</a>; <a href="./references#CD010455-bbs2-0085" title="SinghJA , ChristensenR , WellsGA , Suarez‐AlmazorME , BuchbinderR , Lopes‐OlivoMA , et al. Biologics for rheumatoid arthritis: an overview of Cochrane Reviews. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD007848.pub2] ">Singh 2009</a>; <a href="./references#CD010455-bbs2-0086" title="SinghJA , NoorbaloochiS , SinghJA . Golimumab for rheumatoid arthritis. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD008341] ">Singh 2010</a>). They improve clinical symptoms and functioning and inhibit joint destruction, and have become an important part of treatment prescribed for RA. </p> </section> <section id="CD010455-sec-0025"> <h3 class="title" id="CD010455-sec-0025">Description of the intervention</h3> <p>Treatment of individuals with RA has been evolving from traditional step‐up regimens to more aggressive step‐down strategies. Pivotal to these changes are the early start of treatment (hit early), the use of combination therapy including steroids with rapid escalation to biologics (hit‐hard), and, most important, frequent assessment of disease activity and treatment modification based on assessment (tight control). Strategies incorporating these concepts lead to the swift achievement of low disease activity or remission in most patients, which prevents joint damage and improves function and quality of life (<a href="./references#CD010455-bbs2-0083" title="SchipperLG , vanHulstLTC , GrolR , vanRielPLCM , HulscherMEJL , FransenJ . Meta‐analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome. Rheumatology2010;49:2154‐64. [PUBMED: 20671022] ">Schipper 2010</a>). An important disadvantage of the hit‐hard approach compared with the traditional step‐up approach, however, is that the former method does not allow for individual titration of the minimal effective treatment. Indeed, the traditional step‐up approach largely prevents overtreatment, but high(er) disease activity at the beginning of the disease has to be accepted. To prevent overtreatment when high‐dose or multidrug strategies are used, treatment must be tapered down when low disease activity is reached up to the point that disease activity increases again or medication can be stopped. In this way, the minimal effective dose is found and overtreatment is prevented. Optimal dosing of biologics is especially important because of the risk of dose‐dependent adverse effects and the risk of low cost‐effectiveness due to high cost (<a href="./references#CD010455-bbs2-0060" title="denBroederAA , van derMaasA , van denBemtBJF . Dose de‐escalation strategies and role of therapeutic drug monitoring of biologics in RA. Rheumatology2010;49(10):1801‐3. ">den Broeder 2010</a>; <a href="./references#CD010455-bbs2-0079" title="RamiroS , SeprianoA , ChatzidionysiouK , NamJL , SmolenJS , van derHeijdenD , et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Annals of the Rheumatic Diseases2017;76(6):1101‐1136. [PUBMED: 28298374] ">Ramiro 2017</a>; <a href="./references#CD010455-bbs2-0087" title="SinghJA , WellsGA , ChristensenR , Tanjong GhogomuE , MaxwellL , MacdonaldJK , et al. Adverse effects of biologics: a network meta‐analysis and Cochrane overview. Cochrane Database of Systematic Reviews2011, Issue 16. [DOI: 10.1002/14651858.CD008794.pub2] ">Singh 2011</a>). The concept of dose reduction has been incorporated into current guidelines for the treatment of RA (<a href="./references#CD010455-bbs2-0088" title="SinghJA , SaagKG , BridgesSL , AklEA , BannuruRR , SullivanMC , et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care &amp; Research2016;68(1):1‐25. [PUBMED: 26545825] ">Singh 2016</a>; <a href="./references#CD010455-bbs2-0090" title="SmolenJS , LandewéR , BijlsmaJ , BurmesterG , ChatzidionysiouK , DougadosM , et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease‐modifying antirheumatic drugs: 2016 update. Annals of the Rheumatic Diseases2017;76(6):960‐977. [PUBMED: 28264816] ">Smolen 2017</a>). </p> <p>The intervention that is the subject of this review is therefore dose reduction of anti‐TNF agents (by adaptation of dose or dosing interval) or discontinuation or both in people with RA and low disease activity status. </p> </section> <section id="CD010455-sec-0026"> <h3 class="title" id="CD010455-sec-0026">How the intervention might work</h3> <p>Successful dose reduction or discontinuation of anti‐TNF agents can be expected for several reasons. First, amongst patients who seem to respond to treatment with anti‐TNF agents are those who show spontaneous improvement (regression to the mean) (<a href="./references#CD010455-bbs2-0060" title="denBroederAA , van derMaasA , van denBemtBJF . Dose de‐escalation strategies and role of therapeutic drug monitoring of biologics in RA. Rheumatology2010;49(10):1801‐3. ">den Broeder 2010</a>; <a href="./references#CD010455-bbs2-0101" title="vanVollenhovenRF , BrannemarkS , KlareskogL . Dose escalation of infliximab in clinical practise: improvements seen may be explained by a regression‐like effect. Annals of the Rheumatic Diseases2004;63(4):426‐30. ">van Vollenhoven 2004</a>); this phenomenon applies to 10% to 30% of all patients, as was shown by proportions of placebo group response (<a href="./references#CD010455-bbs2-0061" title="DohertyM , DieppeP . The ‘placebo’ response in osteoarthritis and its implications for clinical practice. Osteoarthritis Cartilage2009;17(10):1255‐62. ">Doherty 2009</a>; <a href="./references#CD010455-bbs2-0091" title="StClairEW , van derHeijdeDM , SmolenJS , MainiRN , BathonJM , EmeryP , et al. Active‐Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis and Rheumatism2004;50(11):3432‐43. ">St Clair 2004</a>). Second, often concomitant medication is given that might induce a response. Both mechanisms are supported by the fact that a proportion of patients who seem to do well while taking the drug have (neutralising) antibodies (less than 5% to 43%) (<a href="./references#CD010455-bbs2-0054" title="BarteldsGM , WijbrandtsCA , NurmohamedMT , StapelS , LemsWF , AardenL , et al. Clinical response to adalimumab: relationship to anti‐adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Annals of the Rheumatic Diseases2007;66(7):921‐6. ">Bartelds 2007</a>; <a href="./references#CD010455-bbs2-0071" title="KlareskogL , GaubitzM , Rodríguez‐ValverdeV , MalaiseM , DougadosM , WajdulaJ . Assessment of long‐term safety and efficacy of etanercept in a 5‐year extension study in patients with rheumatoid arthritis. Clinical Experimental Rheumatology2011;29(2):238‐47. ">Klareskog 2011</a>; <a href="./references#CD010455-bbs2-0105" title="WolbinkGJ , VisM , LemsW , VoskuylAE , deGrootE , NurmohamedMT . Development of anti‐infliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis and Rheumatism2006;54(3):711‐5. ">Wolbink 2006</a>). Finally, a substantial proportion of patients might need a lower than standard dose for a clinical response (<a href="./references#CD010455-bbs2-0062" title="FautrelB , denBroederAA . De‐intensifying treatment in established rheumatoid arthritis (RA): why, how, when and in whom can DMARDs be tapered?. Best Practice &amp; Research: Clinical Rheumatology2015;29(4‐5):550‐65. [PUBMED: 26697766] ">Fautrel 2015</a>; <a href="./references#CD010455-bbs2-0103" title="VerhoefLM , TweehuysenL , HulscherME , FautrelB , denBroederAA . bDMARD dose reduction in rheumatoid arthritis: a narrative review with systematic literature search. Rheumatology and Therapy2017;4(1):1‐24. [PUBMED: 28255897] ">Verhoef 2017</a>). Anti‐TNF agents are registered at the dose that shows the best response for the most patients (top of group level dose‐response curve). However, individual patients might respond to a lower dose as well, which is reflected in response percentages of lower doses in these initial trials (<a href="./references#CD010455-bbs2-0066" title="GenoveseMC , BathonJM , MartinRW , FleischmannRM , TesserJR , SchiffMH , et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two‐year radiographic and clinical outcomes. Arthritis &amp; Rheumatology2002;46(6):1443‐50. [PUBMED: 12115173] ">Genovese 2002</a>; <a href="./references#CD010455-bbs2-0074" title="MainiRN , BreedveldFC , KaldenJR , SmolenJS , DavisD , MacfarlaneJD , et al. Therapeutic efficacy of multiple intravenous infusions of anti‐tumor necrosis factor alpha monoclonal antibody combined with low‐dose weekly methotrexate in rheumatoid arthritis. Arthritis &amp; Rheumatology1998;41(9):1552‐63. [PUBMED: 9751087] ">Maini 1998</a>; <a href="./references#CD010455-bbs2-0104" title="WeinblattME , KeystoneEC , FurstDE , MorelandLW , WeismanMH , BirbaraCA , et al. Adalimumab, a fully human anti‐tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis &amp; Rheumatology2003;48(3):855. [PUBMED: 12528101] ">Weinblatt 2003</a>). </p> <p>Uncontrolled research has shown that down‐titration of anti‐TNF agents can be successful in a relevant proportion of patients. Most data are available for infliximab, adalimumab, and etanercept, and most are derived from discontinuation studies (<a href="./references#CD010455-bbs2-0058" title="BrocqO , MillasseauE , AlbertC , GrisotC , FloryP , RouxCH , et al. Effect of discontinuing TNFa antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine2009;76(4):350‐5. ">Brocq 2009</a>; <a href="./references#CD010455-bbs2-0059" title="denBroederAA , CreemersMCW , vanGestelAM , vanRielPLCM . Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti‐TNF‐α. Rheumatology2002;41(6):638‐42. ">den Broeder 2002</a>; <a href="./references#CD010455-bbs2-0070" title="KavanaughA , EmeryP , vanVollenhovenR , CifaldiM , ShawJ , ChenN , et al. Effect of adalimumab discontinuation on patient‐reported outcomes and work productivity in early rheumatoid arthritis patients who achieved low disease activity following 26 weeks of treatment: data from the OPTIMA study. Annals of the Rheumatic Diseases2012;71 (Suppl 3):663. ">Kavanaugh 2012</a>; <a href="./references#CD010455-bbs2-0077" title="NawataM , SaitoK , NakayamadaS , TanakaY . Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. Modern Rheumatology2008;18:460‐4. ">Nawata 2008</a>; <a href="./references#CD010455-bbs2-0082" title="SaleemB , KeenH , GoebV , ParmarR , NizamS , HensorEMA . Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?. Annals of the Rheumatic Diseases2010;69:1636‐42. ">Saleem 2010</a>; <a href="./references#CD010455-bbs2-0092" title="TanakaY , TakeuchiT , MimoriT , SaitoK , NawataM , KamedaH , et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (Remission induction by Remicade in RA) study. Annals of the Rheumatic Diseases2010;69(7):1286‐91. ">Tanaka 2010</a>; <a href="./references#CD010455-bbs2-0093" title="TanakaY , HirataS , FukuyoS , NawataM , KuboS , YamaokaK , et al. Discontinuation of adalimumab without functional and radiographic damage progression after achieving sustained remission in patients with rheumatoid arthritis (the HONOR study): 1‐year results. Arthritis and Rheumatism2012;64(Suppl 10):771. ">Tanaka 2012</a>; <a href="./references#CD010455-bbs2-0095" title="van denBemtBJF , denBroederAA , SnijdersGF , HeksterYA , vanRielPLCM , BenraadB , et al. Sustained effect after lowering high‐dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study. Annals of the Rheumatic Diseases2008;67(12):1697‐701. ">van den Bemt 2008</a>; <a href="./references#CD010455-bbs2-0096" title="van derBijlAE , Goekoop‐RuitermanYPM , deVries‐BouwstraJK , tenWoldeS , HanKH , vanKrugtenMV , et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis and Rheumatism2007;56(7):2129‐34. ">van der Bijl 2007</a>; <a href="./references#CD010455-bbs2-0099" title="van derMaasA , KievitW , van denBemtBJF , van denHoogenFHJ , vanRielPL , denBroederAA . Down‐titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Annals of the Rheumatic Diseases2012;71(11):1849‐54. ">van der Maas 2012</a>). </p> </section> <section id="CD010455-sec-0027"> <h3 class="title" id="CD010455-sec-0027">Why it is important to do this review</h3> <p>Although the adverse effects of anti‐TNF agents reported in clinical trials were generally mild in severity, these drugs are associated with unintended effects including increased risk of infection and perhaps a dose‐dependent increased risk of malignancy and rare severe adverse events (<a href="./references#CD010455-bbs2-0057" title="BongartzT , SuttonAJ , SweetingMJ , BuchanI , MattesonEL , MontoriV . Anti‐TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta‐analysis of rare harmful effects in randomised controlled trials. JAMA2006;295(19):2275‐85. ">Bongartz 2006</a>). The introduction of anti‐TNF agents ‐ and other biological drugs ‐ has also led to an increase in cost because they are much more expensive than traditional disease‐modifying antirheumatic drugs (DMARDs) (<a href="./references#CD010455-bbs2-0102" title="vanVollenhovenRF . How to dose infliximab in rheumatoid arthritis: new data on a serious issue. Annals of the Rheumatic Diseases2009;48(11):1237‐9. ">van Vollenhoven 2009</a>). </p> <p>It was appropriate at this time to conduct an update of this Cochrane Review of randomised controlled trials (RCTs) of anti‐TNF down‐titration as well as discontinuation studies, because several new RCTs on this topic are emerging, and additional information on the already included studies has been published. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010455-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010455-sec-0028"></div> <p>To evaluate the benefits and harms of down‐titration (dose reduction, discontinuation, or disease activity‐guided dose tapering) of anti‐TNF agents (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab) on disease activity, functioning, costs, safety, and radiographic damage compared with usual care in people with RA and low disease activity. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010455-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010455-sec-0029"></div> <section id="CD010455-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010455-sec-0031"> <h4 class="title">Types of studies</h4> <p>We considered all randomised controlled trials (RCTs) and controlled clinical trials (CCTs) (including cluster randomised and cross‐over trials) according to the Cochrane definition comparing down‐titration of tumour necrosis factor–blocking (anti‐TNF) agents versus usual care/no down‐titration for inclusion. The minimal required follow‐up was six months. Both superiority and non‐inferiority trials were included. </p> </section> <section id="CD010455-sec-0032"> <h4 class="title">Types of participants</h4> <p>People with RA (1987, <a href="./references#CD010455-bbs2-0053" title="ArnettFC , EdworthySM , BlochDA , McShaneDJ , FriesJF , CooperNS , et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism1988;31(3):315‐24. ">Arnett 1988</a>, or 2010, <a href="./references#CD010455-bbs2-0052" title="AletahaD , NeogiT , SilmanAJ , FunovitsJ , FelsonDT , BinghamCO3rd , et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis and Rheumatism2010;62(9):2569‐81. ">Aletaha 2010 RA criteria</a>, or both) American College of Rheumatology (ACR) criteria) using anti‐TNF agents in a standard (or lower) dosing regimen (adalimumab 40 mg every other week, etanercept 50 mg every week or 25 mg twice a week, infliximab 3 mg/kg every eight weeks, golimumab 50 mg every month, certolizumab pegol 200 mg every other week) for longer than six months and with a low disease activity state (clinical judgement of rheumatologist or disease activity score in 28 joints (DAS28) &lt; 3.2; DAS &lt; 2.4; Clinical Disease Activity Index (CDAI) &lt; 10; Simplified Disease Activity Index (SDAI) &lt; 11 or DAS28 &lt; 2.6; DAS &lt; 1.6; CDAI &lt; 2.8; SDAI &lt; 3.3, <a href="./references#CD010455-bbs2-0051" title="AletahaD , SmolenJ . The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clinical and Experimental Rheumatology2005;23(Suppl 39):S100‐8. ">Aletaha 2005</a>; <a href="./references#CD010455-bbs2-0064" title="FransenJ , vanRielPLCM . The Disease Activity Score and the EULAR response criteria. Clinical Experimental Rheumatology2005;23(5 Suppl 39):S93‐9. ">Fransen 2005</a>, or 2011 ACR/European League Against Rheumatism (EULAR) remission (<a href="./references#CD010455-bbs2-0063" title="FelsonDT , SmolenJS , WellsG , ZhangB , vanTuylLHD , FunovitsJ , et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis and Rheumatism2011;63(3):573‐86. ">Felson 2011</a>)). </p> </section> <section id="CD010455-sec-0033"> <h4 class="title">Types of interventions</h4> <p>Protocolised down‐titration or discontinuation of the anti‐TNF agent for optimal dose finding (not for other reasons, including reduction of side effects, availability, planned surgery, pregnancy). Non‐protocolised change in medication (DMARDs, non‐steroidal anti‐inflammatory drugs (NSAIDs), corticosteroids) was allowed. Comparison was usual care/no down‐titration/continuation of anti‐TNF. </p> </section> <section id="CD010455-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD010455-sec-0035"> <h5 class="title">Major outcomes</h5> <p> <ul id="CD010455-list-0001"> <li> <p>Mean disease activity score; DAS28/DAS/CDAI/SDAI at six, 12, 18, and 24 months (<a href="./references#CD010455-bbs2-0051" title="AletahaD , SmolenJ . The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clinical and Experimental Rheumatology2005;23(Suppl 39):S100‐8. ">Aletaha 2005</a>; <a href="./references#CD010455-bbs2-0078" title="PrevooML , van't HofMA , KuperHH , vanLeeuwenMA , van dePutteLB , vanRielPL . Modified disease activity scores that include twenty‐eight‐joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis and Rheumatism1995;38(1):44‐8. ">Prevoo 1995</a>; <a href="./references#CD010455-bbs2-0089" title="SmolenJS , BreedveldFC , SchiffMH , KaldenJR , EmeryP , EberlG , et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford)2003;42(2):244‐57. ">Smolen 2003</a>; <a href="./references#CD010455-bbs2-0097" title="van derHeijdeDM , van't HofMA , vanRielPL , TheunisseLA , LubbertsEW , vanLeeuwenMA , et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Annals of the Rheumatic Diseases1990;49(11):916‐20. ">van der Heijde 1990</a>). </p> </li> <li> <p>Proportion of participants with persistent remission (as specified above) after six, 12, 18, and 24 months. </p> </li> <li> <p>Proportion of participants that switched to another biologic due to persistent loss of response, refractory to re‐instalment of the tapered anti‐TNF in the intervention group. </p> </li> <li> <p>Proportion of participants with minimal radiographic progression, as measured by Larsen (<a href="./references#CD010455-bbs2-0073" title="LarsenA . A radiological method for grading the severity of rheumatoid arthritis. Scandinavian Journal of Rheumatology1973;4(4):225‐33. ">Larsen 1973</a>), Sharp (<a href="./references#CD010455-bbs2-0084" title="SharpJT , LidskyMD , CollinsLC , MorelandJ . Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis and Rheumatism1971;14(6):706‐20. ">Sharp 1971</a>), or modified Sharp‐van der Heijde score (mSvdH score) (<a href="./references#CD010455-bbs2-0098" title="van derHeijdeD . How to read radiographs according to the Sharp/van der Heijde method. Journal of Rheumatology2000;27(1):261‐3. ">van der Heijde 2000</a>). </p> </li> <li> <p>Function (as measured by Health Assessment Questionnaire (HAQ)/Arthritis Impact Measurement Scale (AIMS)). </p> </li> <li> <p>Number of serious adverse events.</p> </li> <li> <p>Withdrawals due to adverse events.</p> </li> </ul> </p> </section> <section id="CD010455-sec-0036"> <h5 class="title">Minor outcomes</h5> <p> <ul id="CD010455-list-0002"> <li> <p>Proportion of participants with a flare (or loss of response) (defined as any composite disease activity index–based flare criteria) during follow‐up time. </p> </li> <li> <p>Quality of life as measured by Short Form (SF) Health Survey‐12/36, Health Utilities Index (HUI), or EuroQoL Quality of Life Scale (EQ‐5D). </p> </li> <li> <p>Costs (direct (e.g. medication, consultations, travel costs) and indirect (e.g. health‐related absenteeism)). </p> </li> <li> <p>Decremental cost‐effectiveness ratio (difference in costs divided by difference in quality of life expressed as utility, thus the potential savings when accepting the loss of one quality‐adjusted life year (QALY)). </p> </li> <li> <p>Time to flare.</p> </li> <li> <p>Change in other medication (including DMARDs, NSAIDs, corticosteroids).</p> </li> </ul> </p> </section> </section> </section> <section id="CD010455-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010455-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases: MEDLINE (1946 to 29 March 2018), Embase (1974 to 29 March 2018), Web of Science (1945 to 2018) and the Cochrane Central Register of Controlled Trials (CENTRAL) 2018 issue 3. The specific search strategy for each of the databases is shown in the appendices (<a href="./appendices#CD010455-sec-0114">Appendix 1</a>; <a href="./appendices#CD010455-sec-0115">Appendix 2</a>; <a href="./appendices#CD010455-sec-0116">Appendix 3</a>; <a href="./appendices#CD010455-sec-0117">Appendix 4</a>). Our search was not limited by language, year of publication, or publication type. The search period for all databases extended from inception to September 2013 for the original review, and from 2013 to 29 March 2018 for the update. </p> </section> <section id="CD010455-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We searched proceedings of conferences from 2005 to 2017 of the ACR and from 2005 to 2017 of the European League Against Rheumatism (EULAR) for abstracts of RCTs and CCTs. We searched reference lists of identified clinical trials and performed citation tracking of the included trials in the ISI Web of Knowledge citation index. We searched trial registries for completed and ongoing trials (<a href="./appendices#CD010455-sec-0118">Appendix 5</a>). We contacted experts (first authors of included studies) to ask about additional trials. </p> </section> </section> <section id="CD010455-sec-0040"> <h3 class="title" id="CD010455-sec-0040">Data collection and analysis</h3> <section id="CD010455-sec-0041"> <h4 class="title">Selection of studies</h4> <p>We selected studies based on the inclusion criteria outlined in the <a href="#CD010455-sec-0030">Criteria for considering studies for this review</a> section. Two review authors (NvH and BJFvdB for the original review; LMV and BJFvdB for the update) independently screened titles and abstracts for inclusion, obtaining full articles if necessary. Any differences were resolved by discussion and consensus or by consultation with a third review author (AAdB) if needed. In case the same study population was described in more than one publication, all publications were used, but for the analysis, all were grouped, with the most informative publication as the primary reference and with other publications as secondary references. We recorded reasons for exclusion of studies. </p> </section> <section id="CD010455-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (NvH and BJFvdB for the original review; LMV and BJFvdB for the update) independently abstracted data from each study using a data extraction form. Any differences were resolved by discussion and consensus or by consultation with a third review author (AAdB) if needed. We pilot‐tested the data extraction form on a selection of trials. If necessary, we contacted the authors of a given study to ask for missing data. </p> <p>We extracted the following data.</p> <p> <ul id="CD010455-list-0003"> <li> <p>General study information: first author, author affiliation, publication source, publication year, and source of funding. </p> </li> <li> <p>Study characteristics: design, setting, participant selection, method of randomisation, allocation procedure, blinding, inclusion/exclusion criteria, and study duration. </p> </li> <li> <p>Population characteristics: age, sex, diagnostic criteria, disease duration, DMARD comedication, previous DMARD use, previous anti‐TNF use, rheumatoid factor status, anti–cyclic citrullinated peptide (CCP) status, disease activity state, total number of participants screened, total number of participants recruited, total number of participants randomly assigned, total number of participants followed, and numbers in each group. </p> </li> <li> <p>Intervention characteristics: anti‐TNF agent, type of intervention (dose reduction/interval widening/discontinuation), treatment comparators. </p> </li> <li> <p>Outcome measures as noted above.</p> </li> <li> <p>Analysis: statistical technique used, intention‐to‐treat analyses and/or per‐protocol analyses used. </p> </li> <li> <p>Results with number, mean and standard deviation.</p> </li> </ul> </p> </section> <section id="CD010455-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (NvH and BJFvdB for the original review; LMV and BJFvdB for the update) assessed risk of bias in the included studies in accordance with the recommendations in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./appendices#CD010455-sec-0119">Appendix 6</a>) (<a href="./references#CD010455-bbs2-0069" title="HigginsJPT , GreenS (editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> <p>We assessed the following 'Risk of bias' domains.</p> <p> <ul id="CD010455-list-0004"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective reporting.</p> </li> <li> <p>Other sources of bias (baseline imbalance in possible prognostic variables: DMARD comedication, duration of anti‐TNF use, and disease duration). </p> </li> </ul> </p> <p>We judged each of these domains as having low, high, or unclear risk of bias.</p> </section> <section id="CD010455-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed the results of the included studies using <a href="./references#CD010455-bbs2-0080" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>. Continuous data were expressed as mean differences (MDs) or standardised mean differences (SMDs). Dichotomous data were expressed as risk ratios (RRs). Rates were expressed as rate ratios (RaRs). We summarised data in meta‐analyses if the studies were sufficiently homogeneous, both clinically and statistically. </p> </section> <section id="CD010455-sec-0045"> <h4 class="title">Unit of analysis issues</h4> <p>The participant was the unit of analysis. Post‐hoc, it was chosen to pool the data from the two dose reduction arms in the study by <a href="./references#CD010455-bbs2-0006" title="GallowayJB , KingsleyG , MaM , Lorente‐CanovasB , CopeA , IbrahimF , et al. Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial. Annals of the Rheumatic Diseases2015;74 (Suppl 2):706. IbrahimF , Lorente‐CánovasB , DoréCJ , BosworthA , MaMH , GallowayJB , et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis ‐ a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology2017;56:2004‐14. [PUBMED: 28968858] ">Ibrahim 2017 (OPTTIRA)</a> for outcomes in which data from multiple studies could be pooled because this facilitated comparison with the 50% dose reduction applied in all other included dose reduction studies (mean dose reduction of 33% and 66% being 50%). </p> </section> <section id="CD010455-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>We accepted missing clinical data in trials when they represented less than 20% of findings. We planned to perform a sensitivity analysis if more than 20% of the data from a given study were missing in order to explore the impact of including or excluding such studies. We attempted to obtain missing information on parameter variability by contacting the authors of the trial. In the event that study authors were not able or were unwilling to provide this information, it was estimated from ranges if provided or from comparable trials. </p> </section> <section id="CD010455-sec-0047"> <h4 class="title">Assessment of heterogeneity</h4> <p>We evaluated heterogeneity first clinically by considering comparability across trials on the following variables: type of intervention (dose reduction/discontinuation/disease activity–guided dose tapering), type of anti‐TNF agent, duration of anti‐TNF use, baseline disease activity (low disease activity versus remission), disease duration, DMARD comedication, and presence of anti‐TNF rescue strategy. We examined forest plots and tested for heterogeneity using the Chi<sup>2</sup> test with a P &lt; 0.10 indicating significant heterogeneity. We used the I<sup>2</sup> statistic to describe the percentage of variability in effect estimates that is due to heterogeneity rather than to chance (<a href="./references#CD010455-bbs2-0068" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>). A value greater than 50% may indicate substantial heterogeneity (<a href="./references#CD010455-bbs2-0069" title="HigginsJPT , GreenS (editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). If we detected significant heterogeneity (I<sup>2</sup> &gt; 80%), we did not pool data but performed subgroup analyses in an attempt to explain the heterogeneity. </p> </section> <section id="CD010455-sec-0048"> <h4 class="title">Assessment of reporting biases</h4> <p>Publication bias implies that studies that report favourable results are more likely to be published than those describing negative or inconclusive (non‐significant) results, leading to a bias in the overall published literature. To minimise the effect of selective reporting of results, we searched trial registries for completed but unpublished studies. We planned to use a funnel plot to assess potential publication bias. However, due to the small number of studies, the funnel plot was not informative. We also searched the trial registries for ongoing studies that are potentially interesting for a future update of this review (see <a href="./references#CD010455-sec-0136" title="">Characteristics of ongoing studies</a> for details), and for additional data on included studies. </p> <p>We assessed reporting bias at the outcome level by using published protocols of the studies along with published results of the study to compare outcomes intended to be analysed with those actually analysed. </p> </section> <section id="CD010455-sec-0049"> <h4 class="title">Data synthesis</h4> <p>When possible, we analysed data using an intention‐to‐treat model and, for non‐inferiority studies, by also using a per‐protocol model. Our reason for this was that intention‐to‐treat analyses can lead to false conclusions of non‐inferiority in non‐inferiority trials. We analysed outcomes of included studies using a random‐effects model. </p> </section> <section id="CD010455-sec-0050"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned that if sufficient data were available we would perform subgroup analyses for the following candidate effect modifiers: type of intervention (dose reduction/discontinuation/disease activity–guided dose tapering), type of anti‐TNF agent, duration of anti‐TNF use, baseline disease activity (low disease activity versus remission), disease duration, DMARD comedication, and presence of anti‐TNF rescue strategy. </p> </section> <section id="CD010455-sec-0051"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform the following sensitivity analyses when possible.</p> <p> <ul id="CD010455-list-0005"> <li> <p>Effect of risk of bias of included studies.</p> </li> <li> <p>Effect of imputation of missing data or statistical transformations.</p> </li> </ul> </p> <section id="CD010455-sec-0052"> <h5 class="title">'Summary of findings' tables</h5> <p>We completed three separate 'Summary of findings' tables included in <a href="./references#CD010455-bbs2-0080" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a> to improve the readability of the review. We examined seven outcomes in a table for each of the three subgroups of down‐titration: (1) dose reduction, (2) discontinuation, and (3) disease activity–guided dose tapering. The study population consisted of people with RA with low disease activity using a standard dose of anti‐TNF. The intervention provided was down‐titration (dose reduction, discontinuation, or disease activity–guided dose tapering). The intervention was compared with usual care (continuation or no formalised dose reduction of anti‐TNF). In addition to the absolute and relative magnitude of effect, the number needed to treat for an additional beneficial outcome (NNTB) and number needed to treat for an additional harmful outcome (NNTH) were calculated by comparing the intervention group with the control group. We used <a href="./references#CD010455-bbs2-0067" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed on 28 June 2018. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEpro 2015</a> to conduct an overall grading of the quality of evidence. </p> <p>The GRADE approach specifies four levels of certainty (high, moderate, low, and very low). The highest certainty rating is given for randomised trial evidence. Randomised trial evidence can be downgraded to moderate, low, or very low depending on the presence of five factors. </p> <p> <ul id="CD010455-list-0006"> <li> <p>Limitations in the design and implementation of available studies suggesting high likelihood of bias. </p> </li> <li> <p>Indirectness of evidence.</p> </li> <li> <p>Unexplained heterogeneity or inconsistency of results.</p> </li> <li> <p>Imprecision of results.</p> </li> <li> <p>High probability of publication bias.</p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010455-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010455-sec-0053"></div> <section id="CD010455-sec-0054"> <h3 class="title">Description of studies</h3> <p>The results of the search are presented in <a href="#CD010455-fig-0001">Figure 1</a> and are described in detail in the following sections of the review. </p> <div class="figure" id="CD010455-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow chart of study selection." data-id="CD010455-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow chart of study selection.</p> </div> </div> </div> <section id="CD010455-sec-0055"> <h4 class="title">Results of the search</h4> <p>The previous version of this review included seven studies. Database searches for this update (2013 to March 2018) resulted in 2352 records, and after de‐duplication 1565 search results. Reference checking, contact with experts, and performing additional searches in congress abstract databases and trial registers resulted in 42 additional records. After title and abstract screening of these 1607 records, 21 studies remained. After assessing these 21 studies for eligibility, we identified eight new studies for inclusion in the review. One of the previously included studies, <a href="./references#CD010455-bbs2-0023" title="HarigaiM , TakeuchiT , Tanaka , Y , MatsubaraT , YamanakaH , MiyasakaN . Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. Modern Rheumatology2012;22:814‐22. ">Harigai 2012 (BRIGHT)</a>, was retrospectively excluded for this updated version of the review because we considered their method of allocation (at the discretion of the physician) as not random or quasi‐random, which is a prerequisite for the classification as RCT or CCT. Newly found studies that used allocation based on physician or patient preference were also not included in this updated version (<a href="./references#CD010455-bbs2-0038" title="TanakaY , HirataS , KuboS , FukuyoS , HanamiK , SawamukaiN , et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1‐year outcome of the HONOR study. Annals of the Rheumatic Diseases2015;74:389‐95. [PUBMED: 24288014] ">Tanaka 2013 (HONOR)</a>; <a href="./references#CD010455-bbs2-0039" title="TanakaY , YamanakaH , IshiguroN , MiyasakaN , KawanaK , HiramatsuK , et al. Attainment of low disease activity is predictive of maintenance of disease control upon adalimumab discontinuation for two years following combination therapy in Japanese patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2014;66:S1059. [Abstract number: 2427] ">Tanaka 2014 (HOPEFUL‐2)</a>). Finally, a total of 14 studies were included in this update of the systematic review, consisting of six old studies and eight new studies. All of the old studies were now available as full text. Of the eight new studies, one was published as abstract and seven as full text. </p> <p>We contacted the authors of 11 studies to obtain missing data or to clarify methods/results. We received a response from authors of 10 studies. </p> <p>The total number of participants in the studies included in this review was 3315. Most participants (2111) were included in the eight studies comparing anti‐TNF discontinuation versus anti‐TNF continuation. Six studies (1148 participants) compared anti‐TNF dose reduction versus continuation. Three studies (365 participants) compared disease activity–guided anti‐TNF dose tapering versus continuation. Eleven studies used a superiority design; two studies used a non‐inferiority design; and one study reported an equivalence design. </p> </section> <section id="CD010455-sec-0056"> <h4 class="title">Included studies</h4> <section id="CD010455-sec-0057"> <h5 class="title">Anti‐TNF dose reduction versus anti‐TNF continuation studies</h5> <section id="CD010455-sec-0058"> <h6 class="title">Design</h6> <p>Six studies compared anti‐TNF fixed‐dose reduction versus anti‐TNF continuation (<a href="./references#CD010455-bbs2-0003" title="ElMiedanyY , ElGaafaryM , AhmedI , BahlasS , HegaziM , NasrA . Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission. Clinical Rheumatology2016;35:2915‐23. [PUBMED: 27658417] ">El Miedany 2016</a>; <a href="./references#CD010455-bbs2-0006" title="GallowayJB , KingsleyG , MaM , Lorente‐CanovasB , CopeA , IbrahimF , et al. Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial. Annals of the Rheumatic Diseases2015;74 (Suppl 2):706. IbrahimF , Lorente‐CánovasB , DoréCJ , BosworthA , MaMH , GallowayJB , et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis ‐ a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology2017;56:2004‐14. [PUBMED: 28968858] ">Ibrahim 2017 (OPTTIRA)</a>; <a href="./references#CD010455-bbs2-0008" title="BotsiosC , FurlanA , OstuniP , SfrisoP , TodescoS , PunziL . Effects of low‐dose etanercept in maintaining DAS‐remission previously achieved with standard‐dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2007;66(Suppl II):54. RaffeinerB , BotsiosC , OmettoF , BernardiL , StramareR , TodescoS , et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology2015;33:63‐8. [PUBMED: 25535985] ">Raffeiner 2015</a>; <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a>; <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a>; <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a>). <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a>, <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a>, and <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a> were randomised, blinded, placebo‐controlled, superiority studies that reported three arms (discontinuation, dose reduction, and continuation). The randomisation ratio was 1:1:1 for <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a> and <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a>; for <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a> this was 2:3:2 (stop; dose reduction; continuation). <a href="./references#CD010455-bbs2-0003" title="ElMiedanyY , ElGaafaryM , AhmedI , BahlasS , HegaziM , NasrA . Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission. Clinical Rheumatology2016;35:2915‐23. [PUBMED: 27658417] ">El Miedany 2016</a>, <a href="./references#CD010455-bbs2-0008" title="BotsiosC , FurlanA , OstuniP , SfrisoP , TodescoS , PunziL . Effects of low‐dose etanercept in maintaining DAS‐remission previously achieved with standard‐dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2007;66(Suppl II):54. RaffeinerB , BotsiosC , OmettoF , BernardiL , StramareR , TodescoS , et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology2015;33:63‐8. [PUBMED: 25535985] ">Raffeiner 2015</a>, and <a href="./references#CD010455-bbs2-0006" title="GallowayJB , KingsleyG , MaM , Lorente‐CanovasB , CopeA , IbrahimF , et al. Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial. Annals of the Rheumatic Diseases2015;74 (Suppl 2):706. IbrahimF , Lorente‐CánovasB , DoréCJ , BosworthA , MaMH , GallowayJB , et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis ‐ a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology2017;56:2004‐14. [PUBMED: 28968858] ">Ibrahim 2017 (OPTTIRA)</a> were open‐label superiority studies. The study by <a href="./references#CD010455-bbs2-0008" title="BotsiosC , FurlanA , OstuniP , SfrisoP , TodescoS , PunziL . Effects of low‐dose etanercept in maintaining DAS‐remission previously achieved with standard‐dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2007;66(Suppl II):54. RaffeinerB , BotsiosC , OmettoF , BernardiL , StramareR , TodescoS , et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology2015;33:63‐8. [PUBMED: 25535985] ">Raffeiner 2015</a> was reported as a prospective long‐term follow‐up study; randomisation was done in a consecutive manner (alternation) in a ratio 1:1, which we defined as quasi‐random, making the study a CCT. The randomisation ratio for <a href="./references#CD010455-bbs2-0006" title="GallowayJB , KingsleyG , MaM , Lorente‐CanovasB , CopeA , IbrahimF , et al. Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial. Annals of the Rheumatic Diseases2015;74 (Suppl 2):706. IbrahimF , Lorente‐CánovasB , DoréCJ , BosworthA , MaMH , GallowayJB , et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis ‐ a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology2017;56:2004‐14. [PUBMED: 28968858] ">Ibrahim 2017 (OPTTIRA)</a> was 1:1:2, and for <a href="./references#CD010455-bbs2-0003" title="ElMiedanyY , ElGaafaryM , AhmedI , BahlasS , HegaziM , NasrA . Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission. Clinical Rheumatology2016;35:2915‐23. [PUBMED: 27658417] ">El Miedany 2016</a> it was 1:1:1:1:1 (only group 1 and group 5 were relevant for this review). </p> <p>The duration of the included studies was 6 months in <a href="./references#CD010455-bbs2-0006" title="GallowayJB , KingsleyG , MaM , Lorente‐CanovasB , CopeA , IbrahimF , et al. Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial. Annals of the Rheumatic Diseases2015;74 (Suppl 2):706. IbrahimF , Lorente‐CánovasB , DoréCJ , BosworthA , MaMH , GallowayJB , et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis ‐ a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology2017;56:2004‐14. [PUBMED: 28968858] ">Ibrahim 2017 (OPTTIRA)</a>; 40 weeks in <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a>; 52 weeks in <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a>, <a href="./references#CD010455-bbs2-0003" title="ElMiedanyY , ElGaafaryM , AhmedI , BahlasS , HegaziM , NasrA . Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission. Clinical Rheumatology2016;35:2915‐23. [PUBMED: 27658417] ">El Miedany 2016</a>, and <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a>; and a mean follow‐up of 3.5 ± 1.5 years in <a href="./references#CD010455-bbs2-0008" title="BotsiosC , FurlanA , OstuniP , SfrisoP , TodescoS , PunziL . Effects of low‐dose etanercept in maintaining DAS‐remission previously achieved with standard‐dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2007;66(Suppl II):54. RaffeinerB , BotsiosC , OmettoF , BernardiL , StramareR , TodescoS , et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology2015;33:63‐8. [PUBMED: 25535985] ">Raffeiner 2015</a>. The study by <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a> had a total follow‐up of 88 weeks, however 52 weeks of follow‐up were provided after randomisation for dose reduction or continuation of etanercept. The total follow‐up for <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a> was 48 weeks, and 40 weeks of follow‐up were provided after randomisation for dose reduction or continuation of etanercept. The study by <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a> describes period 2 of the C‐EARLY study with a duration of 52 weeks, which was a re‐randomisation of participants from the first period, which also lasted 52 weeks. </p> </section> <section id="CD010455-sec-0059"> <h6 class="title">Sample size</h6> <p>The sample size for this comparison varied from 50 participants in the study by <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a> (73 participants in total study due to multiple intervention arms) to 404 participants in <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a> (604 participants in total study due to multiple intervention arms). </p> </section> <section id="CD010455-sec-0060"> <h6 class="title">Setting</h6> <p><a href="./references#CD010455-bbs2-0006" title="GallowayJB , KingsleyG , MaM , Lorente‐CanovasB , CopeA , IbrahimF , et al. Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial. Annals of the Rheumatic Diseases2015;74 (Suppl 2):706. IbrahimF , Lorente‐CánovasB , DoréCJ , BosworthA , MaMH , GallowayJB , et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis ‐ a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology2017;56:2004‐14. [PUBMED: 28968858] ">Ibrahim 2017 (OPTTIRA)</a> reported that participants were screened at 20 centres in the United Kingdom. The study by <a href="./references#CD010455-bbs2-0008" title="BotsiosC , FurlanA , OstuniP , SfrisoP , TodescoS , PunziL . Effects of low‐dose etanercept in maintaining DAS‐remission previously achieved with standard‐dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2007;66(Suppl II):54. RaffeinerB , BotsiosC , OmettoF , BernardiL , StramareR , TodescoS , et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology2015;33:63‐8. [PUBMED: 25535985] ">Raffeiner 2015</a> was reported as a single‐centre study in Italy. <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a> was reported to have been conducted in 80 centres in Europe, Latin America, Asia, and Australia. The study by <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a> was performed in 16 rheumatology units in Sweden (5), Denmark (2), Finland (2), Norway (3), Hungary (3), and Iceland (1). <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a> reported that it recruited participants at 103 centres in in Europe, Australia, North America, and Latin America. <a href="./references#CD010455-bbs2-0003" title="ElMiedanyY , ElGaafaryM , AhmedI , BahlasS , HegaziM , NasrA . Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission. Clinical Rheumatology2016;35:2915‐23. [PUBMED: 27658417] ">El Miedany 2016</a> did not report a specific setting. </p> </section> <section id="CD010455-sec-0061"> <h6 class="title">Participants</h6> <p><a href="./references#CD010455-bbs2-0003" title="ElMiedanyY , ElGaafaryM , AhmedI , BahlasS , HegaziM , NasrA . Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission. Clinical Rheumatology2016;35:2915‐23. [PUBMED: 27658417] ">El Miedany 2016</a> did not provide information on participant characteristics. Most participants were female in the studies by <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a>, <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a>, <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a>, and <a href="./references#CD010455-bbs2-0008" title="BotsiosC , FurlanA , OstuniP , SfrisoP , TodescoS , PunziL . Effects of low‐dose etanercept in maintaining DAS‐remission previously achieved with standard‐dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2007;66(Suppl II):54. RaffeinerB , BotsiosC , OmettoF , BernardiL , StramareR , TodescoS , et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology2015;33:63‐8. [PUBMED: 25535985] ">Raffeiner 2015</a>. Mean age was approximately 47 years in <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a>; 49 years in <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a>; 56 years in <a href="./references#CD010455-bbs2-0008" title="BotsiosC , FurlanA , OstuniP , SfrisoP , TodescoS , PunziL . Effects of low‐dose etanercept in maintaining DAS‐remission previously achieved with standard‐dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2007;66(Suppl II):54. RaffeinerB , BotsiosC , OmettoF , BernardiL , StramareR , TodescoS , et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology2015;33:63‐8. [PUBMED: 25535985] ">Raffeiner 2015</a>; and 57 years in <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a> and <a href="./references#CD010455-bbs2-0006" title="GallowayJB , KingsleyG , MaM , Lorente‐CanovasB , CopeA , IbrahimF , et al. Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial. Annals of the Rheumatic Diseases2015;74 (Suppl 2):706. IbrahimF , Lorente‐CánovasB , DoréCJ , BosworthA , MaMH , GallowayJB , et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis ‐ a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology2017;56:2004‐14. [PUBMED: 28968858] ">Ibrahim 2017 (OPTTIRA)</a>. Disease duration ranged from around 2.6 months in <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a> (median disease duration at baseline of C‐EARLY period 1) to 14 years in <a href="./references#CD010455-bbs2-0008" title="BotsiosC , FurlanA , OstuniP , SfrisoP , TodescoS , PunziL . Effects of low‐dose etanercept in maintaining DAS‐remission previously achieved with standard‐dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2007;66(Suppl II):54. RaffeinerB , BotsiosC , OmettoF , BernardiL , StramareR , TodescoS , et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology2015;33:63‐8. [PUBMED: 25535985] ">Raffeiner 2015</a> and <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a>. Duration of anti‐TNF agents had to be &gt; 3 months in <a href="./references#CD010455-bbs2-0006" title="GallowayJB , KingsleyG , MaM , Lorente‐CanovasB , CopeA , IbrahimF , et al. Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial. Annals of the Rheumatic Diseases2015;74 (Suppl 2):706. IbrahimF , Lorente‐CánovasB , DoréCJ , BosworthA , MaMH , GallowayJB , et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis ‐ a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology2017;56:2004‐14. [PUBMED: 28968858] ">Ibrahim 2017 (OPTTIRA)</a>; ≥ 6 months in <a href="./references#CD010455-bbs2-0003" title="ElMiedanyY , ElGaafaryM , AhmedI , BahlasS , HegaziM , NasrA . Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission. Clinical Rheumatology2016;35:2915‐23. [PUBMED: 27658417] ">El Miedany 2016</a>; ≥ 12 months in <a href="./references#CD010455-bbs2-0008" title="BotsiosC , FurlanA , OstuniP , SfrisoP , TodescoS , PunziL . Effects of low‐dose etanercept in maintaining DAS‐remission previously achieved with standard‐dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2007;66(Suppl II):54. RaffeinerB , BotsiosC , OmettoF , BernardiL , StramareR , TodescoS , et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology2015;33:63‐8. [PUBMED: 25535985] ">Raffeiner 2015</a>; and ≥ 14 months in <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a>. <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a> started the anti‐TNF agent at study start 36 weeks before randomisation for dose reduction or discontinuation. In the study by <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a>, all participants had started certolizumab pegol treatment one year earlier (period 1 of C‐EARLY). <a href="./references#CD010455-bbs2-0003" title="ElMiedanyY , ElGaafaryM , AhmedI , BahlasS , HegaziM , NasrA . Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission. Clinical Rheumatology2016;35:2915‐23. [PUBMED: 27658417] ">El Miedany 2016</a> and <a href="./references#CD010455-bbs2-0006" title="GallowayJB , KingsleyG , MaM , Lorente‐CanovasB , CopeA , IbrahimF , et al. Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial. Annals of the Rheumatic Diseases2015;74 (Suppl 2):706. IbrahimF , Lorente‐CánovasB , DoréCJ , BosworthA , MaMH , GallowayJB , et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis ‐ a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology2017;56:2004‐14. [PUBMED: 28968858] ">Ibrahim 2017 (OPTTIRA)</a> did not report previous use of DMARDs. Participants in <a href="./references#CD010455-bbs2-0008" title="BotsiosC , FurlanA , OstuniP , SfrisoP , TodescoS , PunziL . Effects of low‐dose etanercept in maintaining DAS‐remission previously achieved with standard‐dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2007;66(Suppl II):54. RaffeinerB , BotsiosC , OmettoF , BernardiL , StramareR , TodescoS , et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology2015;33:63‐8. [PUBMED: 25535985] ">Raffeiner 2015</a> and <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a> were biologic disease‐modifying antirheumatic drug (bDMARD) naive before the study. <a href="./references#CD010455-bbs2-0008" title="BotsiosC , FurlanA , OstuniP , SfrisoP , TodescoS , PunziL . Effects of low‐dose etanercept in maintaining DAS‐remission previously achieved with standard‐dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2007;66(Suppl II):54. RaffeinerB , BotsiosC , OmettoF , BernardiL , StramareR , TodescoS , et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology2015;33:63‐8. [PUBMED: 25535985] ">Raffeiner 2015</a> reported a mean (standard deviation (SD)) of 2.4 (1.1) previously used DMARDs in the dose reduction group and 2.4 (1.3) in the continuation group. Participants in <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a> were bDMARD and conventional synthetic disease‐modifying antirheumatic drug (csDMARD) naive. <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a> described that 66% of the participants had used a DMARD other than methotrexate (MTX) before the study. </p> <p>In all included studies, participants had to have low disease activity, <a href="./references#CD010455-bbs2-0006" title="GallowayJB , KingsleyG , MaM , Lorente‐CanovasB , CopeA , IbrahimF , et al. Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial. Annals of the Rheumatic Diseases2015;74 (Suppl 2):706. IbrahimF , Lorente‐CánovasB , DoréCJ , BosworthA , MaMH , GallowayJB , et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis ‐ a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology2017;56:2004‐14. [PUBMED: 28968858] ">Ibrahim 2017 (OPTTIRA)</a>; <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a>; <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a>; <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a>, or remission, <a href="./references#CD010455-bbs2-0003" title="ElMiedanyY , ElGaafaryM , AhmedI , BahlasS , HegaziM , NasrA . Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission. Clinical Rheumatology2016;35:2915‐23. [PUBMED: 27658417] ">El Miedany 2016</a>; <a href="./references#CD010455-bbs2-0008" title="BotsiosC , FurlanA , OstuniP , SfrisoP , TodescoS , PunziL . Effects of low‐dose etanercept in maintaining DAS‐remission previously achieved with standard‐dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2007;66(Suppl II):54. RaffeinerB , BotsiosC , OmettoF , BernardiL , StramareR , TodescoS , et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology2015;33:63‐8. [PUBMED: 25535985] ">Raffeiner 2015</a>. Duration of low disease activity/remission had to be &gt; 3 months in <a href="./references#CD010455-bbs2-0006" title="GallowayJB , KingsleyG , MaM , Lorente‐CanovasB , CopeA , IbrahimF , et al. Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial. Annals of the Rheumatic Diseases2015;74 (Suppl 2):706. IbrahimF , Lorente‐CánovasB , DoréCJ , BosworthA , MaMH , GallowayJB , et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis ‐ a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology2017;56:2004‐14. [PUBMED: 28968858] ">Ibrahim 2017 (OPTTIRA)</a>; ≥ 6 months in <a href="./references#CD010455-bbs2-0003" title="ElMiedanyY , ElGaafaryM , AhmedI , BahlasS , HegaziM , NasrA . Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission. Clinical Rheumatology2016;35:2915‐23. [PUBMED: 27658417] ">El Miedany 2016</a>; ≥ 12 months in <a href="./references#CD010455-bbs2-0008" title="BotsiosC , FurlanA , OstuniP , SfrisoP , TodescoS , PunziL . Effects of low‐dose etanercept in maintaining DAS‐remission previously achieved with standard‐dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2007;66(Suppl II):54. RaffeinerB , BotsiosC , OmettoF , BernardiL , StramareR , TodescoS , et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology2015;33:63‐8. [PUBMED: 25535985] ">Raffeiner 2015</a>; or ≥ 11 months in <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a>. Participants in the study by <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a> had to have a mean DAS28 ≤ 3.2 in the 24‐week period before randomisation and a DAS28 ≤ 3.2 at the moment of randomisation. In the study by <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a>, participants needed to have a DAS28 ≤ 3.2 12 weeks before randomisation and at the moment of randomisation. All included studies used a DAS28‐based criterion to define low disease activity or remission. </p> </section> <section id="CD010455-sec-0062"> <h6 class="title">Intervention and comedication</h6> <p><a href="./references#CD010455-bbs2-0008" title="BotsiosC , FurlanA , OstuniP , SfrisoP , TodescoS , PunziL . Effects of low‐dose etanercept in maintaining DAS‐remission previously achieved with standard‐dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2007;66(Suppl II):54. RaffeinerB , BotsiosC , OmettoF , BernardiL , StramareR , TodescoS , et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology2015;33:63‐8. [PUBMED: 25535985] ">Raffeiner 2015</a> reported etanercept dose reduction by comparing etanercept 25 mg twice a week versus etanercept 25 mg once a week. <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a> and <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a> reported etanercept dose reduction (25 mg/week) compared with etanercept continuation (50 mg/week). <a href="./references#CD010455-bbs2-0006" title="GallowayJB , KingsleyG , MaM , Lorente‐CanovasB , CopeA , IbrahimF , et al. Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial. Annals of the Rheumatic Diseases2015;74 (Suppl 2):706. IbrahimF , Lorente‐CánovasB , DoréCJ , BosworthA , MaMH , GallowayJB , et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis ‐ a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology2017;56:2004‐14. [PUBMED: 28968858] ">Ibrahim 2017 (OPTTIRA)</a> reported 33% and 66% dose reduction of adalimumab and etanercept versus 100%. <a href="./references#CD010455-bbs2-0003" title="ElMiedanyY , ElGaafaryM , AhmedI , BahlasS , HegaziM , NasrA . Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission. Clinical Rheumatology2016;35:2915‐23. [PUBMED: 27658417] ">El Miedany 2016</a> reported 50% dose reduction of bDMARDs versus continuation. <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a> reported 50% dose reduction of certrolizumab pegol (200 mg/4 weeks) versus continuation (200 mg/2 weeks). Participants were required to use MTX comedication (dose ranged from 7.5 to 25 mg/week) in <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a> and <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a>. In <a href="./references#CD010455-bbs2-0008" title="BotsiosC , FurlanA , OstuniP , SfrisoP , TodescoS , PunziL . Effects of low‐dose etanercept in maintaining DAS‐remission previously achieved with standard‐dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2007;66(Suppl II):54. RaffeinerB , BotsiosC , OmettoF , BernardiL , StramareR , TodescoS , et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology2015;33:63‐8. [PUBMED: 25535985] ">Raffeiner 2015</a>, steroids, NSAIDs, and DMARDs were continued at the same dosages. No intra‐articular steroids were permitted during the study period. <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a> allowed up to three intra‐articular corticosteroid injections during the study. In the study by <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a>, participants continued MTX and other medications at the same dose. Participants in <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a> used MTX in the maximum tolerated ("optimised") dose throughout the study. Use of intra‐articular, intramuscular, or intravenous corticosteroids at any dose was prohibited. The maximum allowed dose of oral corticosteroids during the study was ≥ 10 mg/day prednisone or equivalent, and no changes in dose were allowed during the study period. In the study of <a href="./references#CD010455-bbs2-0003" title="ElMiedanyY , ElGaafaryM , AhmedI , BahlasS , HegaziM , NasrA . Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission. Clinical Rheumatology2016;35:2915‐23. [PUBMED: 27658417] ">El Miedany 2016</a>, participants in the relevant study arms used a stable dose of a csDMARD during the trial. No intramuscular or local steroid joint injections were allowed. In five studies (<a href="./references#CD010455-bbs2-0003" title="ElMiedanyY , ElGaafaryM , AhmedI , BahlasS , HegaziM , NasrA . Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission. Clinical Rheumatology2016;35:2915‐23. [PUBMED: 27658417] ">El Miedany 2016</a>; <a href="./references#CD010455-bbs2-0006" title="GallowayJB , KingsleyG , MaM , Lorente‐CanovasB , CopeA , IbrahimF , et al. Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial. Annals of the Rheumatic Diseases2015;74 (Suppl 2):706. IbrahimF , Lorente‐CánovasB , DoréCJ , BosworthA , MaMH , GallowayJB , et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis ‐ a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology2017;56:2004‐14. [PUBMED: 28968858] ">Ibrahim 2017 (OPTTIRA)</a>; <a href="./references#CD010455-bbs2-0008" title="BotsiosC , FurlanA , OstuniP , SfrisoP , TodescoS , PunziL . Effects of low‐dose etanercept in maintaining DAS‐remission previously achieved with standard‐dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2007;66(Suppl II):54. RaffeinerB , BotsiosC , OmettoF , BernardiL , StramareR , TodescoS , et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology2015;33:63‐8. [PUBMED: 25535985] ">Raffeiner 2015</a>; <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a>; <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a>), participants could return to their initial dose of anti‐TNF after disease flare. In <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a>, no attempt was made to recapture low disease activity by reintroducing etanercept in participants whose condition had deteriorated after etanercept withdrawal. </p> </section> <section id="CD010455-sec-0063"> <h6 class="title">Outcomes</h6> <p>All studies reported a primary outcome measure. Three studies reported proportion of participants with low disease activity or remission as the primary outcome. <a href="./references#CD010455-bbs2-0008" title="BotsiosC , FurlanA , OstuniP , SfrisoP , TodescoS , PunziL . Effects of low‐dose etanercept in maintaining DAS‐remission previously achieved with standard‐dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2007;66(Suppl II):54. RaffeinerB , BotsiosC , OmettoF , BernardiL , StramareR , TodescoS , et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology2015;33:63‐8. [PUBMED: 25535985] ">Raffeiner 2015</a> and <a href="./references#CD010455-bbs2-0003" title="ElMiedanyY , ElGaafaryM , AhmedI , BahlasS , HegaziM , NasrA . Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission. Clinical Rheumatology2016;35:2915‐23. [PUBMED: 27658417] ">El Miedany 2016</a> used DAS28 ≤ 2.6, and <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a> used DAS28 ≤ 3.2. The primary outcome in the study by <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a> was proportion of non‐failures for etanercept 50 mg/week versus placebo. The primary outcome for <a href="./references#CD010455-bbs2-0006" title="GallowayJB , KingsleyG , MaM , Lorente‐CanovasB , CopeA , IbrahimF , et al. Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial. Annals of the Rheumatic Diseases2015;74 (Suppl 2):706. IbrahimF , Lorente‐CánovasB , DoréCJ , BosworthA , MaMH , GallowayJB , et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis ‐ a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology2017;56:2004‐14. [PUBMED: 28968858] ">Ibrahim 2017 (OPTTIRA)</a> was reported to be time to flare. <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a> reported maintenance of low disease activity (disease activity score in 28 joints using erythrocyte sedimentation rate (DAS28‐ESR) of ≤ 3.2) for all 5 consecutive study visits to week 52 without flares as the primary outcome measure. Secondary outcomes reported in the included studies were very different. None of the included studies provided data on costs or change in comedication. All studies were analysed with a (modified) intention‐to‐treat approach. </p> </section> </section> <section id="CD010455-sec-0064"> <h5 class="title">Anti‐TNF discontinuation versus anti‐TNF continuation studies</h5> <section id="CD010455-sec-0065"> <h6 class="title">Design</h6> <p>Eight of the included studies reported anti‐TNF discontinuation compared with anti‐TNF continuation (<a href="./references#CD010455-bbs2-0002" title="ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. A multicentre, randomised, controlled, open‐label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open2016;2:e000133. [PUBMED: 26819752 ] ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. Multicenter, randomised, controlled, open‐label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients is stable clinical remission. Arthritis and Rheumatism2012;64(Suppl 10):776. ">Chatzidionysiou 2016 (ADMIRE)</a>; <a href="./references#CD010455-bbs2-0005" title="Ghiti MoghadamM , VonkemanHE , tenKloosterPM , TekstraJ , vanSchaardenburgD , Starmans‐KoolM , et al. Stopping tumor necrosis factor‐inhibitors in patients with established rheumatoid arthritis in remission or stable low disease activity: a pragmatic randomized multicenter open‐label controlled trial. Arthritis and Rheumatology2016;68(8):1810‐7. ">Ghiti Moghadam 2016 (POEET)</a>; <a href="./references#CD010455-bbs2-0007" title="NCT01578850 . Study conducted in subjects with rheumatoid arthritis who have moderate to severe disease activity despite methotrexate therapy with or without other non biologic disease modifying antirheumatic drugs (DMARDs) for at least 12 weeks prior to screening. https://clinicaltrials.gov/ct2/show/results/NCT01578850 First posted April 17, 2012. PavelkaK , AkkoçN , Al‐MainiM , ZerbiniCAF , KarateevDE , NasonovEL , et al. Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat‑to‑target study conducted in regions with limited biologic access. Rheumatology International2017;37:1469‐79. [PUBMED: 28597306] ">Pavelka 2017</a>; <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a>; <a href="./references#CD010455-bbs2-0010" title="EmeryP , SmolenJS , KavanaughA , vanVollenhovenR , PavelkaK , DurezP , et al. Maintenance of biologic‐free disease control in early rheumatoid arthritis patients after induction of low disease activity with adalimumab plus methotrexate. Annals of the Rheumatic Diseases2011;70 (Suppl 3):262. SmolenJS , EmeryP , FleischmannR , vanVollenhovenR , FlorentiusS , SantraS , et al. Biologic free disease control (BFDC) in early RA: predictors of successful withdrawal of adalimumab (ADA) after achieving stable low disease activity with ADA plus methotrexate (MTX) ‐ data from the OPTIMA study. Annals of the Rheumatic Diseases2012;71 (Suppl 3):516. SmolenJS , EmeryP , FleischmannR , vanVollenhovenRF , PavelkaK , DurezP , et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet2014;383:321‐32. [PUBMED: 24168956] ">Smolen 2014 (OPTIMA)</a>; <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a>; <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a>; <a href="./references#CD010455-bbs2-0014" title="YamanakaH , NagaokaS , LeeS , BaeS , KasamaT , KobayashiH , et al. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity ‐ results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Modern Rheumatology2016;26(5):651‐61. [PUBMED: 26698929] ">Yamanaka 2016 (ENCOURAGE)</a>). All included studies were randomised controlled superiority studies comparing anti‐TNF discontinuation versus continuation. <a href="./references#CD010455-bbs2-0010" title="EmeryP , SmolenJS , KavanaughA , vanVollenhovenR , PavelkaK , DurezP , et al. Maintenance of biologic‐free disease control in early rheumatoid arthritis patients after induction of low disease activity with adalimumab plus methotrexate. Annals of the Rheumatic Diseases2011;70 (Suppl 3):262. SmolenJS , EmeryP , FleischmannR , vanVollenhovenR , FlorentiusS , SantraS , et al. Biologic free disease control (BFDC) in early RA: predictors of successful withdrawal of adalimumab (ADA) after achieving stable low disease activity with ADA plus methotrexate (MTX) ‐ data from the OPTIMA study. Annals of the Rheumatic Diseases2012;71 (Suppl 3):516. SmolenJS , EmeryP , FleischmannR , vanVollenhovenRF , PavelkaK , DurezP , et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet2014;383:321‐32. [PUBMED: 24168956] ">Smolen 2014 (OPTIMA)</a>, <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a>, <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a>, <a href="./references#CD010455-bbs2-0007" title="NCT01578850 . Study conducted in subjects with rheumatoid arthritis who have moderate to severe disease activity despite methotrexate therapy with or without other non biologic disease modifying antirheumatic drugs (DMARDs) for at least 12 weeks prior to screening. https://clinicaltrials.gov/ct2/show/results/NCT01578850 First posted April 17, 2012. PavelkaK , AkkoçN , Al‐MainiM , ZerbiniCAF , KarateevDE , NasonovEL , et al. Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat‑to‑target study conducted in regions with limited biologic access. Rheumatology International2017;37:1469‐79. [PUBMED: 28597306] ">Pavelka 2017</a>, and <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a> were blinded placebo‐controlled studies. The other studies were open‐label studies (<a href="./references#CD010455-bbs2-0002" title="ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. A multicentre, randomised, controlled, open‐label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open2016;2:e000133. [PUBMED: 26819752 ] ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. Multicenter, randomised, controlled, open‐label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients is stable clinical remission. Arthritis and Rheumatism2012;64(Suppl 10):776. ">Chatzidionysiou 2016 (ADMIRE)</a>; <a href="./references#CD010455-bbs2-0005" title="Ghiti MoghadamM , VonkemanHE , tenKloosterPM , TekstraJ , vanSchaardenburgD , Starmans‐KoolM , et al. Stopping tumor necrosis factor‐inhibitors in patients with established rheumatoid arthritis in remission or stable low disease activity: a pragmatic randomized multicenter open‐label controlled trial. Arthritis and Rheumatology2016;68(8):1810‐7. ">Ghiti Moghadam 2016 (POEET)</a>; <a href="./references#CD010455-bbs2-0014" title="YamanakaH , NagaokaS , LeeS , BaeS , KasamaT , KobayashiH , et al. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity ‐ results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Modern Rheumatology2016;26(5):651‐61. [PUBMED: 26698929] ">Yamanaka 2016 (ENCOURAGE)</a>). <a href="./references#CD010455-bbs2-0002" title="ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. A multicentre, randomised, controlled, open‐label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open2016;2:e000133. [PUBMED: 26819752 ] ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. Multicenter, randomised, controlled, open‐label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients is stable clinical remission. Arthritis and Rheumatism2012;64(Suppl 10):776. ">Chatzidionysiou 2016 (ADMIRE)</a> was reported to be a pilot study. <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a>, <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a>, and <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a> reported three arms (both discontinuation and dose reduction compared with continuation). </p> <p><a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a> and <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a> reported a 1:1:1 randomisation ratio, and <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a> a randomisation ratio of 2:3:2. <a href="./references#CD010455-bbs2-0002" title="ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. A multicentre, randomised, controlled, open‐label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open2016;2:e000133. [PUBMED: 26819752 ] ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. Multicenter, randomised, controlled, open‐label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients is stable clinical remission. Arthritis and Rheumatism2012;64(Suppl 10):776. ">Chatzidionysiou 2016 (ADMIRE)</a>, <a href="./references#CD010455-bbs2-0007" title="NCT01578850 . Study conducted in subjects with rheumatoid arthritis who have moderate to severe disease activity despite methotrexate therapy with or without other non biologic disease modifying antirheumatic drugs (DMARDs) for at least 12 weeks prior to screening. https://clinicaltrials.gov/ct2/show/results/NCT01578850 First posted April 17, 2012. PavelkaK , AkkoçN , Al‐MainiM , ZerbiniCAF , KarateevDE , NasonovEL , et al. Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat‑to‑target study conducted in regions with limited biologic access. Rheumatology International2017;37:1469‐79. [PUBMED: 28597306] ">Pavelka 2017</a>, <a href="./references#CD010455-bbs2-0010" title="EmeryP , SmolenJS , KavanaughA , vanVollenhovenR , PavelkaK , DurezP , et al. Maintenance of biologic‐free disease control in early rheumatoid arthritis patients after induction of low disease activity with adalimumab plus methotrexate. Annals of the Rheumatic Diseases2011;70 (Suppl 3):262. SmolenJS , EmeryP , FleischmannR , vanVollenhovenR , FlorentiusS , SantraS , et al. Biologic free disease control (BFDC) in early RA: predictors of successful withdrawal of adalimumab (ADA) after achieving stable low disease activity with ADA plus methotrexate (MTX) ‐ data from the OPTIMA study. Annals of the Rheumatic Diseases2012;71 (Suppl 3):516. SmolenJS , EmeryP , FleischmannR , vanVollenhovenRF , PavelkaK , DurezP , et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet2014;383:321‐32. [PUBMED: 24168956] ">Smolen 2014 (OPTIMA)</a>, and <a href="./references#CD010455-bbs2-0014" title="YamanakaH , NagaokaS , LeeS , BaeS , KasamaT , KobayashiH , et al. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity ‐ results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Modern Rheumatology2016;26(5):651‐61. [PUBMED: 26698929] ">Yamanaka 2016 (ENCOURAGE)</a> reported a 1:1 randomisation ratio. <a href="./references#CD010455-bbs2-0005" title="Ghiti MoghadamM , VonkemanHE , tenKloosterPM , TekstraJ , vanSchaardenburgD , Starmans‐KoolM , et al. Stopping tumor necrosis factor‐inhibitors in patients with established rheumatoid arthritis in remission or stable low disease activity: a pragmatic randomized multicenter open‐label controlled trial. Arthritis and Rheumatology2016;68(8):1810‐7. ">Ghiti Moghadam 2016 (POEET)</a> randomised in a ratio of 2:1 (discontinuation versus continuation). <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a>, <a href="./references#CD010455-bbs2-0010" title="EmeryP , SmolenJS , KavanaughA , vanVollenhovenR , PavelkaK , DurezP , et al. Maintenance of biologic‐free disease control in early rheumatoid arthritis patients after induction of low disease activity with adalimumab plus methotrexate. Annals of the Rheumatic Diseases2011;70 (Suppl 3):262. SmolenJS , EmeryP , FleischmannR , vanVollenhovenR , FlorentiusS , SantraS , et al. Biologic free disease control (BFDC) in early RA: predictors of successful withdrawal of adalimumab (ADA) after achieving stable low disease activity with ADA plus methotrexate (MTX) ‐ data from the OPTIMA study. Annals of the Rheumatic Diseases2012;71 (Suppl 3):516. SmolenJS , EmeryP , FleischmannR , vanVollenhovenRF , PavelkaK , DurezP , et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet2014;383:321‐32. [PUBMED: 24168956] ">Smolen 2014 (OPTIMA)</a>, <a href="./references#CD010455-bbs2-0007" title="NCT01578850 . Study conducted in subjects with rheumatoid arthritis who have moderate to severe disease activity despite methotrexate therapy with or without other non biologic disease modifying antirheumatic drugs (DMARDs) for at least 12 weeks prior to screening. https://clinicaltrials.gov/ct2/show/results/NCT01578850 First posted April 17, 2012. PavelkaK , AkkoçN , Al‐MainiM , ZerbiniCAF , KarateevDE , NasonovEL , et al. Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat‑to‑target study conducted in regions with limited biologic access. Rheumatology International2017;37:1469‐79. [PUBMED: 28597306] ">Pavelka 2017</a>, and <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a> reported a "run‐in" period in which anti‐TNF treatment was given open‐label, before randomisation was provided for anti‐TNF continuation, discontinuation, or dose reduction in a double‐blind phase. </p> <p>The duration of the included studies was 48 weeks for <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a> (40 weeks double‐blind period); 52 weeks for <a href="./references#CD010455-bbs2-0002" title="ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. A multicentre, randomised, controlled, open‐label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open2016;2:e000133. [PUBMED: 26819752 ] ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. Multicenter, randomised, controlled, open‐label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients is stable clinical remission. Arthritis and Rheumatism2012;64(Suppl 10):776. ">Chatzidionysiou 2016 (ADMIRE)</a>, <a href="./references#CD010455-bbs2-0005" title="Ghiti MoghadamM , VonkemanHE , tenKloosterPM , TekstraJ , vanSchaardenburgD , Starmans‐KoolM , et al. Stopping tumor necrosis factor‐inhibitors in patients with established rheumatoid arthritis in remission or stable low disease activity: a pragmatic randomized multicenter open‐label controlled trial. Arthritis and Rheumatology2016;68(8):1810‐7. ">Ghiti Moghadam 2016 (POEET)</a>, and <a href="./references#CD010455-bbs2-0007" title="NCT01578850 . Study conducted in subjects with rheumatoid arthritis who have moderate to severe disease activity despite methotrexate therapy with or without other non biologic disease modifying antirheumatic drugs (DMARDs) for at least 12 weeks prior to screening. https://clinicaltrials.gov/ct2/show/results/NCT01578850 First posted April 17, 2012. PavelkaK , AkkoçN , Al‐MainiM , ZerbiniCAF , KarateevDE , NasonovEL , et al. Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat‑to‑target study conducted in regions with limited biologic access. Rheumatology International2017;37:1469‐79. [PUBMED: 28597306] ">Pavelka 2017</a> (28 weeks double‐blind period). <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a> reported a total follow‐up of 104 weeks, in which the second 52‐week double blind period was of interest for this review. <a href="./references#CD010455-bbs2-0010" title="EmeryP , SmolenJS , KavanaughA , vanVollenhovenR , PavelkaK , DurezP , et al. Maintenance of biologic‐free disease control in early rheumatoid arthritis patients after induction of low disease activity with adalimumab plus methotrexate. Annals of the Rheumatic Diseases2011;70 (Suppl 3):262. SmolenJS , EmeryP , FleischmannR , vanVollenhovenR , FlorentiusS , SantraS , et al. Biologic free disease control (BFDC) in early RA: predictors of successful withdrawal of adalimumab (ADA) after achieving stable low disease activity with ADA plus methotrexate (MTX) ‐ data from the OPTIMA study. Annals of the Rheumatic Diseases2012;71 (Suppl 3):516. SmolenJS , EmeryP , FleischmannR , vanVollenhovenRF , PavelkaK , DurezP , et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet2014;383:321‐32. [PUBMED: 24168956] ">Smolen 2014 (OPTIMA)</a> and <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a> reported a total follow‐up of 78 weeks and 88 weeks, respectively; however, both described 52‐week follow‐up after randomisation for discontinuation or continuation of the anti‐TNF agent. <a href="./references#CD010455-bbs2-0014" title="YamanakaH , NagaokaS , LeeS , BaeS , KasamaT , KobayashiH , et al. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity ‐ results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Modern Rheumatology2016;26(5):651‐61. [PUBMED: 26698929] ">Yamanaka 2016 (ENCOURAGE)</a> described a period of one year in which participants were treated with open‐label etanercept and MTX before they were randomised to open‐label continuation or discontinuation. </p> </section> <section id="CD010455-sec-0066"> <h6 class="title">Sample size</h6> <p>The sample size varied from 31 participants in <a href="./references#CD010455-bbs2-0002" title="ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. A multicentre, randomised, controlled, open‐label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open2016;2:e000133. [PUBMED: 26819752 ] ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. Multicenter, randomised, controlled, open‐label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients is stable clinical remission. Arthritis and Rheumatism2012;64(Suppl 10):776. ">Chatzidionysiou 2016 (ADMIRE)</a> to 817 in <a href="./references#CD010455-bbs2-0005" title="Ghiti MoghadamM , VonkemanHE , tenKloosterPM , TekstraJ , vanSchaardenburgD , Starmans‐KoolM , et al. Stopping tumor necrosis factor‐inhibitors in patients with established rheumatoid arthritis in remission or stable low disease activity: a pragmatic randomized multicenter open‐label controlled trial. Arthritis and Rheumatology2016;68(8):1810‐7. ">Ghiti Moghadam 2016 (POEET)</a>. </p> </section> <section id="CD010455-sec-0067"> <h6 class="title">Setting</h6> <p>All eight studies were reported as multicentre studies. <a href="./references#CD010455-bbs2-0002" title="ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. A multicentre, randomised, controlled, open‐label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open2016;2:e000133. [PUBMED: 26819752 ] ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. Multicenter, randomised, controlled, open‐label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients is stable clinical remission. Arthritis and Rheumatism2012;64(Suppl 10):776. ">Chatzidionysiou 2016 (ADMIRE)</a> was performed in several hospitals in Sweden, and <a href="./references#CD010455-bbs2-0005" title="Ghiti MoghadamM , VonkemanHE , tenKloosterPM , TekstraJ , vanSchaardenburgD , Starmans‐KoolM , et al. Stopping tumor necrosis factor‐inhibitors in patients with established rheumatoid arthritis in remission or stable low disease activity: a pragmatic randomized multicenter open‐label controlled trial. Arthritis and Rheumatology2016;68(8):1810‐7. ">Ghiti Moghadam 2016 (POEET)</a> in 47 rheumatology centres throughout the Netherlands. <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a> reported that the study was conducted in 80 centres in Europe, Latin America, Asia, and Australia. <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a> recruited participants at 16 rheumatology units in Sweden (5), Denmark (2), Finland (2), Norway (3), Hungary (3), and Iceland (1). <a href="./references#CD010455-bbs2-0007" title="NCT01578850 . Study conducted in subjects with rheumatoid arthritis who have moderate to severe disease activity despite methotrexate therapy with or without other non biologic disease modifying antirheumatic drugs (DMARDs) for at least 12 weeks prior to screening. https://clinicaltrials.gov/ct2/show/results/NCT01578850 First posted April 17, 2012. PavelkaK , AkkoçN , Al‐MainiM , ZerbiniCAF , KarateevDE , NasonovEL , et al. Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat‑to‑target study conducted in regions with limited biologic access. Rheumatology International2017;37:1469‐79. [PUBMED: 28597306] ">Pavelka 2017</a> was conducted at 61 centres in 19 countries in Africa, Asia, Central and Eastern Europe, Latin America, and the Middle East. <a href="./references#CD010455-bbs2-0010" title="EmeryP , SmolenJS , KavanaughA , vanVollenhovenR , PavelkaK , DurezP , et al. Maintenance of biologic‐free disease control in early rheumatoid arthritis patients after induction of low disease activity with adalimumab plus methotrexate. Annals of the Rheumatic Diseases2011;70 (Suppl 3):262. SmolenJS , EmeryP , FleischmannR , vanVollenhovenR , FlorentiusS , SantraS , et al. Biologic free disease control (BFDC) in early RA: predictors of successful withdrawal of adalimumab (ADA) after achieving stable low disease activity with ADA plus methotrexate (MTX) ‐ data from the OPTIMA study. Annals of the Rheumatic Diseases2012;71 (Suppl 3):516. SmolenJS , EmeryP , FleischmannR , vanVollenhovenRF , PavelkaK , DurezP , et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet2014;383:321‐32. [PUBMED: 24168956] ">Smolen 2014 (OPTIMA)</a> reported 161 sites around the world. <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a> was conducted at 103 participating sites in Europe, Australia, North America, and Latin America. <a href="./references#CD010455-bbs2-0014" title="YamanakaH , NagaokaS , LeeS , BaeS , KasamaT , KobayashiH , et al. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity ‐ results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Modern Rheumatology2016;26(5):651‐61. [PUBMED: 26698929] ">Yamanaka 2016 (ENCOURAGE)</a> was a co‐operation of rheumatology institutes/departments in Japan and Korea. </p> </section> <section id="CD010455-sec-0068"> <h6 class="title">Participants</h6> <p>Six studies reported a minimum age of 18 years for inclusion (<a href="./references#CD010455-bbs2-0002" title="ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. A multicentre, randomised, controlled, open‐label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open2016;2:e000133. [PUBMED: 26819752 ] ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. Multicenter, randomised, controlled, open‐label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients is stable clinical remission. Arthritis and Rheumatism2012;64(Suppl 10):776. ">Chatzidionysiou 2016 (ADMIRE)</a>; <a href="./references#CD010455-bbs2-0007" title="NCT01578850 . Study conducted in subjects with rheumatoid arthritis who have moderate to severe disease activity despite methotrexate therapy with or without other non biologic disease modifying antirheumatic drugs (DMARDs) for at least 12 weeks prior to screening. https://clinicaltrials.gov/ct2/show/results/NCT01578850 First posted April 17, 2012. PavelkaK , AkkoçN , Al‐MainiM , ZerbiniCAF , KarateevDE , NasonovEL , et al. Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat‑to‑target study conducted in regions with limited biologic access. Rheumatology International2017;37:1469‐79. [PUBMED: 28597306] ">Pavelka 2017</a>; <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a>; <a href="./references#CD010455-bbs2-0010" title="EmeryP , SmolenJS , KavanaughA , vanVollenhovenR , PavelkaK , DurezP , et al. Maintenance of biologic‐free disease control in early rheumatoid arthritis patients after induction of low disease activity with adalimumab plus methotrexate. Annals of the Rheumatic Diseases2011;70 (Suppl 3):262. SmolenJS , EmeryP , FleischmannR , vanVollenhovenR , FlorentiusS , SantraS , et al. Biologic free disease control (BFDC) in early RA: predictors of successful withdrawal of adalimumab (ADA) after achieving stable low disease activity with ADA plus methotrexate (MTX) ‐ data from the OPTIMA study. Annals of the Rheumatic Diseases2012;71 (Suppl 3):516. SmolenJS , EmeryP , FleischmannR , vanVollenhovenRF , PavelkaK , DurezP , et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet2014;383:321‐32. [PUBMED: 24168956] ">Smolen 2014 (OPTIMA)</a>; <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a>; <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a>). <a href="./references#CD010455-bbs2-0005" title="Ghiti MoghadamM , VonkemanHE , tenKloosterPM , TekstraJ , vanSchaardenburgD , Starmans‐KoolM , et al. Stopping tumor necrosis factor‐inhibitors in patients with established rheumatoid arthritis in remission or stable low disease activity: a pragmatic randomized multicenter open‐label controlled trial. Arthritis and Rheumatology2016;68(8):1810‐7. ">Ghiti Moghadam 2016 (POEET)</a> was reported to include people 18 years of age or older. <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a> reported an upper age limit (70 years) for inclusion. <a href="./references#CD010455-bbs2-0014" title="YamanakaH , NagaokaS , LeeS , BaeS , KasamaT , KobayashiH , et al. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity ‐ results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Modern Rheumatology2016;26(5):651‐61. [PUBMED: 26698929] ">Yamanaka 2016 (ENCOURAGE)</a> did not report any age criteria. The mean age of participants varied from around 47 in <a href="./references#CD010455-bbs2-0007" title="NCT01578850 . Study conducted in subjects with rheumatoid arthritis who have moderate to severe disease activity despite methotrexate therapy with or without other non biologic disease modifying antirheumatic drugs (DMARDs) for at least 12 weeks prior to screening. https://clinicaltrials.gov/ct2/show/results/NCT01578850 First posted April 17, 2012. PavelkaK , AkkoçN , Al‐MainiM , ZerbiniCAF , KarateevDE , NasonovEL , et al. Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat‑to‑target study conducted in regions with limited biologic access. Rheumatology International2017;37:1469‐79. [PUBMED: 28597306] ">Pavelka 2017</a> and <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a> to early 60s in <a href="./references#CD010455-bbs2-0002" title="ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. A multicentre, randomised, controlled, open‐label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open2016;2:e000133. [PUBMED: 26819752 ] ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. Multicenter, randomised, controlled, open‐label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients is stable clinical remission. Arthritis and Rheumatism2012;64(Suppl 10):776. ">Chatzidionysiou 2016 (ADMIRE)</a> and <a href="./references#CD010455-bbs2-0005" title="Ghiti MoghadamM , VonkemanHE , tenKloosterPM , TekstraJ , vanSchaardenburgD , Starmans‐KoolM , et al. Stopping tumor necrosis factor‐inhibitors in patients with established rheumatoid arthritis in remission or stable low disease activity: a pragmatic randomized multicenter open‐label controlled trial. Arthritis and Rheumatology2016;68(8):1810‐7. ">Ghiti Moghadam 2016 (POEET)</a>. Most participants in the included studies were female. Mean disease duration ranged from seven to 14 years, except in <a href="./references#CD010455-bbs2-0010" title="EmeryP , SmolenJS , KavanaughA , vanVollenhovenR , PavelkaK , DurezP , et al. Maintenance of biologic‐free disease control in early rheumatoid arthritis patients after induction of low disease activity with adalimumab plus methotrexate. Annals of the Rheumatic Diseases2011;70 (Suppl 3):262. SmolenJS , EmeryP , FleischmannR , vanVollenhovenR , FlorentiusS , SantraS , et al. Biologic free disease control (BFDC) in early RA: predictors of successful withdrawal of adalimumab (ADA) after achieving stable low disease activity with ADA plus methotrexate (MTX) ‐ data from the OPTIMA study. Annals of the Rheumatic Diseases2012;71 (Suppl 3):516. SmolenJS , EmeryP , FleischmannR , vanVollenhovenRF , PavelkaK , DurezP , et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet2014;383:321‐32. [PUBMED: 24168956] ">Smolen 2014 (OPTIMA)</a>, in which the mean disease duration was only 3.9 months; <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a>, in which median disease duration was around 2.7 months (measured one year before randomisation); and <a href="./references#CD010455-bbs2-0014" title="YamanakaH , NagaokaS , LeeS , BaeS , KasamaT , KobayashiH , et al. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity ‐ results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Modern Rheumatology2016;26(5):651‐61. [PUBMED: 26698929] ">Yamanaka 2016 (ENCOURAGE)</a>, in which mean disease duration was two years. Duration of the anti‐TNF agent had to be ≥ 6 months in <a href="./references#CD010455-bbs2-0002" title="ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. A multicentre, randomised, controlled, open‐label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open2016;2:e000133. [PUBMED: 26819752 ] ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. Multicenter, randomised, controlled, open‐label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients is stable clinical remission. Arthritis and Rheumatism2012;64(Suppl 10):776. ">Chatzidionysiou 2016 (ADMIRE)</a>; ≥ 1 year in <a href="./references#CD010455-bbs2-0005" title="Ghiti MoghadamM , VonkemanHE , tenKloosterPM , TekstraJ , vanSchaardenburgD , Starmans‐KoolM , et al. Stopping tumor necrosis factor‐inhibitors in patients with established rheumatoid arthritis in remission or stable low disease activity: a pragmatic randomized multicenter open‐label controlled trial. Arthritis and Rheumatology2016;68(8):1810‐7. ">Ghiti Moghadam 2016 (POEET)</a>; and ≥ 14 months in <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a>. <a href="./references#CD010455-bbs2-0007" title="NCT01578850 . Study conducted in subjects with rheumatoid arthritis who have moderate to severe disease activity despite methotrexate therapy with or without other non biologic disease modifying antirheumatic drugs (DMARDs) for at least 12 weeks prior to screening. https://clinicaltrials.gov/ct2/show/results/NCT01578850 First posted April 17, 2012. PavelkaK , AkkoçN , Al‐MainiM , ZerbiniCAF , KarateevDE , NasonovEL , et al. Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat‑to‑target study conducted in regions with limited biologic access. Rheumatology International2017;37:1469‐79. [PUBMED: 28597306] ">Pavelka 2017</a>, <a href="./references#CD010455-bbs2-0010" title="EmeryP , SmolenJS , KavanaughA , vanVollenhovenR , PavelkaK , DurezP , et al. Maintenance of biologic‐free disease control in early rheumatoid arthritis patients after induction of low disease activity with adalimumab plus methotrexate. Annals of the Rheumatic Diseases2011;70 (Suppl 3):262. SmolenJS , EmeryP , FleischmannR , vanVollenhovenR , FlorentiusS , SantraS , et al. Biologic free disease control (BFDC) in early RA: predictors of successful withdrawal of adalimumab (ADA) after achieving stable low disease activity with ADA plus methotrexate (MTX) ‐ data from the OPTIMA study. Annals of the Rheumatic Diseases2012;71 (Suppl 3):516. SmolenJS , EmeryP , FleischmannR , vanVollenhovenRF , PavelkaK , DurezP , et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet2014;383:321‐32. [PUBMED: 24168956] ">Smolen 2014 (OPTIMA)</a>, <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a>, and <a href="./references#CD010455-bbs2-0014" title="YamanakaH , NagaokaS , LeeS , BaeS , KasamaT , KobayashiH , et al. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity ‐ results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Modern Rheumatology2016;26(5):651‐61. [PUBMED: 26698929] ">Yamanaka 2016 (ENCOURAGE)</a> started the anti‐TNF agent at study start, 24 weeks, 26 weeks, 36 weeks, and 1 year, respectively before randomisation for dose reduction or discontinuation. In the study by <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a>, participants were treated with certolizumab pegol (blinded) one year before randomisation for dose reduction or discontinuation. Participants in <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a>, <a href="./references#CD010455-bbs2-0010" title="EmeryP , SmolenJS , KavanaughA , vanVollenhovenR , PavelkaK , DurezP , et al. Maintenance of biologic‐free disease control in early rheumatoid arthritis patients after induction of low disease activity with adalimumab plus methotrexate. Annals of the Rheumatic Diseases2011;70 (Suppl 3):262. SmolenJS , EmeryP , FleischmannR , vanVollenhovenR , FlorentiusS , SantraS , et al. Biologic free disease control (BFDC) in early RA: predictors of successful withdrawal of adalimumab (ADA) after achieving stable low disease activity with ADA plus methotrexate (MTX) ‐ data from the OPTIMA study. Annals of the Rheumatic Diseases2012;71 (Suppl 3):516. SmolenJS , EmeryP , FleischmannR , vanVollenhovenRF , PavelkaK , DurezP , et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet2014;383:321‐32. [PUBMED: 24168956] ">Smolen 2014 (OPTIMA)</a>, and <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a> were bDMARD naive before study start. <a href="./references#CD010455-bbs2-0010" title="EmeryP , SmolenJS , KavanaughA , vanVollenhovenR , PavelkaK , DurezP , et al. Maintenance of biologic‐free disease control in early rheumatoid arthritis patients after induction of low disease activity with adalimumab plus methotrexate. Annals of the Rheumatic Diseases2011;70 (Suppl 3):262. SmolenJS , EmeryP , FleischmannR , vanVollenhovenR , FlorentiusS , SantraS , et al. Biologic free disease control (BFDC) in early RA: predictors of successful withdrawal of adalimumab (ADA) after achieving stable low disease activity with ADA plus methotrexate (MTX) ‐ data from the OPTIMA study. Annals of the Rheumatic Diseases2012;71 (Suppl 3):516. SmolenJS , EmeryP , FleischmannR , vanVollenhovenRF , PavelkaK , DurezP , et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet2014;383:321‐32. [PUBMED: 24168956] ">Smolen 2014 (OPTIMA)</a> reported that 8.8% of participants in the discontinuation group and 9.5% in the continuation group had used ≥ 1 DMARD. <a href="./references#CD010455-bbs2-0002" title="ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. A multicentre, randomised, controlled, open‐label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open2016;2:e000133. [PUBMED: 26819752 ] ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. Multicenter, randomised, controlled, open‐label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients is stable clinical remission. Arthritis and Rheumatism2012;64(Suppl 10):776. ">Chatzidionysiou 2016 (ADMIRE)</a> reported a median of 1 (interquartile range (IQR) 0 to 1) number of previous bDMARDs and 2 (IQR 1 to 3) previous csDMARDs. In the study by <a href="./references#CD010455-bbs2-0005" title="Ghiti MoghadamM , VonkemanHE , tenKloosterPM , TekstraJ , vanSchaardenburgD , Starmans‐KoolM , et al. Stopping tumor necrosis factor‐inhibitors in patients with established rheumatoid arthritis in remission or stable low disease activity: a pragmatic randomized multicenter open‐label controlled trial. Arthritis and Rheumatology2016;68(8):1810‐7. ">Ghiti Moghadam 2016 (POEET)</a>, 13.4% of participants in the discontinuation group and 15% in the continuation group had previously used a bDMARD. In <a href="./references#CD010455-bbs2-0007" title="NCT01578850 . Study conducted in subjects with rheumatoid arthritis who have moderate to severe disease activity despite methotrexate therapy with or without other non biologic disease modifying antirheumatic drugs (DMARDs) for at least 12 weeks prior to screening. https://clinicaltrials.gov/ct2/show/results/NCT01578850 First posted April 17, 2012. PavelkaK , AkkoçN , Al‐MainiM , ZerbiniCAF , KarateevDE , NasonovEL , et al. Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat‑to‑target study conducted in regions with limited biologic access. Rheumatology International2017;37:1469‐79. [PUBMED: 28597306] ">Pavelka 2017</a>, 34% of participants in the discontinuation group had previously used a csDMARD versus 38% in the continuation group. <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a> reported that 66% of all participants had used a DMARD other than MTX before study start. <a href="./references#CD010455-bbs2-0014" title="YamanakaH , NagaokaS , LeeS , BaeS , KasamaT , KobayashiH , et al. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity ‐ results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Modern Rheumatology2016;26(5):651‐61. [PUBMED: 26698929] ">Yamanaka 2016 (ENCOURAGE)</a> did not report on prior DMARD use. </p> <p>Participants in all included studies had to have low disease activity, <a href="./references#CD010455-bbs2-0005" title="Ghiti MoghadamM , VonkemanHE , tenKloosterPM , TekstraJ , vanSchaardenburgD , Starmans‐KoolM , et al. Stopping tumor necrosis factor‐inhibitors in patients with established rheumatoid arthritis in remission or stable low disease activity: a pragmatic randomized multicenter open‐label controlled trial. Arthritis and Rheumatology2016;68(8):1810‐7. ">Ghiti Moghadam 2016 (POEET)</a>; <a href="./references#CD010455-bbs2-0007" title="NCT01578850 . Study conducted in subjects with rheumatoid arthritis who have moderate to severe disease activity despite methotrexate therapy with or without other non biologic disease modifying antirheumatic drugs (DMARDs) for at least 12 weeks prior to screening. https://clinicaltrials.gov/ct2/show/results/NCT01578850 First posted April 17, 2012. PavelkaK , AkkoçN , Al‐MainiM , ZerbiniCAF , KarateevDE , NasonovEL , et al. Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat‑to‑target study conducted in regions with limited biologic access. Rheumatology International2017;37:1469‐79. [PUBMED: 28597306] ">Pavelka 2017</a>; <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a>; <a href="./references#CD010455-bbs2-0010" title="EmeryP , SmolenJS , KavanaughA , vanVollenhovenR , PavelkaK , DurezP , et al. Maintenance of biologic‐free disease control in early rheumatoid arthritis patients after induction of low disease activity with adalimumab plus methotrexate. Annals of the Rheumatic Diseases2011;70 (Suppl 3):262. SmolenJS , EmeryP , FleischmannR , vanVollenhovenR , FlorentiusS , SantraS , et al. Biologic free disease control (BFDC) in early RA: predictors of successful withdrawal of adalimumab (ADA) after achieving stable low disease activity with ADA plus methotrexate (MTX) ‐ data from the OPTIMA study. Annals of the Rheumatic Diseases2012;71 (Suppl 3):516. SmolenJS , EmeryP , FleischmannR , vanVollenhovenRF , PavelkaK , DurezP , et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet2014;383:321‐32. [PUBMED: 24168956] ">Smolen 2014 (OPTIMA)</a>; <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a>; <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a>, or remission, <a href="./references#CD010455-bbs2-0002" title="ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. A multicentre, randomised, controlled, open‐label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open2016;2:e000133. [PUBMED: 26819752 ] ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. Multicenter, randomised, controlled, open‐label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients is stable clinical remission. Arthritis and Rheumatism2012;64(Suppl 10):776. ">Chatzidionysiou 2016 (ADMIRE)</a>; <a href="./references#CD010455-bbs2-0014" title="YamanakaH , NagaokaS , LeeS , BaeS , KasamaT , KobayashiH , et al. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity ‐ results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Modern Rheumatology2016;26(5):651‐61. [PUBMED: 26698929] ">Yamanaka 2016 (ENCOURAGE)</a>. The duration of low disease activity had to be 4 weeks in <a href="./references#CD010455-bbs2-0010" title="EmeryP , SmolenJS , KavanaughA , vanVollenhovenR , PavelkaK , DurezP , et al. Maintenance of biologic‐free disease control in early rheumatoid arthritis patients after induction of low disease activity with adalimumab plus methotrexate. Annals of the Rheumatic Diseases2011;70 (Suppl 3):262. SmolenJS , EmeryP , FleischmannR , vanVollenhovenR , FlorentiusS , SantraS , et al. Biologic free disease control (BFDC) in early RA: predictors of successful withdrawal of adalimumab (ADA) after achieving stable low disease activity with ADA plus methotrexate (MTX) ‐ data from the OPTIMA study. Annals of the Rheumatic Diseases2012;71 (Suppl 3):516. SmolenJS , EmeryP , FleischmannR , vanVollenhovenRF , PavelkaK , DurezP , et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet2014;383:321‐32. [PUBMED: 24168956] ">Smolen 2014 (OPTIMA)</a>; ≥ 3 months in <a href="./references#CD010455-bbs2-0002" title="ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. A multicentre, randomised, controlled, open‐label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open2016;2:e000133. [PUBMED: 26819752 ] ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. Multicenter, randomised, controlled, open‐label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients is stable clinical remission. Arthritis and Rheumatism2012;64(Suppl 10):776. ">Chatzidionysiou 2016 (ADMIRE)</a>; ≥ 6 months in <a href="./references#CD010455-bbs2-0005" title="Ghiti MoghadamM , VonkemanHE , tenKloosterPM , TekstraJ , vanSchaardenburgD , Starmans‐KoolM , et al. Stopping tumor necrosis factor‐inhibitors in patients with established rheumatoid arthritis in remission or stable low disease activity: a pragmatic randomized multicenter open‐label controlled trial. Arthritis and Rheumatology2016;68(8):1810‐7. ">Ghiti Moghadam 2016 (POEET)</a>; or ≥ 11 months in <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a>. Participants in the study by <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a> had to have a mean DAS28 ≤ 3.2 in the 24‐week period before randomisation and a DAS28 ≤ 3.2 at the moment of randomisation. In the study by <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a>, participants needed to have a DAS28 ≤ 3.2 12 weeks before randomisation and at the moment of randomisation. In <a href="./references#CD010455-bbs2-0014" title="YamanakaH , NagaokaS , LeeS , BaeS , KasamaT , KobayashiH , et al. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity ‐ results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Modern Rheumatology2016;26(5):651‐61. [PUBMED: 26698929] ">Yamanaka 2016 (ENCOURAGE)</a>, participants had to have a DAS &lt; 2.6 at 6 and 12 months after study start. <a href="./references#CD010455-bbs2-0007" title="NCT01578850 . Study conducted in subjects with rheumatoid arthritis who have moderate to severe disease activity despite methotrexate therapy with or without other non biologic disease modifying antirheumatic drugs (DMARDs) for at least 12 weeks prior to screening. https://clinicaltrials.gov/ct2/show/results/NCT01578850 First posted April 17, 2012. PavelkaK , AkkoçN , Al‐MainiM , ZerbiniCAF , KarateevDE , NasonovEL , et al. Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat‑to‑target study conducted in regions with limited biologic access. Rheumatology International2017;37:1469‐79. [PUBMED: 28597306] ">Pavelka 2017</a> reported that participants had to have low disease activity after period 1 (24 weeks after study start). All included studies used a DAS28‐based criterion to define low disease activity or remission. </p> </section> <section id="CD010455-sec-0069"> <h6 class="title">Intervention and comedication</h6> <p><a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a>, <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a>, <a href="./references#CD010455-bbs2-0014" title="YamanakaH , NagaokaS , LeeS , BaeS , KasamaT , KobayashiH , et al. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity ‐ results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Modern Rheumatology2016;26(5):651‐61. [PUBMED: 26698929] ">Yamanaka 2016 (ENCOURAGE)</a>, and <a href="./references#CD010455-bbs2-0007" title="NCT01578850 . Study conducted in subjects with rheumatoid arthritis who have moderate to severe disease activity despite methotrexate therapy with or without other non biologic disease modifying antirheumatic drugs (DMARDs) for at least 12 weeks prior to screening. https://clinicaltrials.gov/ct2/show/results/NCT01578850 First posted April 17, 2012. PavelkaK , AkkoçN , Al‐MainiM , ZerbiniCAF , KarateevDE , NasonovEL , et al. Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat‑to‑target study conducted in regions with limited biologic access. Rheumatology International2017;37:1469‐79. [PUBMED: 28597306] ">Pavelka 2017</a> reported etanercept discontinuation compared with etanercept continuation. The studies by <a href="./references#CD010455-bbs2-0002" title="ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. A multicentre, randomised, controlled, open‐label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open2016;2:e000133. [PUBMED: 26819752 ] ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. Multicenter, randomised, controlled, open‐label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients is stable clinical remission. Arthritis and Rheumatism2012;64(Suppl 10):776. ">Chatzidionysiou 2016 (ADMIRE)</a> and <a href="./references#CD010455-bbs2-0010" title="EmeryP , SmolenJS , KavanaughA , vanVollenhovenR , PavelkaK , DurezP , et al. Maintenance of biologic‐free disease control in early rheumatoid arthritis patients after induction of low disease activity with adalimumab plus methotrexate. Annals of the Rheumatic Diseases2011;70 (Suppl 3):262. SmolenJS , EmeryP , FleischmannR , vanVollenhovenR , FlorentiusS , SantraS , et al. Biologic free disease control (BFDC) in early RA: predictors of successful withdrawal of adalimumab (ADA) after achieving stable low disease activity with ADA plus methotrexate (MTX) ‐ data from the OPTIMA study. Annals of the Rheumatic Diseases2012;71 (Suppl 3):516. SmolenJS , EmeryP , FleischmannR , vanVollenhovenRF , PavelkaK , DurezP , et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet2014;383:321‐32. [PUBMED: 24168956] ">Smolen 2014 (OPTIMA)</a> reported adalimumab discontinuation compared with adalimumab continuation. <a href="./references#CD010455-bbs2-0005" title="Ghiti MoghadamM , VonkemanHE , tenKloosterPM , TekstraJ , vanSchaardenburgD , Starmans‐KoolM , et al. Stopping tumor necrosis factor‐inhibitors in patients with established rheumatoid arthritis in remission or stable low disease activity: a pragmatic randomized multicenter open‐label controlled trial. Arthritis and Rheumatology2016;68(8):1810‐7. ">Ghiti Moghadam 2016 (POEET)</a> reported discontinuation of all anti‐TNF agents versus anti‐TNF continuation. <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a> reported discontinuation of certolizumab pegol compared to continuation of the standard dose. </p> <p>Participants in most included studies were required to use MTX comedication (dose ranged from 6 to 25 mg/week). <a href="./references#CD010455-bbs2-0005" title="Ghiti MoghadamM , VonkemanHE , tenKloosterPM , TekstraJ , vanSchaardenburgD , Starmans‐KoolM , et al. Stopping tumor necrosis factor‐inhibitors in patients with established rheumatoid arthritis in remission or stable low disease activity: a pragmatic randomized multicenter open‐label controlled trial. Arthritis and Rheumatology2016;68(8):1810‐7. ">Ghiti Moghadam 2016 (POEET)</a> included participants using any csDMARD comedication. Participants included in <a href="./references#CD010455-bbs2-0010" title="EmeryP , SmolenJS , KavanaughA , vanVollenhovenR , PavelkaK , DurezP , et al. Maintenance of biologic‐free disease control in early rheumatoid arthritis patients after induction of low disease activity with adalimumab plus methotrexate. Annals of the Rheumatic Diseases2011;70 (Suppl 3):262. SmolenJS , EmeryP , FleischmannR , vanVollenhovenR , FlorentiusS , SantraS , et al. Biologic free disease control (BFDC) in early RA: predictors of successful withdrawal of adalimumab (ADA) after achieving stable low disease activity with ADA plus methotrexate (MTX) ‐ data from the OPTIMA study. Annals of the Rheumatic Diseases2012;71 (Suppl 3):516. SmolenJS , EmeryP , FleischmannR , vanVollenhovenRF , PavelkaK , DurezP , et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet2014;383:321‐32. [PUBMED: 24168956] ">Smolen 2014 (OPTIMA)</a> were MTX naive at the start of the study (26 weeks before randomisation for discontinuation or continuation of adalimumab). Seven studies stated that participants could restart the anti‐TNF after disease flare (<a href="./references#CD010455-bbs2-0002" title="ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. A multicentre, randomised, controlled, open‐label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open2016;2:e000133. [PUBMED: 26819752 ] ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. Multicenter, randomised, controlled, open‐label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients is stable clinical remission. Arthritis and Rheumatism2012;64(Suppl 10):776. ">Chatzidionysiou 2016 (ADMIRE)</a>; <a href="./references#CD010455-bbs2-0005" title="Ghiti MoghadamM , VonkemanHE , tenKloosterPM , TekstraJ , vanSchaardenburgD , Starmans‐KoolM , et al. Stopping tumor necrosis factor‐inhibitors in patients with established rheumatoid arthritis in remission or stable low disease activity: a pragmatic randomized multicenter open‐label controlled trial. Arthritis and Rheumatology2016;68(8):1810‐7. ">Ghiti Moghadam 2016 (POEET)</a>; <a href="./references#CD010455-bbs2-0007" title="NCT01578850 . Study conducted in subjects with rheumatoid arthritis who have moderate to severe disease activity despite methotrexate therapy with or without other non biologic disease modifying antirheumatic drugs (DMARDs) for at least 12 weeks prior to screening. https://clinicaltrials.gov/ct2/show/results/NCT01578850 First posted April 17, 2012. PavelkaK , AkkoçN , Al‐MainiM , ZerbiniCAF , KarateevDE , NasonovEL , et al. Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat‑to‑target study conducted in regions with limited biologic access. Rheumatology International2017;37:1469‐79. [PUBMED: 28597306] ">Pavelka 2017</a>; <a href="./references#CD010455-bbs2-0010" title="EmeryP , SmolenJS , KavanaughA , vanVollenhovenR , PavelkaK , DurezP , et al. Maintenance of biologic‐free disease control in early rheumatoid arthritis patients after induction of low disease activity with adalimumab plus methotrexate. Annals of the Rheumatic Diseases2011;70 (Suppl 3):262. SmolenJS , EmeryP , FleischmannR , vanVollenhovenR , FlorentiusS , SantraS , et al. Biologic free disease control (BFDC) in early RA: predictors of successful withdrawal of adalimumab (ADA) after achieving stable low disease activity with ADA plus methotrexate (MTX) ‐ data from the OPTIMA study. Annals of the Rheumatic Diseases2012;71 (Suppl 3):516. SmolenJS , EmeryP , FleischmannR , vanVollenhovenRF , PavelkaK , DurezP , et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet2014;383:321‐32. [PUBMED: 24168956] ">Smolen 2014 (OPTIMA)</a>; <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a>; <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a>; <a href="./references#CD010455-bbs2-0014" title="YamanakaH , NagaokaS , LeeS , BaeS , KasamaT , KobayashiH , et al. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity ‐ results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Modern Rheumatology2016;26(5):651‐61. [PUBMED: 26698929] ">Yamanaka 2016 (ENCOURAGE)</a>). The study by <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a> allowed up to three intra‐articular corticosteroid injections during the study; however, no attempt was made to recapture low disease activity by reintroducing etanercept in participants whose condition had deteriorated after etanercept withdrawal. </p> </section> <section id="CD010455-sec-0070"> <h6 class="title">Outcomes</h6> <p>All studies reported a primary outcome measure; for most studies this was proportion of participants with low disease activity or remission. All studies used DAS28‐based criteria, but different definitions were employed. <a href="./references#CD010455-bbs2-0002" title="ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. A multicentre, randomised, controlled, open‐label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open2016;2:e000133. [PUBMED: 26819752 ] ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. Multicenter, randomised, controlled, open‐label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients is stable clinical remission. Arthritis and Rheumatism2012;64(Suppl 10):776. ">Chatzidionysiou 2016 (ADMIRE)</a> and <a href="./references#CD010455-bbs2-0014" title="YamanakaH , NagaokaS , LeeS , BaeS , KasamaT , KobayashiH , et al. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity ‐ results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Modern Rheumatology2016;26(5):651‐61. [PUBMED: 26698929] ">Yamanaka 2016 (ENCOURAGE)</a> used DAS28 remission (&lt; 2.6). <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a> and <a href="./references#CD010455-bbs2-0007" title="NCT01578850 . Study conducted in subjects with rheumatoid arthritis who have moderate to severe disease activity despite methotrexate therapy with or without other non biologic disease modifying antirheumatic drugs (DMARDs) for at least 12 weeks prior to screening. https://clinicaltrials.gov/ct2/show/results/NCT01578850 First posted April 17, 2012. PavelkaK , AkkoçN , Al‐MainiM , ZerbiniCAF , KarateevDE , NasonovEL , et al. Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat‑to‑target study conducted in regions with limited biologic access. Rheumatology International2017;37:1469‐79. [PUBMED: 28597306] ">Pavelka 2017</a> used DAS28 low disease activity (≤ 3.2 for <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a> and &lt; 3.2 for <a href="./references#CD010455-bbs2-0007" title="NCT01578850 . Study conducted in subjects with rheumatoid arthritis who have moderate to severe disease activity despite methotrexate therapy with or without other non biologic disease modifying antirheumatic drugs (DMARDs) for at least 12 weeks prior to screening. https://clinicaltrials.gov/ct2/show/results/NCT01578850 First posted April 17, 2012. PavelkaK , AkkoçN , Al‐MainiM , ZerbiniCAF , KarateevDE , NasonovEL , et al. Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat‑to‑target study conducted in regions with limited biologic access. Rheumatology International2017;37:1469‐79. [PUBMED: 28597306] ">Pavelka 2017</a>). <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a> reported maintenance of low disease activity (DAS28‐ESR of ≤ 3.2) for all 5 consecutive study visits to week 52 without flares as the primary outcome measure. <a href="./references#CD010455-bbs2-0005" title="Ghiti MoghadamM , VonkemanHE , tenKloosterPM , TekstraJ , vanSchaardenburgD , Starmans‐KoolM , et al. Stopping tumor necrosis factor‐inhibitors in patients with established rheumatoid arthritis in remission or stable low disease activity: a pragmatic randomized multicenter open‐label controlled trial. Arthritis and Rheumatology2016;68(8):1810‐7. ">Ghiti Moghadam 2016 (POEET)</a> reported proportion of participants with a flare (DAS28 ≥ 3.2 plus an increase &gt; 0.6) as the primary outcome. The primary outcome in the study by <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a> was proportion of non‐failure. The primary outcome in <a href="./references#CD010455-bbs2-0010" title="EmeryP , SmolenJS , KavanaughA , vanVollenhovenR , PavelkaK , DurezP , et al. Maintenance of biologic‐free disease control in early rheumatoid arthritis patients after induction of low disease activity with adalimumab plus methotrexate. Annals of the Rheumatic Diseases2011;70 (Suppl 3):262. SmolenJS , EmeryP , FleischmannR , vanVollenhovenR , FlorentiusS , SantraS , et al. Biologic free disease control (BFDC) in early RA: predictors of successful withdrawal of adalimumab (ADA) after achieving stable low disease activity with ADA plus methotrexate (MTX) ‐ data from the OPTIMA study. Annals of the Rheumatic Diseases2012;71 (Suppl 3):516. SmolenJS , EmeryP , FleischmannR , vanVollenhovenRF , PavelkaK , DurezP , et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet2014;383:321‐32. [PUBMED: 24168956] ">Smolen 2014 (OPTIMA)</a> was the proportion of participants with both low disease activity and radiographic non‐progression; however, this concerned a comparison of study groups that was not of interest for this review (adalimumab continuation versus methotrexate monotherapy). Secondary outcomes reported in the included studies concerned many different domains, including participant‐reported outcomes (function, quality of life), radiographic outcomes, number of flares, relapse‐free survival, and safety outcomes. None of the included studies provided data on costs or change in comedication. All studies were analysed with a (modified) intention‐to‐treat approach. </p> </section> </section> <section id="CD010455-sec-0071"> <h5 class="title">Disease activity–guided dose tapering until stop versus anti‐TNF continuation studies</h5> <section id="CD010455-sec-0072"> <h6 class="title">Design</h6> <p>Three studies compared disease activity–guided anti‐TNF dose tapering with anti‐TNF continuation (<a href="./references#CD010455-bbs2-0001" title="BejeranoC , OreiroN , Fernandez‐LopezC , Pinto‐TasendeJA , AtanesA , DeAspeB , et al. Clinical evaluation usefulness of standardized protocol strategies of dose reduction in patients with rheumatoid arthritis in clinical remission treated with biologic therapies. The OPTIBIO study [abstract]. Arthritis and Rheumatology2016;68:(Suppl 10). ">Bejerano 2016 (OPTIBIO)</a> (abstract only); <a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a>; <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a>). All studies were open‐label RCTs. <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a> and <a href="./references#CD010455-bbs2-0001" title="BejeranoC , OreiroN , Fernandez‐LopezC , Pinto‐TasendeJA , AtanesA , DeAspeB , et al. Clinical evaluation usefulness of standardized protocol strategies of dose reduction in patients with rheumatoid arthritis in clinical remission treated with biologic therapies. The OPTIBIO study [abstract]. Arthritis and Rheumatology2016;68:(Suppl 10). ">Bejerano 2016 (OPTIBIO)</a> were reported to be non‐inferiority studies. <a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a> reported an equivalence design. Randomisation ratio was 2:1 (dose tapering versus continuation) in <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a> and 1:1 in <a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a> and <a href="./references#CD010455-bbs2-0001" title="BejeranoC , OreiroN , Fernandez‐LopezC , Pinto‐TasendeJA , AtanesA , DeAspeB , et al. Clinical evaluation usefulness of standardized protocol strategies of dose reduction in patients with rheumatoid arthritis in clinical remission treated with biologic therapies. The OPTIBIO study [abstract]. Arthritis and Rheumatology2016;68:(Suppl 10). ">Bejerano 2016 (OPTIBIO)</a>. Study duration was 1 year for <a href="./references#CD010455-bbs2-0001" title="BejeranoC , OreiroN , Fernandez‐LopezC , Pinto‐TasendeJA , AtanesA , DeAspeB , et al. Clinical evaluation usefulness of standardized protocol strategies of dose reduction in patients with rheumatoid arthritis in clinical remission treated with biologic therapies. The OPTIBIO study [abstract]. Arthritis and Rheumatology2016;68:(Suppl 10). ">Bejerano 2016 (OPTIBIO)</a> and 18 months for <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a> and <a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a>. </p> </section> <section id="CD010455-sec-0073"> <h6 class="title">Sample size</h6> <p>The sample size varied from 48 in <a href="./references#CD010455-bbs2-0001" title="BejeranoC , OreiroN , Fernandez‐LopezC , Pinto‐TasendeJA , AtanesA , DeAspeB , et al. Clinical evaluation usefulness of standardized protocol strategies of dose reduction in patients with rheumatoid arthritis in clinical remission treated with biologic therapies. The OPTIBIO study [abstract]. Arthritis and Rheumatology2016;68:(Suppl 10). ">Bejerano 2016 (OPTIBIO)</a> (66 in the total study, which also included other biologics besides anti‐TNF) to 180 in <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a>. The projected sample size for the study by <a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a> was 250 participants; however, only 137 participants were included. The abstract on <a href="./references#CD010455-bbs2-0001" title="BejeranoC , OreiroN , Fernandez‐LopezC , Pinto‐TasendeJA , AtanesA , DeAspeB , et al. Clinical evaluation usefulness of standardized protocol strategies of dose reduction in patients with rheumatoid arthritis in clinical remission treated with biologic therapies. The OPTIBIO study [abstract]. Arthritis and Rheumatology2016;68:(Suppl 10). ">Bejerano 2016 (OPTIBIO)</a> reported preliminary data. </p> </section> <section id="CD010455-sec-0074"> <h6 class="title">Setting</h6> <p><a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a> and <a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a> were reported to be multicentre studies. <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a> included patients from two hospitals in the Netherlands, and <a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a> recruited participants at 22 rheumatology departments in France and one department in Monaco. <a href="./references#CD010455-bbs2-0001" title="BejeranoC , OreiroN , Fernandez‐LopezC , Pinto‐TasendeJA , AtanesA , DeAspeB , et al. Clinical evaluation usefulness of standardized protocol strategies of dose reduction in patients with rheumatoid arthritis in clinical remission treated with biologic therapies. The OPTIBIO study [abstract]. Arthritis and Rheumatology2016;68:(Suppl 10). ">Bejerano 2016 (OPTIBIO)</a> was a monocentre study conducted in a hospital in Spain. </p> </section> <section id="CD010455-sec-0075"> <h6 class="title">Participants</h6> <p>The abstract by <a href="./references#CD010455-bbs2-0001" title="BejeranoC , OreiroN , Fernandez‐LopezC , Pinto‐TasendeJA , AtanesA , DeAspeB , et al. Clinical evaluation usefulness of standardized protocol strategies of dose reduction in patients with rheumatoid arthritis in clinical remission treated with biologic therapies. The OPTIBIO study [abstract]. Arthritis and Rheumatology2016;68:(Suppl 10). ">Bejerano 2016 (OPTIBIO)</a> provided no information on participant characteristics of anti‐TNF users only. The mean age of participants was 56 years in the study by <a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a> and 59 years in the study by <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a>. Most participants were female in <a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a> and <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a>. Mean disease duration at baseline was about 10 years for both <a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a> and <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a>. Participants in <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a> had a median of 2 (IQR 1 to 3) previous DMARDs and 0 (IQR 0 to 1) previous anti‐TNF agents. <a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a> reported a mean (SD) of 2.7 (1.7) previous DMARDs, and 24% of participants had previously used a bDMARD. </p> <p>The duration of anti‐TNF agents had to be ≥ 6 months in <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a> and &gt; 1 year in <a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a>. <a href="./references#CD010455-bbs2-0001" title="BejeranoC , OreiroN , Fernandez‐LopezC , Pinto‐TasendeJA , AtanesA , DeAspeB , et al. Clinical evaluation usefulness of standardized protocol strategies of dose reduction in patients with rheumatoid arthritis in clinical remission treated with biologic therapies. The OPTIBIO study [abstract]. Arthritis and Rheumatology2016;68:(Suppl 10). ">Bejerano 2016 (OPTIBIO)</a> reported no minimal duration of anti‐TNF use. Participants in <a href="./references#CD010455-bbs2-0001" title="BejeranoC , OreiroN , Fernandez‐LopezC , Pinto‐TasendeJA , AtanesA , DeAspeB , et al. Clinical evaluation usefulness of standardized protocol strategies of dose reduction in patients with rheumatoid arthritis in clinical remission treated with biologic therapies. The OPTIBIO study [abstract]. Arthritis and Rheumatology2016;68:(Suppl 10). ">Bejerano 2016 (OPTIBIO)</a> had to have clinical remission (DAS &lt; 2.6, SDAI &lt; 5, or ACR/EULAR 2011 criteria) for ≥ 6 months. Participants in <a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a> needed to have a DAS28 ≤ 2.6 for ≥ 6 months with no structural damage progression. Participants in <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a> had to have stable low disease activity (DAS28 &lt; 3.2) at two subsequent visits. </p> </section> <section id="CD010455-sec-0076"> <h6 class="title">Intervention and comedication</h6> <p>All three studies reported disease activity–guided dose tapering. <a href="./references#CD010455-bbs2-0001" title="BejeranoC , OreiroN , Fernandez‐LopezC , Pinto‐TasendeJA , AtanesA , DeAspeB , et al. Clinical evaluation usefulness of standardized protocol strategies of dose reduction in patients with rheumatoid arthritis in clinical remission treated with biologic therapies. The OPTIBIO study [abstract]. Arthritis and Rheumatology2016;68:(Suppl 10). ">Bejerano 2016 (OPTIBIO)</a> included all anti‐TNF agents, while <a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a> and <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a> included adalimumab and etanercept. Dose tapering in <a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a> was done by increasing the interval between two subcutaneous injections by 50% every three months up to a complete stop in the fourth step; if DAS28 remission (DAS28 ≤ 2.6) was not maintained, dose tapering was suspended or was reversed to the previous interval based on DAS28 level. The dose reduction strategy in <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a> consisted of stepwise increases of the time interval between injections every three months until complete stop in the third step. In the instance of a flare (∆DAS28‐CRP score &gt; 1.2, or ∆DAS28‐CRP &gt; 0.6, and a current score of ≥ 3.2), the last effective interval was reinstated. The dose reduction strategy in <a href="./references#CD010455-bbs2-0001" title="BejeranoC , OreiroN , Fernandez‐LopezC , Pinto‐TasendeJA , AtanesA , DeAspeB , et al. Clinical evaluation usefulness of standardized protocol strategies of dose reduction in patients with rheumatoid arthritis in clinical remission treated with biologic therapies. The OPTIBIO study [abstract]. Arthritis and Rheumatology2016;68:(Suppl 10). ">Bejerano 2016 (OPTIBIO)</a> consisted of a stepwise increase in interval every year with withdrawal as the third step. In case of flare (DAS28 &gt; 2.6 or SDAI &gt; 5 or ACR/EULAR criteria not fulfilled), participants returned to the standard dose. In all studies, the dose‐tapering intervention was compared with unchanged continuation of the anti‐TNF agents. </p> </section> <section id="CD010455-sec-0077"> <h6 class="title">Outcomes</h6> <p>All studies reported a primary outcome measure that was based on the DAS28 score. <a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a> reported standardised difference of DAS28 slopes based on a linear mixed‐effects model as the primary outcome compared to an equivalence margin of ±30%. For <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a>, this was difference in proportions of participants with major flare (DAS28‐CRP‐based flare longer than three months) compared with a non‐inferiority margin of 20%. The primary outcome measure in <a href="./references#CD010455-bbs2-0001" title="BejeranoC , OreiroN , Fernandez‐LopezC , Pinto‐TasendeJA , AtanesA , DeAspeB , et al. Clinical evaluation usefulness of standardized protocol strategies of dose reduction in patients with rheumatoid arthritis in clinical remission treated with biologic therapies. The OPTIBIO study [abstract]. Arthritis and Rheumatology2016;68:(Suppl 10). ">Bejerano 2016 (OPTIBIO)</a> was the proportion of participants that maintained clinical remission after one year. The abstract for this study did not report on secondary outcome measures. Several secondary measures were reported in <a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a> and <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a>, including function, radiographic progression, and adverse events. <a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a> and <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a> primarily performed a per‐protocol analysis and additionally performed an intention‐to‐treat analysis. <a href="./references#CD010455-bbs2-0001" title="BejeranoC , OreiroN , Fernandez‐LopezC , Pinto‐TasendeJA , AtanesA , DeAspeB , et al. Clinical evaluation usefulness of standardized protocol strategies of dose reduction in patients with rheumatoid arthritis in clinical remission treated with biologic therapies. The OPTIBIO study [abstract]. Arthritis and Rheumatology2016;68:(Suppl 10). ">Bejerano 2016 (OPTIBIO)</a> did not specify their analysis approach, which was therefore labelled as intention‐to‐treat. </p> </section> </section> </section> <section id="CD010455-sec-0078"> <h4 class="title">Excluded studies</h4> <p>We excluded 29 articles from this review (15 for the original publication and 14 from the updated version). Fourteen articles (concerning 13 studies) reported anti‐TNF down‐titration without an anti‐TNF continuation control arm (<a href="./references#CD010455-bbs2-0016" title="AwanS , BannonC , O'Sullivan , DuffyM , MurphyE , BarryM . Sustained remission at 6 months, despite reduction in anti‐TNF dosing frequency in inflammatory arthritis. Irish Journal of Medical Science2011;181(Suppl 2):54. ">Awan 2011</a>; <a href="./references#CD010455-bbs2-0017" title="BejaranoV , ConoghanP , QuinnMA , SaleemB , EmeryP . Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis. Rheumatology2010;49:1971‐4. ">Bejarano 2010</a>; <a href="./references#CD010455-bbs2-0019" title="DetertJ , BastionH , ListingJ , WeissA , WassenbergS , LiebhaberA , et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD‐naïve patients with early rheumatoid arthritis: HIT HARD, an investigator‐initiated study. Annals of the Rheumatic Diseases2013;72:844‐50. ">Detert 2013 (HIT‐HARD)</a>; <a href="./references#CD010455-bbs2-0020" title="EmeryP , HammoudehM , FitzGeraldO , CombeB , Martin MolaE , BukowskiJ , et al. Assessing maintenance of remission with reduced dose etanercept plus methotrexate, methotrexate alone or placebo in patients with early rheumatoid arthritis who achieved remission with etanercept and methotrexate: the PRIZE study. Annals of the Rheumatic Diseases2013;72 (Suppl 3):399. ">Emery 2013 (PRIZE)</a>; <a href="./references#CD010455-bbs2-0025" title="HeimansL , AkdemirG , Wevers‐de BoerKVC , Goekoop‐RuitermanYP , MolenaarET , vanGroenendaelJHLM , et al. Two‐year results of disease activity score (DAS)‐remission‐steered treatment strategies aiming at drug‐free remission in early arthritis patients (the IMPROVED‐study). Arthritis Research and Therapy2016;28:23. [26794605] ">Heimans 2016 (IMPROVED)</a>; <a href="./references#CD010455-bbs2-0028" title="KlarenbeekNB , van derKooijSM , Güler‐YükselM , vanGroenendaelJHLM , HanKH , KerstensPJSM , et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Annals of the Rheumatic Diseases2011;70:315‐9. ">Klarenbeek 2011</a>; <a href="./references#CD010455-bbs2-0031" title="ObaK , NorieN , SatoN , SaitoK , TakeuchiT , MimoriT , et al. Remission induction by Raising the dose of Remicade in RA (RRRR) study: rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritis. Contemporary Clinical Trials Communications2017;8:49‐54. [PUBMED: 29696196 ] ">Oba 2017 (RRRR study)</a>; <a href="./references#CD010455-bbs2-0032" title="QuinnMA , ConaghanPG , O'ConnorPJ , KarimZ , GreensteinA , BrownA , et al. Very early treatment with infliximab in addition to methotrexate in early, poor‐prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve‐month randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatism2005;52(1):27‐35. ">Quinn 2005</a>; <a href="./references#CD010455-bbs2-0035" title="SeddighzadehM . NORD‐STAR: a multicentre, randomized, open‐label, blinded‐assessor, phase 4 study in patients with early rheumatoid arthritis. Scandinavian Journal of Rheumatology2014;43 (Suppl 127):31‐2. ">Seddighzadeh 2014 (NORD‐STAR)</a>; <a href="./references#CD010455-bbs2-0036" title="SmolenJS , EmeryP , FerraccioliG , SamborskiW , BerenbaumF , DaviesO , et al. Maintenance of remission in rheumatoid arthritis patients with low‐moderate disease activity following withdrawal of certolizumab pegol treatment: week 52 results from the CERTAIN study. Annals of the Rheumatic Diseases2012;71 (Suppl 3):25. ">Smolen 2012 (CERTAIN)</a>; <a href="./references#CD010455-bbs2-0040" title="van denBroekM , KlarenbeekNB , DirvenL , vanSchaardenburgD , HulsmansHMJ , KerstensPJSM , et al. Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score‐steered therapy: subanalysis of the BeSt study. Annals of the Rheumatic Diseases2011;70:1389‐94. ">van den Broek 2011</a>; <a href="./references#CD010455-bbs2-0041" title="van derKooijSM , Goekoop‐RuitermanYPM , deVries‐BouwstraJK , Guler‐YukselM , ZwindermanAH , KerstensPJSM , et al. Drug‐free remission, functioning and radiographic damage after 4 years of response‐driven treatment in patients with recent‐onset rheumatoid arthritis. Annals of the Rheumatic Diseases2009;68:914‐21. ">van der Kooij 2009</a>; <a href="./references#CD010455-bbs2-0042" title="VilleneuveE , NamE , HensorJL , WakefieldE , ConoghanRJ , GreenPG , et al. Preliminary results of a multicentre randomised controlled trial of etanercept and methotrexate to induce remission in patients with newly diagnosed inflammatory arthritis. Arthritis and Rheumatism2011;63 (Suppl 10):2465. ">Villeneuve 2012</a>; <a href="./references#CD010455-bbs2-0043" title="WilandP , DudlerJ , VealeD , TahirH , PedersenR , BukowskiJ , et al. The effect of reduced or withdrawn etanercept‐methotrexate therapy on patient‐reported outcomes in patients with early rheumatoid arthritis. Journal of Rheumatology2016;43:1268‐77. [PUBMED: 27252426] ">Wiland 2016 (PRIZE)</a>). In four studies, allocation to anti‐TNF continuation or discontinuation was based on patient or physician preference (<a href="./references#CD010455-bbs2-0023" title="HarigaiM , TakeuchiT , Tanaka , Y , MatsubaraT , YamanakaH , MiyasakaN . Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. Modern Rheumatology2012;22:814‐22. ">Harigai 2012 (BRIGHT)</a>; <a href="./references#CD010455-bbs2-0033" title="RakiehC , SaleemB , TakaseK , NamJL , KeenH , WakefieldRJ , et al. Long term outcomes of stopping tumour necrosis factor inhibitors (TNFi) in patients with established rheumatoid arthritis (RA) who are in sustained remission: is it worth the risk?. Annals of the Rheumatic Diseases2013;72 (Suppl 3):208‐9. ">Rakieh 2013</a>; <a href="./references#CD010455-bbs2-0038" title="TanakaY , HirataS , KuboS , FukuyoS , HanamiK , SawamukaiN , et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1‐year outcome of the HONOR study. Annals of the Rheumatic Diseases2015;74:389‐95. [PUBMED: 24288014] ">Tanaka 2013 (HONOR)</a>; <a href="./references#CD010455-bbs2-0039" title="TanakaY , YamanakaH , IshiguroN , MiyasakaN , KawanaK , HiramatsuK , et al. Attainment of low disease activity is predictive of maintenance of disease control upon adalimumab discontinuation for two years following combination therapy in Japanese patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2014;66:S1059. [Abstract number: 2427] ">Tanaka 2014 (HOPEFUL‐2)</a>), therefore these study were not classified as RCT or CCT. <a href="./references#CD010455-bbs2-0037" title="TadaM , KoikiT , OkanoT , SugiokaY , WakitaniS , FukushimaK , et al. Comparison of joint destruction between standard‐ and low‐dose etanercept in rheumatoid arthritis from the Prevention of Cartilage Destruction by Etanercept (PRECEPT) study. Rheumatology2012;51:2164‐9. ">Tada 2012 (PRECEPT)</a> reported low‐dose versus standard‐dose etanercept from study start. In the study by <a href="./references#CD010455-bbs2-0024" title="HaschkaJ , EnglbrechtM , HueberAJ , MangerB , KleyerA , ReiserM , et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Annals of the Rheumatic Diseases2016;75:45‐51. [PUBMED: 25660991] ">Haschka 2016 (RETRO)</a>, participants were randomised to dose reduction or discontinuation of all DMARDs, therefore the intervention was too broad for this review. The studies by <a href="./references#CD010455-bbs2-0029" title="KobeltG , LekanderI , LangA , RaffeinerB , BotsiosC , GeborekP . Cost‐effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment. International Journal of Technology Assessment in Health Care2011;27(3):193‐200. ">Kobelt 2011</a> and <a href="./references#CD010455-bbs2-0030" title="KobeltG . Treating to target with etanercept in rheumatoid arthritis: cost‐effectiveness of dose reductions when remission is achieved. Value in Health2014;17:537‐44. [PUBMED: 25128046] ">Kobelt 2014</a> provided data from a Markov model. <a href="./references#CD010455-bbs2-0015" title="AletahaD . Challenging the course of RA: time for drug‐free remission?. Nature Reviews Rheumatology2010;6:442‐3. ">Aletaha 2010</a>, <a href="./references#CD010455-bbs2-0026" title="IchikawaN , YamanakaH . Maintenance therapy for rheumatoid arthritis after remission following successful treatment using biologics. Nihon Rinsho2007;65(7):1293‐8. ">Ichikawa 2007</a>, and <a href="./references#CD010455-bbs2-0027" title="KeystoneEC , HaraouiB , BykerkVP . Role of infliximab in the treatment of early rheumatoid arthritis. Clinical and Experimental Rheumatology2003;21 (Suppl 31):S200‐2. ">Keystone 2003</a> were overview articles. <a href="./references#CD010455-bbs2-0034" title="Ramírez‐HerráizE , Escudero‐VilaplanaV , Alañón‐PlazaE , Trovato‐LópezN , Herranz‐AlonsoA , Morell‐BaladrónA , et al. Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practice. Clinical and Experimental Rheumatology2013;31(4):559‐65. ">Ramírez‐Herráiz 2013</a> was a retrospective study; <a href="./references#CD010455-bbs2-0018" title="Unknown . Long‐term sustained clinical remission after stopping first‐line anti‐TNF agents in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis: clinical effectiveness. Canadian Agency for Drugs and Technologies in Health2014. ">CADTH Report 2014</a> described a literature study; and <a href="./references#CD010455-bbs2-0021" title="GreenbergJD , ShanY , ReedGW , BitmanB , CollierD . Comparison of switching to reduced dose vs continuation of standard dose etanercept for rheumatoid arthritis patients in the CORRONA registry. Annals of the Rheumatic Diseases2014;73 (Suppl 2):241. ">Greenberg 2014</a> was a cohort study. In the study by <a href="./references#CD010455-bbs2-0022" title="HaraouiB , BykerkVP , vanVollenhovenR , deLonguevilleM , LuijtensK , RalstonP , et al. Analysis of pooled data from two randomized controlled trials and their open‐label extensions: long‐term safety in rheumatoid arthritis before and after certolizumab pegol dose increase/decrease. Arthritis &amp; Rheumatology2014;66:S199. ">Haraoui 2014</a>, no doses below standard dose were investigated. </p> <p>See <a href="./references#CD010455-sec-0135" title="">Characteristics of excluded studies</a> for more information. </p> </section> </section> <section id="CD010455-sec-0079"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="./references#CD010455-sec-0134" title="">Characteristics of included studies</a> for 'Risk of bias' tables with information on all aspects of risk of bias. Graphic summaries of the risk of bias in included studies are shown in <a href="#CD010455-fig-0002">Figure 2</a> and <a href="#CD010455-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD010455-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010455-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD010455-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010455-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD010455-sec-0080"> <h4 class="title">Allocation</h4> <p>Seven included studies described an adequate random sequence generation and allocation concealment procedure, resulting in an assessment of low risk of selection bias (<a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a>; <a href="./references#CD010455-bbs2-0006" title="GallowayJB , KingsleyG , MaM , Lorente‐CanovasB , CopeA , IbrahimF , et al. Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial. Annals of the Rheumatic Diseases2015;74 (Suppl 2):706. IbrahimF , Lorente‐CánovasB , DoréCJ , BosworthA , MaMH , GallowayJB , et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis ‐ a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology2017;56:2004‐14. [PUBMED: 28968858] ">Ibrahim 2017 (OPTTIRA)</a>; <a href="./references#CD010455-bbs2-0007" title="NCT01578850 . Study conducted in subjects with rheumatoid arthritis who have moderate to severe disease activity despite methotrexate therapy with or without other non biologic disease modifying antirheumatic drugs (DMARDs) for at least 12 weeks prior to screening. https://clinicaltrials.gov/ct2/show/results/NCT01578850 First posted April 17, 2012. PavelkaK , AkkoçN , Al‐MainiM , ZerbiniCAF , KarateevDE , NasonovEL , et al. Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat‑to‑target study conducted in regions with limited biologic access. Rheumatology International2017;37:1469‐79. [PUBMED: 28597306] ">Pavelka 2017</a>; <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a>; <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a>; <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a>; <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a>). The precise method of random sequence generation was not described in three studies (<a href="./references#CD010455-bbs2-0002" title="ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. A multicentre, randomised, controlled, open‐label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open2016;2:e000133. [PUBMED: 26819752 ] ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. Multicenter, randomised, controlled, open‐label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients is stable clinical remission. Arthritis and Rheumatism2012;64(Suppl 10):776. ">Chatzidionysiou 2016 (ADMIRE)</a>; <a href="./references#CD010455-bbs2-0010" title="EmeryP , SmolenJS , KavanaughA , vanVollenhovenR , PavelkaK , DurezP , et al. Maintenance of biologic‐free disease control in early rheumatoid arthritis patients after induction of low disease activity with adalimumab plus methotrexate. Annals of the Rheumatic Diseases2011;70 (Suppl 3):262. SmolenJS , EmeryP , FleischmannR , vanVollenhovenR , FlorentiusS , SantraS , et al. Biologic free disease control (BFDC) in early RA: predictors of successful withdrawal of adalimumab (ADA) after achieving stable low disease activity with ADA plus methotrexate (MTX) ‐ data from the OPTIMA study. Annals of the Rheumatic Diseases2012;71 (Suppl 3):516. SmolenJS , EmeryP , FleischmannR , vanVollenhovenRF , PavelkaK , DurezP , et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet2014;383:321‐32. [PUBMED: 24168956] ">Smolen 2014 (OPTIMA)</a>; <a href="./references#CD010455-bbs2-0014" title="YamanakaH , NagaokaS , LeeS , BaeS , KasamaT , KobayashiH , et al. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity ‐ results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Modern Rheumatology2016;26(5):651‐61. [PUBMED: 26698929] ">Yamanaka 2016 (ENCOURAGE)</a>). <a href="./references#CD010455-bbs2-0005" title="Ghiti MoghadamM , VonkemanHE , tenKloosterPM , TekstraJ , vanSchaardenburgD , Starmans‐KoolM , et al. Stopping tumor necrosis factor‐inhibitors in patients with established rheumatoid arthritis in remission or stable low disease activity: a pragmatic randomized multicenter open‐label controlled trial. Arthritis and Rheumatology2016;68(8):1810‐7. ">Ghiti Moghadam 2016 (POEET)</a> did not describe allocation concealment. The methods of randomisation and allocation concealment were not described in the abstract by <a href="./references#CD010455-bbs2-0001" title="BejeranoC , OreiroN , Fernandez‐LopezC , Pinto‐TasendeJA , AtanesA , DeAspeB , et al. Clinical evaluation usefulness of standardized protocol strategies of dose reduction in patients with rheumatoid arthritis in clinical remission treated with biologic therapies. The OPTIBIO study [abstract]. Arthritis and Rheumatology2016;68:(Suppl 10). ">Bejerano 2016 (OPTIBIO)</a> and the study by <a href="./references#CD010455-bbs2-0003" title="ElMiedanyY , ElGaafaryM , AhmedI , BahlasS , HegaziM , NasrA . Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission. Clinical Rheumatology2016;35:2915‐23. [PUBMED: 27658417] ">El Miedany 2016</a>. The study by <a href="./references#CD010455-bbs2-0008" title="BotsiosC , FurlanA , OstuniP , SfrisoP , TodescoS , PunziL . Effects of low‐dose etanercept in maintaining DAS‐remission previously achieved with standard‐dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2007;66(Suppl II):54. RaffeinerB , BotsiosC , OmettoF , BernardiL , StramareR , TodescoS , et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology2015;33:63‐8. [PUBMED: 25535985] ">Raffeiner 2015</a> described alternation as the method of randomisation, which resulted in a judgement of high risk of selection bias. </p> </section> <section id="CD010455-sec-0081"> <h4 class="title">Blinding</h4> <p>Five studies were reported to be placebo controlled (<a href="./references#CD010455-bbs2-0007" title="NCT01578850 . Study conducted in subjects with rheumatoid arthritis who have moderate to severe disease activity despite methotrexate therapy with or without other non biologic disease modifying antirheumatic drugs (DMARDs) for at least 12 weeks prior to screening. https://clinicaltrials.gov/ct2/show/results/NCT01578850 First posted April 17, 2012. PavelkaK , AkkoçN , Al‐MainiM , ZerbiniCAF , KarateevDE , NasonovEL , et al. Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat‑to‑target study conducted in regions with limited biologic access. Rheumatology International2017;37:1469‐79. [PUBMED: 28597306] ">Pavelka 2017</a>; <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a>; <a href="./references#CD010455-bbs2-0010" title="EmeryP , SmolenJS , KavanaughA , vanVollenhovenR , PavelkaK , DurezP , et al. Maintenance of biologic‐free disease control in early rheumatoid arthritis patients after induction of low disease activity with adalimumab plus methotrexate. Annals of the Rheumatic Diseases2011;70 (Suppl 3):262. SmolenJS , EmeryP , FleischmannR , vanVollenhovenR , FlorentiusS , SantraS , et al. Biologic free disease control (BFDC) in early RA: predictors of successful withdrawal of adalimumab (ADA) after achieving stable low disease activity with ADA plus methotrexate (MTX) ‐ data from the OPTIMA study. Annals of the Rheumatic Diseases2012;71 (Suppl 3):516. SmolenJS , EmeryP , FleischmannR , vanVollenhovenRF , PavelkaK , DurezP , et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet2014;383:321‐32. [PUBMED: 24168956] ">Smolen 2014 (OPTIMA)</a>; <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a>; <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a>). The remaining nine studies were open‐label (<a href="./references#CD010455-bbs2-0001" title="BejeranoC , OreiroN , Fernandez‐LopezC , Pinto‐TasendeJA , AtanesA , DeAspeB , et al. Clinical evaluation usefulness of standardized protocol strategies of dose reduction in patients with rheumatoid arthritis in clinical remission treated with biologic therapies. The OPTIBIO study [abstract]. Arthritis and Rheumatology2016;68:(Suppl 10). ">Bejerano 2016 (OPTIBIO)</a>; <a href="./references#CD010455-bbs2-0002" title="ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. A multicentre, randomised, controlled, open‐label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open2016;2:e000133. [PUBMED: 26819752 ] ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. Multicenter, randomised, controlled, open‐label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients is stable clinical remission. Arthritis and Rheumatism2012;64(Suppl 10):776. ">Chatzidionysiou 2016 (ADMIRE)</a>; <a href="./references#CD010455-bbs2-0003" title="ElMiedanyY , ElGaafaryM , AhmedI , BahlasS , HegaziM , NasrA . Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission. Clinical Rheumatology2016;35:2915‐23. [PUBMED: 27658417] ">El Miedany 2016</a>; <a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a>; <a href="./references#CD010455-bbs2-0005" title="Ghiti MoghadamM , VonkemanHE , tenKloosterPM , TekstraJ , vanSchaardenburgD , Starmans‐KoolM , et al. Stopping tumor necrosis factor‐inhibitors in patients with established rheumatoid arthritis in remission or stable low disease activity: a pragmatic randomized multicenter open‐label controlled trial. Arthritis and Rheumatology2016;68(8):1810‐7. ">Ghiti Moghadam 2016 (POEET)</a>; <a href="./references#CD010455-bbs2-0006" title="GallowayJB , KingsleyG , MaM , Lorente‐CanovasB , CopeA , IbrahimF , et al. Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial. Annals of the Rheumatic Diseases2015;74 (Suppl 2):706. IbrahimF , Lorente‐CánovasB , DoréCJ , BosworthA , MaMH , GallowayJB , et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis ‐ a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology2017;56:2004‐14. [PUBMED: 28968858] ">Ibrahim 2017 (OPTTIRA)</a>; <a href="./references#CD010455-bbs2-0008" title="BotsiosC , FurlanA , OstuniP , SfrisoP , TodescoS , PunziL . Effects of low‐dose etanercept in maintaining DAS‐remission previously achieved with standard‐dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2007;66(Suppl II):54. RaffeinerB , BotsiosC , OmettoF , BernardiL , StramareR , TodescoS , et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology2015;33:63‐8. [PUBMED: 25535985] ">Raffeiner 2015</a>; <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a>; <a href="./references#CD010455-bbs2-0014" title="YamanakaH , NagaokaS , LeeS , BaeS , KasamaT , KobayashiH , et al. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity ‐ results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Modern Rheumatology2016;26(5):651‐61. [PUBMED: 26698929] ">Yamanaka 2016 (ENCOURAGE)</a>); five of these described blinding of X‐ray reading (<a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a>; <a href="./references#CD010455-bbs2-0006" title="GallowayJB , KingsleyG , MaM , Lorente‐CanovasB , CopeA , IbrahimF , et al. Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial. Annals of the Rheumatic Diseases2015;74 (Suppl 2):706. IbrahimF , Lorente‐CánovasB , DoréCJ , BosworthA , MaMH , GallowayJB , et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis ‐ a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology2017;56:2004‐14. [PUBMED: 28968858] ">Ibrahim 2017 (OPTTIRA)</a>; <a href="./references#CD010455-bbs2-0008" title="BotsiosC , FurlanA , OstuniP , SfrisoP , TodescoS , PunziL . Effects of low‐dose etanercept in maintaining DAS‐remission previously achieved with standard‐dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2007;66(Suppl II):54. RaffeinerB , BotsiosC , OmettoF , BernardiL , StramareR , TodescoS , et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology2015;33:63‐8. [PUBMED: 25535985] ">Raffeiner 2015</a>; <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a>; <a href="./references#CD010455-bbs2-0014" title="YamanakaH , NagaokaS , LeeS , BaeS , KasamaT , KobayashiH , et al. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity ‐ results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Modern Rheumatology2016;26(5):651‐61. [PUBMED: 26698929] ">Yamanaka 2016 (ENCOURAGE)</a>, and the study by <a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a> also reported blinded DAS28 measurements, which resulted in an assessment of low risk of detection bias. </p> </section> <section id="CD010455-sec-0082"> <h4 class="title">Incomplete outcome data</h4> <p>We used three criteria for judging this item: intention‐to‐treat analyses, imputation of missing data, and attrition rate. </p> <p>Most studies performed an intention‐to‐treat analysis (<a href="./references#CD010455-bbs2-0002" title="ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. A multicentre, randomised, controlled, open‐label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open2016;2:e000133. [PUBMED: 26819752 ] ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. Multicenter, randomised, controlled, open‐label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients is stable clinical remission. Arthritis and Rheumatism2012;64(Suppl 10):776. ">Chatzidionysiou 2016 (ADMIRE)</a>; <a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a>; <a href="./references#CD010455-bbs2-0005" title="Ghiti MoghadamM , VonkemanHE , tenKloosterPM , TekstraJ , vanSchaardenburgD , Starmans‐KoolM , et al. Stopping tumor necrosis factor‐inhibitors in patients with established rheumatoid arthritis in remission or stable low disease activity: a pragmatic randomized multicenter open‐label controlled trial. Arthritis and Rheumatology2016;68(8):1810‐7. ">Ghiti Moghadam 2016 (POEET)</a>; <a href="./references#CD010455-bbs2-0006" title="GallowayJB , KingsleyG , MaM , Lorente‐CanovasB , CopeA , IbrahimF , et al. Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial. Annals of the Rheumatic Diseases2015;74 (Suppl 2):706. IbrahimF , Lorente‐CánovasB , DoréCJ , BosworthA , MaMH , GallowayJB , et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis ‐ a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology2017;56:2004‐14. [PUBMED: 28968858] ">Ibrahim 2017 (OPTTIRA)</a>; <a href="./references#CD010455-bbs2-0007" title="NCT01578850 . Study conducted in subjects with rheumatoid arthritis who have moderate to severe disease activity despite methotrexate therapy with or without other non biologic disease modifying antirheumatic drugs (DMARDs) for at least 12 weeks prior to screening. https://clinicaltrials.gov/ct2/show/results/NCT01578850 First posted April 17, 2012. PavelkaK , AkkoçN , Al‐MainiM , ZerbiniCAF , KarateevDE , NasonovEL , et al. Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat‑to‑target study conducted in regions with limited biologic access. Rheumatology International2017;37:1469‐79. [PUBMED: 28597306] ">Pavelka 2017</a>; <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a>; <a href="./references#CD010455-bbs2-0010" title="EmeryP , SmolenJS , KavanaughA , vanVollenhovenR , PavelkaK , DurezP , et al. Maintenance of biologic‐free disease control in early rheumatoid arthritis patients after induction of low disease activity with adalimumab plus methotrexate. Annals of the Rheumatic Diseases2011;70 (Suppl 3):262. SmolenJS , EmeryP , FleischmannR , vanVollenhovenR , FlorentiusS , SantraS , et al. Biologic free disease control (BFDC) in early RA: predictors of successful withdrawal of adalimumab (ADA) after achieving stable low disease activity with ADA plus methotrexate (MTX) ‐ data from the OPTIMA study. Annals of the Rheumatic Diseases2012;71 (Suppl 3):516. SmolenJS , EmeryP , FleischmannR , vanVollenhovenRF , PavelkaK , DurezP , et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet2014;383:321‐32. [PUBMED: 24168956] ">Smolen 2014 (OPTIMA)</a>; <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a>; <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a>; <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a>; <a href="./references#CD010455-bbs2-0014" title="YamanakaH , NagaokaS , LeeS , BaeS , KasamaT , KobayashiH , et al. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity ‐ results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Modern Rheumatology2016;26(5):651‐61. [PUBMED: 26698929] ">Yamanaka 2016 (ENCOURAGE)</a>). The abstract by <a href="./references#CD010455-bbs2-0001" title="BejeranoC , OreiroN , Fernandez‐LopezC , Pinto‐TasendeJA , AtanesA , DeAspeB , et al. Clinical evaluation usefulness of standardized protocol strategies of dose reduction in patients with rheumatoid arthritis in clinical remission treated with biologic therapies. The OPTIBIO study [abstract]. Arthritis and Rheumatology2016;68:(Suppl 10). ">Bejerano 2016 (OPTIBIO)</a> and the studies by <a href="./references#CD010455-bbs2-0008" title="BotsiosC , FurlanA , OstuniP , SfrisoP , TodescoS , PunziL . Effects of low‐dose etanercept in maintaining DAS‐remission previously achieved with standard‐dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2007;66(Suppl II):54. RaffeinerB , BotsiosC , OmettoF , BernardiL , StramareR , TodescoS , et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology2015;33:63‐8. [PUBMED: 25535985] ">Raffeiner 2015</a> and <a href="./references#CD010455-bbs2-0003" title="ElMiedanyY , ElGaafaryM , AhmedI , BahlasS , HegaziM , NasrA . Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission. Clinical Rheumatology2016;35:2915‐23. [PUBMED: 27658417] ">El Miedany 2016</a> did not report on the type of analysis. Five studies did not report any imputation of missing data (<a href="./references#CD010455-bbs2-0003" title="ElMiedanyY , ElGaafaryM , AhmedI , BahlasS , HegaziM , NasrA . Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission. Clinical Rheumatology2016;35:2915‐23. [PUBMED: 27658417] ">El Miedany 2016</a>; <a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a>; <a href="./references#CD010455-bbs2-0006" title="GallowayJB , KingsleyG , MaM , Lorente‐CanovasB , CopeA , IbrahimF , et al. Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial. Annals of the Rheumatic Diseases2015;74 (Suppl 2):706. IbrahimF , Lorente‐CánovasB , DoréCJ , BosworthA , MaMH , GallowayJB , et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis ‐ a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology2017;56:2004‐14. [PUBMED: 28968858] ">Ibrahim 2017 (OPTTIRA)</a>; <a href="./references#CD010455-bbs2-0008" title="BotsiosC , FurlanA , OstuniP , SfrisoP , TodescoS , PunziL . Effects of low‐dose etanercept in maintaining DAS‐remission previously achieved with standard‐dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2007;66(Suppl II):54. RaffeinerB , BotsiosC , OmettoF , BernardiL , StramareR , TodescoS , et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology2015;33:63‐8. [PUBMED: 25535985] ">Raffeiner 2015</a>; <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a>). <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a> reported a modified non‐responder imputation analysis in which participants who discontinued early due to poor efficacy were imputed as non‐responders for all time points; all other participants were analysed by the last observation carried forward (LOCF) method. All other postbaseline analyses were based on the LOCF method (except radiographic endpoints). <a href="./references#CD010455-bbs2-0002" title="ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. A multicentre, randomised, controlled, open‐label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open2016;2:e000133. [PUBMED: 26819752 ] ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. Multicenter, randomised, controlled, open‐label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients is stable clinical remission. Arthritis and Rheumatism2012;64(Suppl 10):776. ">Chatzidionysiou 2016 (ADMIRE)</a> used non‐responder imputation for participants with no available DAS28 at the time of the primary outcome (this included most participants who had a flare in the adalimumab discontinuation group). <a href="./references#CD010455-bbs2-0005" title="Ghiti MoghadamM , VonkemanHE , tenKloosterPM , TekstraJ , vanSchaardenburgD , Starmans‐KoolM , et al. Stopping tumor necrosis factor‐inhibitors in patients with established rheumatoid arthritis in remission or stable low disease activity: a pragmatic randomized multicenter open‐label controlled trial. Arthritis and Rheumatology2016;68(8):1810‐7. ">Ghiti Moghadam 2016 (POEET)</a> reported imputation of DAS28 components based on the expectation‐maximisation algorithm using the participant's values of the remaining components of the DAS28. <a href="./references#CD010455-bbs2-0007" title="NCT01578850 . Study conducted in subjects with rheumatoid arthritis who have moderate to severe disease activity despite methotrexate therapy with or without other non biologic disease modifying antirheumatic drugs (DMARDs) for at least 12 weeks prior to screening. https://clinicaltrials.gov/ct2/show/results/NCT01578850 First posted April 17, 2012. PavelkaK , AkkoçN , Al‐MainiM , ZerbiniCAF , KarateevDE , NasonovEL , et al. Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat‑to‑target study conducted in regions with limited biologic access. Rheumatology International2017;37:1469‐79. [PUBMED: 28597306] ">Pavelka 2017</a> reported that efficacy analyses were conducted in the full analysis set population in each period using the last observation before rescue carried forward approach. The study by <a href="./references#CD010455-bbs2-0010" title="EmeryP , SmolenJS , KavanaughA , vanVollenhovenR , PavelkaK , DurezP , et al. Maintenance of biologic‐free disease control in early rheumatoid arthritis patients after induction of low disease activity with adalimumab plus methotrexate. Annals of the Rheumatic Diseases2011;70 (Suppl 3):262. SmolenJS , EmeryP , FleischmannR , vanVollenhovenR , FlorentiusS , SantraS , et al. Biologic free disease control (BFDC) in early RA: predictors of successful withdrawal of adalimumab (ADA) after achieving stable low disease activity with ADA plus methotrexate (MTX) ‐ data from the OPTIMA study. Annals of the Rheumatic Diseases2012;71 (Suppl 3):516. SmolenJS , EmeryP , FleischmannR , vanVollenhovenRF , PavelkaK , DurezP , et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet2014;383:321‐32. [PUBMED: 24168956] ">Smolen 2014 (OPTIMA)</a> used non‐responder imputation for the primary endpoint, and non‐responder imputation and LOCF, or both, for additional clinical outcomes; LOCF was used for functional outcomes. Markov chain Monte Carlo method was used to impute missing radiographic data 10 times (multiple imputation). <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a> reported that missing data from participants who entered period 2 but withdrew before the end of the study were imputed using non‐responder imputation for the primary and key secondary endpoints. Radiographic analyses used linear extrapolation. In post hoc analyses, LOCF imputation was used for the proportions of participants achieving low disease activity, remission, and normative physical function. The study by <a href="./references#CD010455-bbs2-0014" title="YamanakaH , NagaokaS , LeeS , BaeS , KasamaT , KobayashiH , et al. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity ‐ results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Modern Rheumatology2016;26(5):651‐61. [PUBMED: 26698929] ">Yamanaka 2016 (ENCOURAGE)</a> described LOCF to impute missing data. <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a> reported that a non‐responder imputation was applied for dichotomous clinical outcomes. The abstract by <a href="./references#CD010455-bbs2-0001" title="BejeranoC , OreiroN , Fernandez‐LopezC , Pinto‐TasendeJA , AtanesA , DeAspeB , et al. Clinical evaluation usefulness of standardized protocol strategies of dose reduction in patients with rheumatoid arthritis in clinical remission treated with biologic therapies. The OPTIBIO study [abstract]. Arthritis and Rheumatology2016;68:(Suppl 10). ">Bejerano 2016 (OPTIBIO)</a> did not describe the procedure for handling missing data. Most studies reported some participants that were lost to follow‐up (<a href="./references#CD010455-bbs2-0002" title="ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. A multicentre, randomised, controlled, open‐label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open2016;2:e000133. [PUBMED: 26819752 ] ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. Multicenter, randomised, controlled, open‐label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients is stable clinical remission. Arthritis and Rheumatism2012;64(Suppl 10):776. ">Chatzidionysiou 2016 (ADMIRE)</a>; <a href="./references#CD010455-bbs2-0003" title="ElMiedanyY , ElGaafaryM , AhmedI , BahlasS , HegaziM , NasrA . Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission. Clinical Rheumatology2016;35:2915‐23. [PUBMED: 27658417] ">El Miedany 2016</a>; <a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a>; <a href="./references#CD010455-bbs2-0005" title="Ghiti MoghadamM , VonkemanHE , tenKloosterPM , TekstraJ , vanSchaardenburgD , Starmans‐KoolM , et al. Stopping tumor necrosis factor‐inhibitors in patients with established rheumatoid arthritis in remission or stable low disease activity: a pragmatic randomized multicenter open‐label controlled trial. Arthritis and Rheumatology2016;68(8):1810‐7. ">Ghiti Moghadam 2016 (POEET)</a>; <a href="./references#CD010455-bbs2-0006" title="GallowayJB , KingsleyG , MaM , Lorente‐CanovasB , CopeA , IbrahimF , et al. Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial. Annals of the Rheumatic Diseases2015;74 (Suppl 2):706. IbrahimF , Lorente‐CánovasB , DoréCJ , BosworthA , MaMH , GallowayJB , et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis ‐ a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology2017;56:2004‐14. [PUBMED: 28968858] ">Ibrahim 2017 (OPTTIRA)</a>; <a href="./references#CD010455-bbs2-0007" title="NCT01578850 . Study conducted in subjects with rheumatoid arthritis who have moderate to severe disease activity despite methotrexate therapy with or without other non biologic disease modifying antirheumatic drugs (DMARDs) for at least 12 weeks prior to screening. https://clinicaltrials.gov/ct2/show/results/NCT01578850 First posted April 17, 2012. PavelkaK , AkkoçN , Al‐MainiM , ZerbiniCAF , KarateevDE , NasonovEL , et al. Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat‑to‑target study conducted in regions with limited biologic access. Rheumatology International2017;37:1469‐79. [PUBMED: 28597306] ">Pavelka 2017</a>; <a href="./references#CD010455-bbs2-0008" title="BotsiosC , FurlanA , OstuniP , SfrisoP , TodescoS , PunziL . Effects of low‐dose etanercept in maintaining DAS‐remission previously achieved with standard‐dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2007;66(Suppl II):54. RaffeinerB , BotsiosC , OmettoF , BernardiL , StramareR , TodescoS , et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology2015;33:63‐8. [PUBMED: 25535985] ">Raffeiner 2015</a>; <a href="./references#CD010455-bbs2-0010" title="EmeryP , SmolenJS , KavanaughA , vanVollenhovenR , PavelkaK , DurezP , et al. Maintenance of biologic‐free disease control in early rheumatoid arthritis patients after induction of low disease activity with adalimumab plus methotrexate. Annals of the Rheumatic Diseases2011;70 (Suppl 3):262. SmolenJS , EmeryP , FleischmannR , vanVollenhovenR , FlorentiusS , SantraS , et al. Biologic free disease control (BFDC) in early RA: predictors of successful withdrawal of adalimumab (ADA) after achieving stable low disease activity with ADA plus methotrexate (MTX) ‐ data from the OPTIMA study. Annals of the Rheumatic Diseases2012;71 (Suppl 3):516. SmolenJS , EmeryP , FleischmannR , vanVollenhovenRF , PavelkaK , DurezP , et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet2014;383:321‐32. [PUBMED: 24168956] ">Smolen 2014 (OPTIMA)</a>; <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a>; <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a>; <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a>). The study by <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a> reported that fewer participants completed the study in the placebo group than in the etanercept 50 mg and 25 mg groups (141 versus 181 and 175 participants). <a href="./references#CD010455-bbs2-0014" title="YamanakaH , NagaokaS , LeeS , BaeS , KasamaT , KobayashiH , et al. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity ‐ results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Modern Rheumatology2016;26(5):651‐61. [PUBMED: 26698929] ">Yamanaka 2016 (ENCOURAGE)</a> reported high dropout rates in both groups (16/49 in the continuation group and 16/50 in the discontinuation group). The abstract by <a href="./references#CD010455-bbs2-0001" title="BejeranoC , OreiroN , Fernandez‐LopezC , Pinto‐TasendeJA , AtanesA , DeAspeB , et al. Clinical evaluation usefulness of standardized protocol strategies of dose reduction in patients with rheumatoid arthritis in clinical remission treated with biologic therapies. The OPTIBIO study [abstract]. Arthritis and Rheumatology2016;68:(Suppl 10). ">Bejerano 2016 (OPTIBIO)</a> did not describe completion rate. </p> </section> <section id="CD010455-sec-0083"> <h4 class="title">Selective reporting</h4> <p>Most studies, with the exception of <a href="./references#CD010455-bbs2-0008" title="BotsiosC , FurlanA , OstuniP , SfrisoP , TodescoS , PunziL . Effects of low‐dose etanercept in maintaining DAS‐remission previously achieved with standard‐dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2007;66(Suppl II):54. RaffeinerB , BotsiosC , OmettoF , BernardiL , StramareR , TodescoS , et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology2015;33:63‐8. [PUBMED: 25535985] ">Raffeiner 2015</a> and <a href="./references#CD010455-bbs2-0003" title="ElMiedanyY , ElGaafaryM , AhmedI , BahlasS , HegaziM , NasrA . Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission. Clinical Rheumatology2016;35:2915‐23. [PUBMED: 27658417] ">El Miedany 2016</a>, had a study protocol that was available. <a href="./references#CD010455-bbs2-0001" title="BejeranoC , OreiroN , Fernandez‐LopezC , Pinto‐TasendeJA , AtanesA , DeAspeB , et al. Clinical evaluation usefulness of standardized protocol strategies of dose reduction in patients with rheumatoid arthritis in clinical remission treated with biologic therapies. The OPTIBIO study [abstract]. Arthritis and Rheumatology2016;68:(Suppl 10). ">Bejerano 2016 (OPTIBIO)</a> was published as abstract only, and therefore did not report all prespecified outcomes. All other studies reported the prespecified outcomes (<a href="./references#CD010455-bbs2-0002" title="ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. A multicentre, randomised, controlled, open‐label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open2016;2:e000133. [PUBMED: 26819752 ] ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. Multicenter, randomised, controlled, open‐label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients is stable clinical remission. Arthritis and Rheumatism2012;64(Suppl 10):776. ">Chatzidionysiou 2016 (ADMIRE)</a>; <a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a>; <a href="./references#CD010455-bbs2-0005" title="Ghiti MoghadamM , VonkemanHE , tenKloosterPM , TekstraJ , vanSchaardenburgD , Starmans‐KoolM , et al. Stopping tumor necrosis factor‐inhibitors in patients with established rheumatoid arthritis in remission or stable low disease activity: a pragmatic randomized multicenter open‐label controlled trial. Arthritis and Rheumatology2016;68(8):1810‐7. ">Ghiti Moghadam 2016 (POEET)</a>; <a href="./references#CD010455-bbs2-0006" title="GallowayJB , KingsleyG , MaM , Lorente‐CanovasB , CopeA , IbrahimF , et al. Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial. Annals of the Rheumatic Diseases2015;74 (Suppl 2):706. IbrahimF , Lorente‐CánovasB , DoréCJ , BosworthA , MaMH , GallowayJB , et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis ‐ a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology2017;56:2004‐14. [PUBMED: 28968858] ">Ibrahim 2017 (OPTTIRA)</a>; <a href="./references#CD010455-bbs2-0007" title="NCT01578850 . Study conducted in subjects with rheumatoid arthritis who have moderate to severe disease activity despite methotrexate therapy with or without other non biologic disease modifying antirheumatic drugs (DMARDs) for at least 12 weeks prior to screening. https://clinicaltrials.gov/ct2/show/results/NCT01578850 First posted April 17, 2012. PavelkaK , AkkoçN , Al‐MainiM , ZerbiniCAF , KarateevDE , NasonovEL , et al. Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat‑to‑target study conducted in regions with limited biologic access. Rheumatology International2017;37:1469‐79. [PUBMED: 28597306] ">Pavelka 2017</a>; <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a>; <a href="./references#CD010455-bbs2-0010" title="EmeryP , SmolenJS , KavanaughA , vanVollenhovenR , PavelkaK , DurezP , et al. Maintenance of biologic‐free disease control in early rheumatoid arthritis patients after induction of low disease activity with adalimumab plus methotrexate. Annals of the Rheumatic Diseases2011;70 (Suppl 3):262. SmolenJS , EmeryP , FleischmannR , vanVollenhovenR , FlorentiusS , SantraS , et al. Biologic free disease control (BFDC) in early RA: predictors of successful withdrawal of adalimumab (ADA) after achieving stable low disease activity with ADA plus methotrexate (MTX) ‐ data from the OPTIMA study. Annals of the Rheumatic Diseases2012;71 (Suppl 3):516. SmolenJS , EmeryP , FleischmannR , vanVollenhovenRF , PavelkaK , DurezP , et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet2014;383:321‐32. [PUBMED: 24168956] ">Smolen 2014 (OPTIMA)</a>; <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a>; <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a>; <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a>; <a href="./references#CD010455-bbs2-0014" title="YamanakaH , NagaokaS , LeeS , BaeS , KasamaT , KobayashiH , et al. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity ‐ results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Modern Rheumatology2016;26(5):651‐61. [PUBMED: 26698929] ">Yamanaka 2016 (ENCOURAGE)</a>). </p> </section> <section id="CD010455-sec-0084"> <h4 class="title">Other potential sources of bias</h4> <p>Eight studies appeared to be free of other potential sources of bias (<a href="./references#CD010455-bbs2-0002" title="ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. A multicentre, randomised, controlled, open‐label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open2016;2:e000133. [PUBMED: 26819752 ] ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. Multicenter, randomised, controlled, open‐label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients is stable clinical remission. Arthritis and Rheumatism2012;64(Suppl 10):776. ">Chatzidionysiou 2016 (ADMIRE)</a>; <a href="./references#CD010455-bbs2-0003" title="ElMiedanyY , ElGaafaryM , AhmedI , BahlasS , HegaziM , NasrA . Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission. Clinical Rheumatology2016;35:2915‐23. [PUBMED: 27658417] ">El Miedany 2016</a>; <a href="./references#CD010455-bbs2-0006" title="GallowayJB , KingsleyG , MaM , Lorente‐CanovasB , CopeA , IbrahimF , et al. Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial. Annals of the Rheumatic Diseases2015;74 (Suppl 2):706. IbrahimF , Lorente‐CánovasB , DoréCJ , BosworthA , MaMH , GallowayJB , et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis ‐ a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology2017;56:2004‐14. [PUBMED: 28968858] ">Ibrahim 2017 (OPTTIRA)</a>; <a href="./references#CD010455-bbs2-0007" title="NCT01578850 . Study conducted in subjects with rheumatoid arthritis who have moderate to severe disease activity despite methotrexate therapy with or without other non biologic disease modifying antirheumatic drugs (DMARDs) for at least 12 weeks prior to screening. https://clinicaltrials.gov/ct2/show/results/NCT01578850 First posted April 17, 2012. PavelkaK , AkkoçN , Al‐MainiM , ZerbiniCAF , KarateevDE , NasonovEL , et al. Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat‑to‑target study conducted in regions with limited biologic access. Rheumatology International2017;37:1469‐79. [PUBMED: 28597306] ">Pavelka 2017</a>; <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a>; <a href="./references#CD010455-bbs2-0010" title="EmeryP , SmolenJS , KavanaughA , vanVollenhovenR , PavelkaK , DurezP , et al. Maintenance of biologic‐free disease control in early rheumatoid arthritis patients after induction of low disease activity with adalimumab plus methotrexate. Annals of the Rheumatic Diseases2011;70 (Suppl 3):262. SmolenJS , EmeryP , FleischmannR , vanVollenhovenR , FlorentiusS , SantraS , et al. Biologic free disease control (BFDC) in early RA: predictors of successful withdrawal of adalimumab (ADA) after achieving stable low disease activity with ADA plus methotrexate (MTX) ‐ data from the OPTIMA study. Annals of the Rheumatic Diseases2012;71 (Suppl 3):516. SmolenJS , EmeryP , FleischmannR , vanVollenhovenRF , PavelkaK , DurezP , et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet2014;383:321‐32. [PUBMED: 24168956] ">Smolen 2014 (OPTIMA)</a>; <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a>; <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a>). There was insufficient information in the abstract by <a href="./references#CD010455-bbs2-0001" title="BejeranoC , OreiroN , Fernandez‐LopezC , Pinto‐TasendeJA , AtanesA , DeAspeB , et al. Clinical evaluation usefulness of standardized protocol strategies of dose reduction in patients with rheumatoid arthritis in clinical remission treated with biologic therapies. The OPTIBIO study [abstract]. Arthritis and Rheumatology2016;68:(Suppl 10). ">Bejerano 2016 (OPTIBIO)</a> to assess this domain. The study by <a href="./references#CD010455-bbs2-0005" title="Ghiti MoghadamM , VonkemanHE , tenKloosterPM , TekstraJ , vanSchaardenburgD , Starmans‐KoolM , et al. Stopping tumor necrosis factor‐inhibitors in patients with established rheumatoid arthritis in remission or stable low disease activity: a pragmatic randomized multicenter open‐label controlled trial. Arthritis and Rheumatology2016;68(8):1810‐7. ">Ghiti Moghadam 2016 (POEET)</a> reported a different flare criterion in their final publication compared to the information in the trial register. No study protocol was present for <a href="./references#CD010455-bbs2-0008" title="BotsiosC , FurlanA , OstuniP , SfrisoP , TodescoS , PunziL . Effects of low‐dose etanercept in maintaining DAS‐remission previously achieved with standard‐dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2007;66(Suppl II):54. RaffeinerB , BotsiosC , OmettoF , BernardiL , StramareR , TodescoS , et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology2015;33:63‐8. [PUBMED: 25535985] ">Raffeiner 2015</a>, but information from an earlier abstract indicated that the inclusion criteria, outcome measures, and duration of follow‐up had changed over time. A lower than anticipated number of participants was included in <a href="./references#CD010455-bbs2-0014" title="YamanakaH , NagaokaS , LeeS , BaeS , KasamaT , KobayashiH , et al. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity ‐ results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Modern Rheumatology2016;26(5):651‐61. [PUBMED: 26698929] ">Yamanaka 2016 (ENCOURAGE)</a>, <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a>, and <a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a>. </p> </section> </section> <section id="CD010455-sec-0085"> <h3 class="title" id="CD010455-sec-0085">Effects of interventions</h3> <p>See: <a href="./full#CD010455-tbl-0001"><b>Summary of findings for the main comparison</b> Anti‐TNF dose reduction versus anti‐TNF continuation</a>; <a href="./full#CD010455-tbl-0002"><b>Summary of findings 2</b> Anti‐TNF discontinuation versus anti‐TNF continuation</a>; <a href="./full#CD010455-tbl-0003"><b>Summary of findings 3</b> Anti‐TNF disease activity–guided dose tapering versus anti‐TNF continuation</a> </p> <p>We have presented study results by type of intervention: (1) dose reduction, (2) discontinuation, and (3) disease activity–guided dose tapering. </p> <section id="CD010455-sec-0086"> <h4 class="title">Anti‐TNF dose reduction versus anti‐TNF continuation</h4> <section id="CD010455-sec-0087"> <h5 class="title">Major outcomes</h5> <p>See <a href="./full#CD010455-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p> <ul id="CD010455-list-0007"> <li> <p>Mean disease activity: Of the six studies included for this comparison (1148 participants), two studies, <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a> and <a href="./references#CD010455-bbs2-0006" title="GallowayJB , KingsleyG , MaM , Lorente‐CanovasB , CopeA , IbrahimF , et al. Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial. Annals of the Rheumatic Diseases2015;74 (Suppl 2):706. IbrahimF , Lorente‐CánovasB , DoréCJ , BosworthA , MaMH , GallowayJB , et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis ‐ a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology2017;56:2004‐14. [PUBMED: 28968858] ">Ibrahim 2017 (OPTTIRA)</a>, with 501 participants provided data on mean disease activity (DAS28). Anti‐TNF dose reduction resulted in little or no difference in mean disease activity score after 26 to 52 weeks' follow‐up (mean difference (MD) 0.06, 95% confidence interval (CI) −0.11 to 0.24). We pooled data from the two dose reduction arms in the study by <a href="./references#CD010455-bbs2-0006" title="GallowayJB , KingsleyG , MaM , Lorente‐CanovasB , CopeA , IbrahimF , et al. Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial. Annals of the Rheumatic Diseases2015;74 (Suppl 2):706. IbrahimF , Lorente‐CánovasB , DoréCJ , BosworthA , MaMH , GallowayJB , et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis ‐ a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology2017;56:2004‐14. [PUBMED: 28968858] ">Ibrahim 2017 (OPTTIRA)</a> for this outcome. <a href="./references#CD010455-fig-0004" title="">Analysis 1.1</a> </p> </li> <li> <p>Proportion persistent remission: Of the six studies included for this comparison (1148 participants), two studies, <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a> and <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a>, with 612 participants provided data on persistent remission. Anti‐TNF dose reduction may result in little or no difference in the proportion of participants with persistent remission (DAS28 &lt; 2.6) after 52 weeks (risk ratio (RR) 1.01, 95% CI 0.80 to 1.28). <a href="./references#CD010455-fig-0005" title="">Analysis 1.2</a> </p> </li> <li> <p>Proportion of participants that switched to another biologic: Of the six studies included for this comparison (1148 participants), only one study with 323 participants provided data on this outcome (<a href="./references#CD010455-bbs2-0008" title="BotsiosC , FurlanA , OstuniP , SfrisoP , TodescoS , PunziL . Effects of low‐dose etanercept in maintaining DAS‐remission previously achieved with standard‐dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2007;66(Suppl II):54. RaffeinerB , BotsiosC , OmettoF , BernardiL , StramareR , TodescoS , et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology2015;33:63‐8. [PUBMED: 25535985] ">Raffeiner 2015</a>). The data showed that anti‐TNF dose reduction may slightly reduce the proportion of participants who are switched to another biologic (RR 0.40, 95% CI 0.17 to 0.93; mean follow‐up period 3.5 ± 1.5 years). This result might be explained by a difference in treatment strategy after flare in the two treatment groups. In the continuation group, a flare resulted in a switch of biologic treatment, while in the dose reduction group the standard dose of etanercept was reinstated first (<a href="./references#CD010455-bbs2-0008" title="BotsiosC , FurlanA , OstuniP , SfrisoP , TodescoS , PunziL . Effects of low‐dose etanercept in maintaining DAS‐remission previously achieved with standard‐dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2007;66(Suppl II):54. RaffeinerB , BotsiosC , OmettoF , BernardiL , StramareR , TodescoS , et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology2015;33:63‐8. [PUBMED: 25535985] ">Raffeiner 2015</a>). <a href="./references#CD010455-fig-0006" title="">Analysis 1.3</a> </p> </li> <li> <p>Proportion of participants with minimal radiographic progression: Of the six studies included for this comparison (1148 participants), two studies provided data on radiographic progression, <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a> and <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a>, with 553 participants. Anti‐TNF dose reduction probably slightly increases the proportion of participants with minimal radiographic progression (mSvdH &gt; 0.5) after 52 weeks (RR 1.22, 95% CI 0.76 to 1.95). <a href="./references#CD010455-fig-0007" title="">Analysis 1.4</a> </p> </li> <li> <p>Function: Of the six studies included for this comparison (1148 participants), two studies, <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a> and <a href="./references#CD010455-bbs2-0006" title="GallowayJB , KingsleyG , MaM , Lorente‐CanovasB , CopeA , IbrahimF , et al. Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial. Annals of the Rheumatic Diseases2015;74 (Suppl 2):706. IbrahimF , Lorente‐CánovasB , DoréCJ , BosworthA , MaMH , GallowayJB , et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis ‐ a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology2017;56:2004‐14. [PUBMED: 28968858] ">Ibrahim 2017 (OPTTIRA)</a>, with 501 participants provided data on this outcome. Anti‐TNF dose reduction does not result in an important deterioration in function (HAQ Disability Index (HAQ‐DI)) after 26 to 52 weeks' follow‐up (MD 0.09, 95% CI 0.00 to 0.19). We pooled data from the two dose reduction arms in the study by <a href="./references#CD010455-bbs2-0006" title="GallowayJB , KingsleyG , MaM , Lorente‐CanovasB , CopeA , IbrahimF , et al. Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial. Annals of the Rheumatic Diseases2015;74 (Suppl 2):706. IbrahimF , Lorente‐CánovasB , DoréCJ , BosworthA , MaMH , GallowayJB , et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis ‐ a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology2017;56:2004‐14. [PUBMED: 28968858] ">Ibrahim 2017 (OPTTIRA)</a> for this outcome. <a href="./references#CD010455-fig-0008" title="">Analysis 1.5</a> </p> </li> <li> <p>Number of serious adverse events: Of the six studies included for this comparison (1148 participants), five studies with 1084 participants provided data on this outcome (<a href="./references#CD010455-bbs2-0006" title="GallowayJB , KingsleyG , MaM , Lorente‐CanovasB , CopeA , IbrahimF , et al. Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial. Annals of the Rheumatic Diseases2015;74 (Suppl 2):706. IbrahimF , Lorente‐CánovasB , DoréCJ , BosworthA , MaMH , GallowayJB , et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis ‐ a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology2017;56:2004‐14. [PUBMED: 28968858] ">Ibrahim 2017 (OPTTIRA)</a>; <a href="./references#CD010455-bbs2-0008" title="BotsiosC , FurlanA , OstuniP , SfrisoP , TodescoS , PunziL . Effects of low‐dose etanercept in maintaining DAS‐remission previously achieved with standard‐dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2007;66(Suppl II):54. RaffeinerB , BotsiosC , OmettoF , BernardiL , StramareR , TodescoS , et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology2015;33:63‐8. [PUBMED: 25535985] ">Raffeiner 2015</a>; <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a>; <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a>; <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a>). Anti‐TNF dose reduction may cause little or no difference inthe number of serious adverse events after 26 to 52 weeks' follow‐up (RR 1.09, 95% CI 0.65 to 1.82). We pooled data from the two dose reduction arms in the study by <a href="./references#CD010455-bbs2-0006" title="GallowayJB , KingsleyG , MaM , Lorente‐CanovasB , CopeA , IbrahimF , et al. Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial. Annals of the Rheumatic Diseases2015;74 (Suppl 2):706. IbrahimF , Lorente‐CánovasB , DoréCJ , BosworthA , MaMH , GallowayJB , et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis ‐ a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology2017;56:2004‐14. [PUBMED: 28968858] ">Ibrahim 2017 (OPTTIRA)</a> for this outcome. <a href="./references#CD010455-fig-0009" title="">Analysis 1.6</a> </p> </li> <li> <p>Withdrawals due to adverse events: Of the six studies included for this comparison (1148 participants), three studies with 937 participants provided data on this outcome (<a href="./references#CD010455-bbs2-0008" title="BotsiosC , FurlanA , OstuniP , SfrisoP , TodescoS , PunziL . Effects of low‐dose etanercept in maintaining DAS‐remission previously achieved with standard‐dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2007;66(Suppl II):54. RaffeinerB , BotsiosC , OmettoF , BernardiL , StramareR , TodescoS , et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology2015;33:63‐8. [PUBMED: 25535985] ">Raffeiner 2015</a>; <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a>; <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a>). Anti‐TNF dose reduction may cause little or no difference in the number of withdrawals due to adverse events after 52 weeks (RR 1.07, 95% CI 0.51 to 2.24). <a href="./references#CD010455-fig-0010" title="">Analysis 1.7</a> </p> </li> </ul> </p> </section> <section id="CD010455-sec-0088"> <h5 class="title">Minor outcomes</h5> <p> <ul id="CD010455-list-0008"> <li> <p>Proportion of participants with a flare: Of the six included studies for this comparison (1148 participants), three studies with 357 participants provided data on this outcome (<a href="./references#CD010455-bbs2-0006" title="GallowayJB , KingsleyG , MaM , Lorente‐CanovasB , CopeA , IbrahimF , et al. Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial. Annals of the Rheumatic Diseases2015;74 (Suppl 2):706. IbrahimF , Lorente‐CánovasB , DoréCJ , BosworthA , MaMH , GallowayJB , et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis ‐ a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology2017;56:2004‐14. [PUBMED: 28968858] ">Ibrahim 2017 (OPTTIRA)</a>; <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a>; <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a>). The three studies used different criteria for flare. <a href="./references#CD010455-bbs2-0006" title="GallowayJB , KingsleyG , MaM , Lorente‐CanovasB , CopeA , IbrahimF , et al. Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial. Annals of the Rheumatic Diseases2015;74 (Suppl 2):706. IbrahimF , Lorente‐CánovasB , DoréCJ , BosworthA , MaMH , GallowayJB , et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis ‐ a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology2017;56:2004‐14. [PUBMED: 28968858] ">Ibrahim 2017 (OPTTIRA)</a> defined a flare as an increase in DAS28 scores ≥ 0.6 resulting in a DAS28 &gt; 3.2 together with an increase in the swollen joint count; both had to be present on two occasions at least one week apart. An increase in DAS28 score ≥ 1.2 resulting in DAS28 &gt; 3.2 was defined as flare irrespective of changes in swollen joints. <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a> defined a flare as (a) a DAS28‐ESR &gt; 5.1; (b) a DAS28‐ESR &gt; 3.2 and an increase ≥ 1.2 from baseline; (c) DAS28‐ESR &gt; 3.2 and an increase in DAS28 ≥ 0.6 from baseline on two consecutive visits at least one to three weeks apart; or (d) disease progression as determined by either the investigator or disease flare as experienced by the participant. <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a> stated that participants reporting a flare also had to meet the following three criteria at two consecutive visits two weeks apart: 1) an increase in the DAS28‐ESR of ≥ 0.6 above the DAS28‐ESR at week 52; 2) a DAS28‐ESR of &gt; 3.2; and 3) in the investigator’s judgement, an increase in the participant’s RA activity. Furthermore, <a href="./references#CD010455-bbs2-0006" title="GallowayJB , KingsleyG , MaM , Lorente‐CanovasB , CopeA , IbrahimF , et al. Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial. Annals of the Rheumatic Diseases2015;74 (Suppl 2):706. IbrahimF , Lorente‐CánovasB , DoréCJ , BosworthA , MaMH , GallowayJB , et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis ‐ a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology2017;56:2004‐14. [PUBMED: 28968858] ">Ibrahim 2017 (OPTTIRA)</a> included two intervention groups: 33% and 66% dose reduction. Due to this heterogeneity data were not pooled. The studies did not show a difference between the anti‐TNF dose reduction group(s) and the continuation group; risk ratios were found between 0.29 and 1.79. </p> </li> <li> <p>Quality of life: Of the six studies included for this comparison (1148 participants), two studies, <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a> and <a href="./references#CD010455-bbs2-0006" title="GallowayJB , KingsleyG , MaM , Lorente‐CanovasB , CopeA , IbrahimF , et al. Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial. Annals of the Rheumatic Diseases2015;74 (Suppl 2):706. IbrahimF , Lorente‐CánovasB , DoréCJ , BosworthA , MaMH , GallowayJB , et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis ‐ a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology2017;56:2004‐14. [PUBMED: 28968858] ">Ibrahim 2017 (OPTTIRA)</a>, with 501 participants provided data on this outcome. Anti‐TNF dose reduction resulted in little or no difference in mean EQ‐5D after 26 to 52 weeks' follow‐up (MD 0.00, 95% CI −0.04 to 0.03). We pooled data from the two dose reduction arms in the study by <a href="./references#CD010455-bbs2-0006" title="GallowayJB , KingsleyG , MaM , Lorente‐CanovasB , CopeA , IbrahimF , et al. Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial. Annals of the Rheumatic Diseases2015;74 (Suppl 2):706. IbrahimF , Lorente‐CánovasB , DoréCJ , BosworthA , MaMH , GallowayJB , et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis ‐ a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology2017;56:2004‐14. [PUBMED: 28968858] ">Ibrahim 2017 (OPTTIRA)</a> for this outcome. </p> </li> <li> <p>Costs: None of the six included studies provided data on this outcome.</p> </li> <li> <p>Decremental cost‐effectiveness ratio: None of the six included studies provided data on this outcome. </p> </li> <li> <p>Time to flare: Of the six studies included for this comparison (1148 participants), one study with 50 participants provided data on this outcome (<a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a>). Median time to failure was 48 weeks in the etanercept 50 mg/week continuation group and 36 weeks in the etanercept 25 mg/week dose reduction group, but no SDs were available. </p> </li> <li> <p>Change in other medication: None of the six included studies reported data on this outcome. </p> </li> </ul> </p> </section> </section> <section id="CD010455-sec-0089"> <h4 class="title">Anti‐TNF discontinuation versus anti‐TNF continuation</h4> <p>See <a href="./full#CD010455-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD010455-sec-0090"> <h5 class="title">Major outcomes</h5> <p> <ul id="CD010455-list-0009"> <li> <p>Mean disease activity: Of the eight studies (2111 participants) included for this comparison, three studies, <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a>, <a href="./references#CD010455-bbs2-0005" title="Ghiti MoghadamM , VonkemanHE , tenKloosterPM , TekstraJ , vanSchaardenburgD , Starmans‐KoolM , et al. Stopping tumor necrosis factor‐inhibitors in patients with established rheumatoid arthritis in remission or stable low disease activity: a pragmatic randomized multicenter open‐label controlled trial. Arthritis and Rheumatology2016;68(8):1810‐7. ">Ghiti Moghadam 2016 (POEET)</a>, and <a href="./references#CD010455-bbs2-0007" title="NCT01578850 . Study conducted in subjects with rheumatoid arthritis who have moderate to severe disease activity despite methotrexate therapy with or without other non biologic disease modifying antirheumatic drugs (DMARDs) for at least 12 weeks prior to screening. https://clinicaltrials.gov/ct2/show/results/NCT01578850 First posted April 17, 2012. PavelkaK , AkkoçN , Al‐MainiM , ZerbiniCAF , KarateevDE , NasonovEL , et al. Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat‑to‑target study conducted in regions with limited biologic access. Rheumatology International2017;37:1469‐79. [PUBMED: 28597306] ">Pavelka 2017</a>, with 402, 692, and 331 participants, respectively, provided data on mean disease activity. We pooled data from <a href="./references#CD010455-bbs2-0007" title="NCT01578850 . Study conducted in subjects with rheumatoid arthritis who have moderate to severe disease activity despite methotrexate therapy with or without other non biologic disease modifying antirheumatic drugs (DMARDs) for at least 12 weeks prior to screening. https://clinicaltrials.gov/ct2/show/results/NCT01578850 First posted April 17, 2012. PavelkaK , AkkoçN , Al‐MainiM , ZerbiniCAF , KarateevDE , NasonovEL , et al. Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat‑to‑target study conducted in regions with limited biologic access. Rheumatology International2017;37:1469‐79. [PUBMED: 28597306] ">Pavelka 2017</a> and <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a>. Anti‐TNF discontinuation probably increases the mean disease activity score (DAS28) slightly after 28 to 52 weeks' follow‐up (MD 0.96, 95% CI 0.67 to 1.25). We considered the study by <a href="./references#CD010455-bbs2-0005" title="Ghiti MoghadamM , VonkemanHE , tenKloosterPM , TekstraJ , vanSchaardenburgD , Starmans‐KoolM , et al. Stopping tumor necrosis factor‐inhibitors in patients with established rheumatoid arthritis in remission or stable low disease activity: a pragmatic randomized multicenter open‐label controlled trial. Arthritis and Rheumatology2016;68(8):1810‐7. ">Ghiti Moghadam 2016 (POEET)</a> to be different since participants could return to standard dose in case of flare, and no LOCF was described, therefore the results will reflect the effect of a discontinuation and restarting strategy. This strategy resulted in a small, possibly unimportant increase in mean disease activity score after 52 weeks (MD 0.29, 95% CI 0.14 to 0.44). <a href="./references#CD010455-fig-0013" title="">Analysis 2.1</a> </p> </li> <li> <p>Proportion persistent remission: Of the eight studies reporting on this comparison (2111 participants), six studies with 1188 participants provided data on the proportion of participants with persistent remission (<a href="./references#CD010455-bbs2-0002" title="ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. A multicentre, randomised, controlled, open‐label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open2016;2:e000133. [PUBMED: 26819752 ] ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. Multicenter, randomised, controlled, open‐label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients is stable clinical remission. Arthritis and Rheumatism2012;64(Suppl 10):776. ">Chatzidionysiou 2016 (ADMIRE)</a>; <a href="./references#CD010455-bbs2-0007" title="NCT01578850 . Study conducted in subjects with rheumatoid arthritis who have moderate to severe disease activity despite methotrexate therapy with or without other non biologic disease modifying antirheumatic drugs (DMARDs) for at least 12 weeks prior to screening. https://clinicaltrials.gov/ct2/show/results/NCT01578850 First posted April 17, 2012. PavelkaK , AkkoçN , Al‐MainiM , ZerbiniCAF , KarateevDE , NasonovEL , et al. Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat‑to‑target study conducted in regions with limited biologic access. Rheumatology International2017;37:1469‐79. [PUBMED: 28597306] ">Pavelka 2017</a>; <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a>; <a href="./references#CD010455-bbs2-0010" title="EmeryP , SmolenJS , KavanaughA , vanVollenhovenR , PavelkaK , DurezP , et al. Maintenance of biologic‐free disease control in early rheumatoid arthritis patients after induction of low disease activity with adalimumab plus methotrexate. Annals of the Rheumatic Diseases2011;70 (Suppl 3):262. SmolenJS , EmeryP , FleischmannR , vanVollenhovenR , FlorentiusS , SantraS , et al. Biologic free disease control (BFDC) in early RA: predictors of successful withdrawal of adalimumab (ADA) after achieving stable low disease activity with ADA plus methotrexate (MTX) ‐ data from the OPTIMA study. Annals of the Rheumatic Diseases2012;71 (Suppl 3):516. SmolenJS , EmeryP , FleischmannR , vanVollenhovenRF , PavelkaK , DurezP , et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet2014;383:321‐32. [PUBMED: 24168956] ">Smolen 2014 (OPTIMA)</a>; <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a>; <a href="./references#CD010455-bbs2-0014" title="YamanakaH , NagaokaS , LeeS , BaeS , KasamaT , KobayashiH , et al. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity ‐ results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Modern Rheumatology2016;26(5):651‐61. [PUBMED: 26698929] ">Yamanaka 2016 (ENCOURAGE)</a>). We were unable to pool data due to heterogeneity. The RR after 28 to 52 weeks varied between 0.16 in <a href="./references#CD010455-bbs2-0002" title="ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. A multicentre, randomised, controlled, open‐label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open2016;2:e000133. [PUBMED: 26819752 ] ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. Multicenter, randomised, controlled, open‐label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients is stable clinical remission. Arthritis and Rheumatism2012;64(Suppl 10):776. ">Chatzidionysiou 2016 (ADMIRE)</a> and 0.77 in <a href="./references#CD010455-bbs2-0010" title="EmeryP , SmolenJS , KavanaughA , vanVollenhovenR , PavelkaK , DurezP , et al. Maintenance of biologic‐free disease control in early rheumatoid arthritis patients after induction of low disease activity with adalimumab plus methotrexate. Annals of the Rheumatic Diseases2011;70 (Suppl 3):262. SmolenJS , EmeryP , FleischmannR , vanVollenhovenR , FlorentiusS , SantraS , et al. Biologic free disease control (BFDC) in early RA: predictors of successful withdrawal of adalimumab (ADA) after achieving stable low disease activity with ADA plus methotrexate (MTX) ‐ data from the OPTIMA study. Annals of the Rheumatic Diseases2012;71 (Suppl 3):516. SmolenJS , EmeryP , FleischmannR , vanVollenhovenRF , PavelkaK , DurezP , et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet2014;383:321‐32. [PUBMED: 24168956] ">Smolen 2014 (OPTIMA)</a> and <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a>. The absolute risk difference varied between 15% fewer in <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a> and 68% fewer in <a href="./references#CD010455-bbs2-0002" title="ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. A multicentre, randomised, controlled, open‐label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open2016;2:e000133. [PUBMED: 26819752 ] ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. Multicenter, randomised, controlled, open‐label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients is stable clinical remission. Arthritis and Rheumatism2012;64(Suppl 10):776. ">Chatzidionysiou 2016 (ADMIRE)</a>. <a href="./references#CD010455-fig-0014" title="">Analysis 2.2</a> </p> </li> <li> <p>Proportion of participants that switched to another biologic due to persistent loss of response (refractory to re‐instalment of the tapered anti‐TNF in the intervention group): None of the eight included studies provided data on this outcome. <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a> reported that no attempt was made to recapture low disease activity by reintroducing etanercept in participants whose condition had deteriorated after etanercept withdrawal, raising some ethical issues in our view. </p> </li> <li> <p>Proportion of participants with minimal radiographic progression: Of the eight studies (2111 participants) included for this comparison, three studies, <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a>, <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a>, and <a href="./references#CD010455-bbs2-0014" title="YamanakaH , NagaokaS , LeeS , BaeS , KasamaT , KobayashiH , et al. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity ‐ results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Modern Rheumatology2016;26(5):651‐61. [PUBMED: 26698929] ">Yamanaka 2016 (ENCOURAGE)</a>), with 549 participants provided data on this outcome. The meta‐analysis showed that anti‐TNF discontinuation increases the proportion of participants with minimal radiographic progression &gt; 0.5 mSvdH point after 52 weeks (RR 1.69, 95% 1.10 to 2.59). <a href="./references#CD010455-fig-0015" title="">Analysis 2.3</a> </p> </li> <li> <p>Function: Of the eight studies (2111 participants) included for this comparison, four studies with 1498 participants provided data on this outcome (<a href="./references#CD010455-bbs2-0005" title="Ghiti MoghadamM , VonkemanHE , tenKloosterPM , TekstraJ , vanSchaardenburgD , Starmans‐KoolM , et al. Stopping tumor necrosis factor‐inhibitors in patients with established rheumatoid arthritis in remission or stable low disease activity: a pragmatic randomized multicenter open‐label controlled trial. Arthritis and Rheumatology2016;68(8):1810‐7. ">Ghiti Moghadam 2016 (POEET)</a>; <a href="./references#CD010455-bbs2-0007" title="NCT01578850 . Study conducted in subjects with rheumatoid arthritis who have moderate to severe disease activity despite methotrexate therapy with or without other non biologic disease modifying antirheumatic drugs (DMARDs) for at least 12 weeks prior to screening. https://clinicaltrials.gov/ct2/show/results/NCT01578850 First posted April 17, 2012. PavelkaK , AkkoçN , Al‐MainiM , ZerbiniCAF , KarateevDE , NasonovEL , et al. Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat‑to‑target study conducted in regions with limited biologic access. Rheumatology International2017;37:1469‐79. [PUBMED: 28597306] ">Pavelka 2017</a>; <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a>; <a href="./references#CD010455-bbs2-0010" title="EmeryP , SmolenJS , KavanaughA , vanVollenhovenR , PavelkaK , DurezP , et al. Maintenance of biologic‐free disease control in early rheumatoid arthritis patients after induction of low disease activity with adalimumab plus methotrexate. Annals of the Rheumatic Diseases2011;70 (Suppl 3):262. SmolenJS , EmeryP , FleischmannR , vanVollenhovenR , FlorentiusS , SantraS , et al. Biologic free disease control (BFDC) in early RA: predictors of successful withdrawal of adalimumab (ADA) after achieving stable low disease activity with ADA plus methotrexate (MTX) ‐ data from the OPTIMA study. Annals of the Rheumatic Diseases2012;71 (Suppl 3):516. SmolenJS , EmeryP , FleischmannR , vanVollenhovenRF , PavelkaK , DurezP , et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet2014;383:321‐32. [PUBMED: 24168956] ">Smolen 2014 (OPTIMA)</a>). The results showed that anti‐TNF discontinuation may lead to a slight deterioration in function after 28 to 52 weeks' follow‐up (MD 0.18, 95% CI 0.05 to 0.31). <a href="./references#CD010455-fig-0016" title="">Analysis 2.4</a> </p> </li> <li> <p>Number of serious adverse events: All eight studies included for this comparison provided data on this outcome, with 2095 participants. Due to the very low certainty of the evidence and imprecision of the results, it is uncertain whether anti‐TNF discontinuation influences the number of serious adverse events after 28 to 52 weeks (RR 1.29, 95% CI 0.82 to 2.03). <a href="./references#CD010455-fig-0017" title="">Analysis 2.5</a> </p> </li> <li> <p>Withdrawals due to adverse events: Of the eight studies (2111 participants) included for this comparison, four studies with 1116 participants provided data on this outcome (<a href="./references#CD010455-bbs2-0007" title="NCT01578850 . Study conducted in subjects with rheumatoid arthritis who have moderate to severe disease activity despite methotrexate therapy with or without other non biologic disease modifying antirheumatic drugs (DMARDs) for at least 12 weeks prior to screening. https://clinicaltrials.gov/ct2/show/results/NCT01578850 First posted April 17, 2012. PavelkaK , AkkoçN , Al‐MainiM , ZerbiniCAF , KarateevDE , NasonovEL , et al. Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat‑to‑target study conducted in regions with limited biologic access. Rheumatology International2017;37:1469‐79. [PUBMED: 28597306] ">Pavelka 2017</a>; <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a>; <a href="./references#CD010455-bbs2-0010" title="EmeryP , SmolenJS , KavanaughA , vanVollenhovenR , PavelkaK , DurezP , et al. Maintenance of biologic‐free disease control in early rheumatoid arthritis patients after induction of low disease activity with adalimumab plus methotrexate. Annals of the Rheumatic Diseases2011;70 (Suppl 3):262. SmolenJS , EmeryP , FleischmannR , vanVollenhovenR , FlorentiusS , SantraS , et al. Biologic free disease control (BFDC) in early RA: predictors of successful withdrawal of adalimumab (ADA) after achieving stable low disease activity with ADA plus methotrexate (MTX) ‐ data from the OPTIMA study. Annals of the Rheumatic Diseases2012;71 (Suppl 3):516. SmolenJS , EmeryP , FleischmannR , vanVollenhovenRF , PavelkaK , DurezP , et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet2014;383:321‐32. [PUBMED: 24168956] ">Smolen 2014 (OPTIMA)</a>; <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a>). Anti‐TNF discontinuation probably slightly increases the number of withdrawals due to adverse events after 28 to 52 weeks (RR 1.46, 95% CI 0.75 to 2.84). <a href="./references#CD010455-fig-0018" title="">Analysis 2.6</a> </p> </li> </ul> </p> </section> <section id="CD010455-sec-0091"> <h5 class="title">Minor outcomes</h5> <p> <ul id="CD010455-list-0010"> <li> <p>Proportion of participants with a flare: Of the eight studies (2111 participants) included for this comparison, five studies provided data on this outcome (<a href="./references#CD010455-bbs2-0002" title="ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. A multicentre, randomised, controlled, open‐label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open2016;2:e000133. [PUBMED: 26819752 ] ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. Multicenter, randomised, controlled, open‐label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients is stable clinical remission. Arthritis and Rheumatism2012;64(Suppl 10):776. ">Chatzidionysiou 2016 (ADMIRE)</a>; <a href="./references#CD010455-bbs2-0005" title="Ghiti MoghadamM , VonkemanHE , tenKloosterPM , TekstraJ , vanSchaardenburgD , Starmans‐KoolM , et al. Stopping tumor necrosis factor‐inhibitors in patients with established rheumatoid arthritis in remission or stable low disease activity: a pragmatic randomized multicenter open‐label controlled trial. Arthritis and Rheumatology2016;68(8):1810‐7. ">Ghiti Moghadam 2016 (POEET)</a>; <a href="./references#CD010455-bbs2-0007" title="NCT01578850 . Study conducted in subjects with rheumatoid arthritis who have moderate to severe disease activity despite methotrexate therapy with or without other non biologic disease modifying antirheumatic drugs (DMARDs) for at least 12 weeks prior to screening. https://clinicaltrials.gov/ct2/show/results/NCT01578850 First posted April 17, 2012. PavelkaK , AkkoçN , Al‐MainiM , ZerbiniCAF , KarateevDE , NasonovEL , et al. Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat‑to‑target study conducted in regions with limited biologic access. Rheumatology International2017;37:1469‐79. [PUBMED: 28597306] ">Pavelka 2017</a>; <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a>; <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a>), with 31, 46, 331, 817, and 163 participants, respectively. We did not pool data because of clinical and statistical heterogeneity. The study by <a href="./references#CD010455-bbs2-0002" title="ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. A multicentre, randomised, controlled, open‐label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open2016;2:e000133. [PUBMED: 26819752 ] ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. Multicenter, randomised, controlled, open‐label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients is stable clinical remission. Arthritis and Rheumatism2012;64(Suppl 10):776. ">Chatzidionysiou 2016 (ADMIRE)</a> defined flare as DAS28 ≥ 2.6 or an increase of more than 1.2 from baseline. After 28 weeks, proportion of flare in the adalimumab discontinuation group was not statistically significantly different from that in the adalimumab continuation group (RR 1.6, 95% CI 0.92 to 2.78). <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a> defined flare as (a) a DAS28‐ESR &gt; 5.1; (b) a DAS28‐ESR &gt; 3.2 and an increase ≥ 1.2 from baseline; (c) DAS28‐ESR &gt; 3.2 and an increase in DAS28 ≥ 0.6 from baseline on two consecutive visits at least one to three weeks apart; or (d) disease progression as determined by either the investigator or disease flare as experienced by the participant. After 48 weeks' follow‐up, the proportion of participants with flare was higher in the discontinuation group compared to the continuation group (RR 1.82, 95% CI 1.15 to 2.87). <a href="./references#CD010455-bbs2-0005" title="Ghiti MoghadamM , VonkemanHE , tenKloosterPM , TekstraJ , vanSchaardenburgD , Starmans‐KoolM , et al. Stopping tumor necrosis factor‐inhibitors in patients with established rheumatoid arthritis in remission or stable low disease activity: a pragmatic randomized multicenter open‐label controlled trial. Arthritis and Rheumatology2016;68(8):1810‐7. ">Ghiti Moghadam 2016 (POEET)</a>, <a href="./references#CD010455-bbs2-0007" title="NCT01578850 . Study conducted in subjects with rheumatoid arthritis who have moderate to severe disease activity despite methotrexate therapy with or without other non biologic disease modifying antirheumatic drugs (DMARDs) for at least 12 weeks prior to screening. https://clinicaltrials.gov/ct2/show/results/NCT01578850 First posted April 17, 2012. PavelkaK , AkkoçN , Al‐MainiM , ZerbiniCAF , KarateevDE , NasonovEL , et al. Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat‑to‑target study conducted in regions with limited biologic access. Rheumatology International2017;37:1469‐79. [PUBMED: 28597306] ">Pavelka 2017</a>, and <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a> used the same criterion for flare: DAS28 ≥ 3.2 and an increase of 0.6 or more. <a href="./references#CD010455-bbs2-0005" title="Ghiti MoghadamM , VonkemanHE , tenKloosterPM , TekstraJ , vanSchaardenburgD , Starmans‐KoolM , et al. Stopping tumor necrosis factor‐inhibitors in patients with established rheumatoid arthritis in remission or stable low disease activity: a pragmatic randomized multicenter open‐label controlled trial. Arthritis and Rheumatology2016;68(8):1810‐7. ">Ghiti Moghadam 2016 (POEET)</a> found that the proportion of participants with flare was higher in the anti‐TNF discontinuation group than in the continuation group (after 24 weeks RR 3.37, 95% CI 2.42 to 4.70; after 52 weeks RR 2.82, 95% CI 2.17 to 3.65). <a href="./references#CD010455-bbs2-0007" title="NCT01578850 . Study conducted in subjects with rheumatoid arthritis who have moderate to severe disease activity despite methotrexate therapy with or without other non biologic disease modifying antirheumatic drugs (DMARDs) for at least 12 weeks prior to screening. https://clinicaltrials.gov/ct2/show/results/NCT01578850 First posted April 17, 2012. PavelkaK , AkkoçN , Al‐MainiM , ZerbiniCAF , KarateevDE , NasonovEL , et al. Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat‑to‑target study conducted in regions with limited biologic access. Rheumatology International2017;37:1469‐79. [PUBMED: 28597306] ">Pavelka 2017</a> found a higher proportion of flare in the participants that stopped anti‐TNF after 28 weeks (RR 1.53, 95% CI 1.30 to 1.81). <a href="./references#CD010455-bbs2-0013" title="WeinblattME , BinghamCO3rd , BurmesterG , BykerkVP , FurstDE , MarietteX , et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69:1937‐48. [PUBMED: 28666080] ">Weinblatt 2017 (C‐EARLY)</a> found no difference in the proportion of participants with flare between the anti‐TNF discontinuation group and the continuation group (RR 1.52, 95% CI 0.61 to 3.80). </p> </li> <li> <p>Quality of life: Of the eight studies (2111 participants) included for this comparison, two studies, <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a> and <a href="./references#CD010455-bbs2-0007" title="NCT01578850 . Study conducted in subjects with rheumatoid arthritis who have moderate to severe disease activity despite methotrexate therapy with or without other non biologic disease modifying antirheumatic drugs (DMARDs) for at least 12 weeks prior to screening. https://clinicaltrials.gov/ct2/show/results/NCT01578850 First posted April 17, 2012. PavelkaK , AkkoçN , Al‐MainiM , ZerbiniCAF , KarateevDE , NasonovEL , et al. Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat‑to‑target study conducted in regions with limited biologic access. Rheumatology International2017;37:1469‐79. [PUBMED: 28597306] ">Pavelka 2017</a>, with 733 participants provided data on this outcome. Anti‐TNF discontinuation led to a deterioration in quality of life after 28 to 52 weeks (MD −0.10, 95% CI −0.13 to −0.07). </p> </li> <li> <p>Costs: None of the eight included studies provided data on direct or indirect costs.</p> </li> <li> <p>Decremental cost‐effectiveness ratio: None of the eight included studies provided data on this outcome. </p> </li> <li> <p>Time to flare: Of the eight studies included for this comparison (2111 participants), two studies, <a href="./references#CD010455-bbs2-0002" title="ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. A multicentre, randomised, controlled, open‐label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open2016;2:e000133. [PUBMED: 26819752 ] ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. Multicenter, randomised, controlled, open‐label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients is stable clinical remission. Arthritis and Rheumatism2012;64(Suppl 10):776. ">Chatzidionysiou 2016 (ADMIRE)</a> and <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a>, provided data on this outcome, with 31 and 46 participants, respectively. These two studies used different flare/failure criteria. <a href="./references#CD010455-bbs2-0002" title="ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. A multicentre, randomised, controlled, open‐label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open2016;2:e000133. [PUBMED: 26819752 ] ChatzidionysiouK , TuressonC , TelemanA , KnightA , LindqvistE , LarssonP , et al. Multicenter, randomised, controlled, open‐label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients is stable clinical remission. Arthritis and Rheumatism2012;64(Suppl 10):776. ">Chatzidionysiou 2016 (ADMIRE)</a> reported that survival curves suggested higher flare‐free survival over time in participants randomised to continue treatment with adalimumab, but that the difference did not reach statistical significance (P = 0.07). The study by <a href="./references#CD010455-bbs2-0012" title="vanVollenhovenR , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , KlackenbergA , et al. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3‐armed, double‐blind clinical trial. Arthritis and Rheumatism2012;64(12):4171. vanVollenhovenRF , ØstergaardM , Leirisalo‐RepoM , UhligT , JanssonM , LarssonE , et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases2016;75(1):52‐8. [PUBMED: 25873634] ">van Vollenhoven 2016 (DOSERA)</a> reported a median time to failure of 48 weeks in the etanercept 50 mg/week continuation group and six weeks in the etanercept discontinuation (placebo) group, but no SDs were available. </p> </li> <li> <p>Change in other medication: None of the eight included studies provided data on change in other medication. </p> </li> </ul> </p> </section> </section> <section id="CD010455-sec-0092"> <h4 class="title">Anti‐TNF disease activity–guided dose tapering versus anti‐TNF continuation</h4> <p>See <a href="./full#CD010455-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD010455-sec-0093"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD010455-list-0011"> <li> <p>Mean disease activity: All three studies included in this comparison reported on this outcome, with 357 participants (<a href="./references#CD010455-bbs2-0001" title="BejeranoC , OreiroN , Fernandez‐LopezC , Pinto‐TasendeJA , AtanesA , DeAspeB , et al. Clinical evaluation usefulness of standardized protocol strategies of dose reduction in patients with rheumatoid arthritis in clinical remission treated with biologic therapies. The OPTIBIO study [abstract]. Arthritis and Rheumatology2016;68:(Suppl 10). ">Bejerano 2016 (OPTIBIO)</a> (abstract only); <a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a>; <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a>). Anti‐TNF disease activity–guided dose tapering may result in little or no difference in mean disease activity score (MD 0.25, 95% CI −0.17 to 0.67). <a href="./references#CD010455-fig-0021" title="">Analysis 3.1</a> </p> </li> <li> <p>Proportion persistent remission: Of the three studies included in this comparison (365 participants), one study with 180 participants reported on this outcome (<a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a>). Anti‐TNF disease activity–guided dose tapering resulted in little or no difference in the proportion of participants with persistent remission (DAS28 &lt; 2.6) after 18 months (RR 0.89, 95% CI 0.75 to 1.06). <a href="./references#CD010455-fig-0022" title="">Analysis 3.2</a> </p> </li> <li> <p>Proportion of participants that switched to another biologic due to persistent loss of response (refractory to re‐instalment of the tapered anti‐TNF in the intervention group): Of the three studies included in this comparison (365 participants), two studies, <a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a> and <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a>, with 317 participants reported on this outcome. Anti‐TNF disease activity–guided dose tapering may result in little or no difference in the proportion of participants that switch to another biologic after 18 months (RR 0.62, 95% CI 0.25 to 1.54). <a href="./references#CD010455-fig-0023" title="">Analysis 3.3</a> </p> </li> <li> <p>Proportion of participants with minimal radiographic progression: Of the three studies included in this comparison (365 participants), two studies, <a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a> and <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a>, with 312 participants reported on this outcome. Although <a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a> used a cut‐off value of 1 point and <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a> a cut‐off value of 0.5 point mSvdH score, data could be pooled. Anti‐TNF disease activity–guided dose tapering may slightly increase the proportion of participants with minimal radiographic progression (mSvdH &gt; 0.5 or &gt; 1.0) after 18 months (RR 1.45, 95% CI 0.77 to 2.73). <a href="./references#CD010455-fig-0024" title="">Analysis 3.4</a> </p> </li> <li> <p>Function: Of the three studies included in this comparison (365 participants), one study with 123 participants reported on this outcome (<a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a>). IAnti‐TNF disease activity–guided dose tapering probably leads to a slight deterioration in function after 18 months (MD 0.20, 95% CI −0.02 to 0.42). <a href="./references#CD010455-fig-0025" title="">Analysis 3.5</a> </p> </li> <li> <p>Number of serious adverse events: Of the three studies included in this comparison (365 participants), two studies, <a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a> and <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a>, reported on this outcome, with 137 and 180 participants, respectively. Due to the very low certainty of the evidence and imprecision, it is uncertain whether anti‐TNF disease activity‐guided dose tapering influences the number of serious adverse events after 18 months. <a href="./references#CD010455-fig-0026" title="">Analysis 3.6</a> </p> </li> <li> <p>Withdrawals due to adverse events: None of the three included studies provided data on this outcome. </p> </li> </ul> </p> </section> <section id="CD010455-sec-0094"> <h5 class="title">Minor outcomes</h5> <p> <ul id="CD010455-list-0012"> <li> <p>Proportion of participants with a flare: All three studies (365 participants) included in this comparison reported on this outcome. The studies used different criteria for flare. In <a href="./references#CD010455-bbs2-0001" title="BejeranoC , OreiroN , Fernandez‐LopezC , Pinto‐TasendeJA , AtanesA , DeAspeB , et al. Clinical evaluation usefulness of standardized protocol strategies of dose reduction in patients with rheumatoid arthritis in clinical remission treated with biologic therapies. The OPTIBIO study [abstract]. Arthritis and Rheumatology2016;68:(Suppl 10). ">Bejerano 2016 (OPTIBIO)</a> (abstract only), participants had a flare if DAS28 &gt; 2.6; SDAI &gt; 5; or when ACR/EULAR criteria were not fulfilled. <a href="./references#CD010455-bbs2-0001" title="BejeranoC , OreiroN , Fernandez‐LopezC , Pinto‐TasendeJA , AtanesA , DeAspeB , et al. Clinical evaluation usefulness of standardized protocol strategies of dose reduction in patients with rheumatoid arthritis in clinical remission treated with biologic therapies. The OPTIBIO study [abstract]. Arthritis and Rheumatology2016;68:(Suppl 10). ">Bejerano 2016 (OPTIBIO)</a> (abstract only) found no difference in the proportion of participants with a flare between the anti‐TNF disease activity‐guided dose tapering group and the anti‐TNF continuation group after 24, 48, 72, and 96 weeks' follow‐up (24 weeks: RR 3.25, 95% CI 0.14 to 76.01; 48 weeks: RR 1.09, 95% CI 0.24 to 4.86; 72 weeks: RR 1.09, 95% CI 0.36 to 3.27; 96 weeks: RR 1.27, 95% CI 0.50 to 3.22). <a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a> defined flare as DAS28 &gt; 2.6 with an increase in DAS28 of &gt; 0.6. They reported a higher proportion of participants with flare in the anti‐TNF disease activity‐guided dose tapering group compared to the anti‐TNF continuation group after 18 months' follow‐up (RR 1.64, 95% CI 1.24 to 2.18). In <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a>, participants had a flare if DAS28 increased &gt; 1.2, or if DAS28 increased &gt; 0.6 and current DAS28 was ≥ 3.2. The authors reported a higher proportion of participants with flare in the anti‐TNF disease activity‐guided dose tapering group compared to the anti‐TNF continuation group after 9 and 18 months (9 months: RR 2.68, 95% CI 1.58 to 4.56; 18 months: RR 2.68, 95% CI 1.74 to 4.13). <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a> found no difference in major flares (duration &gt; 3 months) after 9 and 18 months (9 months: RR 1.71, 95% CI 0.37 to 7.96; 18 months: RR 1.22, 95% CI 0.50 to 2.98). </p> </li> <li> <p>Quality of life: Of the three studies included in this comparison (365 participants), two studies, <a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a> and <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a>, reported on this outcome, with 98 and 180 participants, respectively. Both studies reported mean quality‐adjusted life years (QALYs) of the 18‐month study period. <a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a> found that the anti‐TNF disease activity‐guided dose tapering group gained fewer QALYs during the 18‐month study period than the anti‐TNF continuation group (MD −0.158). No confidence intervals were available. <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a> reported no difference between the anti‐TNF disease activity‐guided dose tapering group versus the anti‐TNF continuation group (MD −0.02, 95% percentiles −0.06 to 0.02). </p> </li> <li> <p>Costs: Of the three studies included in this comparison (365 participants), two studies, <a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a> and <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a>, reported on this outcome, with 98 and 180 participants, respectively. Both studies reported lower costs in the anti‐TNF disease activity‐guided dose tapering group compared to the anti‐TNF continuation group after 18 months' follow‐up (<a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a>: MD EUR −8440. No confidence intervals were available. <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a>: MD EUR −9051, 95% percentiles −10,278 to −7731 (rectification submitted)). </p> </li> <li> <p>Decremental cost‐effectiveness ratio: Of the three studies included in this comparison (365 participants), two studies, <a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a> and <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a>, reported on this outcome, with 98 and 180 participants, respectively. <a href="./references#CD010455-bbs2-0004" title="FautrelB , GandjbakhchF , FoltzT , PhamT , MorelJ , AlfaiateT , et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step‐down strategy trial based on progressive spacing of TNF‐blocker injections (STRASS trial). Annals of Rheumatic Disease2013;72(Suppl 3):72. FautrelB , PhamT , AlfaiateT , GandjbakhchF , FoltzV , MorelJ , et al. Step‐down strategy of spacing TNF‐blocker injections for established rheumatoid arthritis in remission: results of the multicentre non‐inferiority randomised open‐label controlled trial (STRASS: Spacing of TNF‐blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases2016;75(1):59‐67. [PUBMED: 26103979 ] FautrelB , PhamT , TubachF , AlfaiateT , MorelJ , DernisE , et al. Tapering TNF‐blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28‐driven step‐down strategy randomized controlled trial. Arthritis and Rheumatism2012;64(12):4169‐70. VanierA , MarietteX , TubachF , FautrelB . Cost‐Effectiveness of TNF‐Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF‐Blocker Injections in Rheumatoid Arthritis Trial.. Value in Health2017;20(4):577‐585. ">Fautrel 2016 (STRASS)</a> reported a decremental cost‐effectiveness ratio (DCER) of EUR 53,417 per QALY loss. <a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a> reported a DCER of EUR 379,433 per QALY loss (rectification submitted). </p> </li> <li> <p>Time to flare: None of the three included studies reported data on this outcome.</p> </li> <li> <p>Change in other medication: Of the three studies included in this comparison (365 participants), one study with 180 participants reported on this outcome (<a href="./references#CD010455-bbs2-0011" title="KievitW , vanHerwaardenN , van denHoogenFHJ , vanVollenhovenRF , BijlsmaJWJ , van denBemtBJF , et al. Disease activity‐guided dose optimisation of adalimumab and etanercept is a cost‐effective strategy compared with non‐tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases2016;75(11):1939‐1944. [PUBMED: 26764260] vanHerwaardenN , van derMaasA , MintenMJM , van denHoogenFHJ , KievitW , vanVollenhovenRF , et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non‐inferiority trial. BMJ2015;350:h1389. [PUBMED: 25858265] ">van Herwaarden 2015 (DRESS)</a>). No difference was found between the anti‐TNF disease activity‐guided dose tapering group and the anti‐TNF continuation group after 18 months concerning use of intramuscular or intra‐articular glucocorticosteroids (RR 1.50, 95% CI 0.89 to 2.51); use of oral glucocorticosteroids (RR 0.65, 95% CI 0.24 to 1.79); DMARD initiation or dose escalation (RR 3.90, 95% CI 0.93 to 16.41); and use of a DMARD (RR 0.88, 95% CI 0.71 to 1.10). The proportion of participants that reduced the dose of their DMARD or discontinued the DMARD after 18 months' follow‐up was lower in the anti‐TNF disease activity‐guided dose tapering group compared to the anti‐TNF continuation group (RR 0.37, 95% CI 0.19 to 0.72). </p> </li> </ul> </p> </section> </section> <section id="CD010455-sec-0095"> <h4 class="title">Subgroup and sensitivity analyses</h4> <p>We planned to perform a subgroup analysis as described in the <a href="#CD010455-sec-0050">Subgroup analysis and investigation of heterogeneity</a> section. However, because of the small number of included studies, analyses were not informative. </p> <p>We also planned to perform sensitivity analyses as described in the <a href="#CD010455-sec-0051">Sensitivity analysis</a> section. However, because of the small number of included studies, analyses were not informative. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010455-sec-0096" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010455-sec-0096"></div> <p>This is the first update of the original Cochrane Review first published in 2014. We identified eight new studies for inclusion in this update and additional data on old studies, which changed some results. We retrospectively excluded one study that had been included in the original review. Our main conclusions remained largely the same. </p> <section id="CD010455-sec-0097"> <h3 class="title" id="CD010455-sec-0097">Summary of main results</h3> <p>This systematic review summarises evidence from 14 studies (13 RCTs and one CCT) of down‐titration of anti‐TNF agents in people with RA with low disease activity. We considered three down‐titration strategies to be sufficiently different to warrant separate reviewing: (1) anti‐TNF dose reduction, (2) anti‐TNF discontinuation, and (3) anti‐TNF disease activity–guided dose tapering. We presented the available data on these strategies separately. </p> <section id="CD010455-sec-0098"> <h4 class="title">Anti‐TNF dose reduction compared with anti‐TNF continuation</h4> <p>Six studies (three on etanercept, one on etanercept and adalimumab, one on certolizumab pegol, and one on all anti‐TNF agents) reported data on fixed anti‐TNF dose reduction compared with anti‐TNF continuation. After pooling of data where possible, we can conclude that anti‐TNF dose reduction leads to little or no difference in mean disease activity, the proportion of participants with persistent remission, number of serious adverse events and withdrawals due to adverse events compared to continuation. Also, anti‐TNF dose reduction does not result in an important deterioration in function but probably slightly increases the proportion of participants with minimal radiographic damage. Next to this, anti‐TNF dose reduction may slightly reduce the proportion of participants switched to another biologic. We found no data on important outcomes like cost‐effectiveness. </p> </section> <section id="CD010455-sec-0099"> <h4 class="title">Anti‐TNF discontinuation compared with anti‐TNF continuation</h4> <p>Eight RCTs reported data on anti‐TNF discontinuation compared with anti‐TNF continuation for all anti‐TNF agents, but mainly adalimumab and etanercept. Different types of outcome measures were reported, and marked heterogeneity was present. The results showed that anti‐TNF discontinuation probably increases the mean disease activity score slightly, and that the risk ratio of persistent remission lies between 0.16 and 0.77 (data not pooled). Anti‐TNF discontinuation increases the proportion participants with minimal radiographic progression of &gt; 0.5 mSvdH point per year and may lead to a slight deterioration in function and probably slightly increases the number of withdrawals due to adverse events. It is uncertain whether anti‐TNF discontinuation influences the number of serious adverse events due to very low‐certainty evidence. Again, we found no data on cost‐effectiveness. </p> </section> <section id="CD010455-sec-0100"> <h4 class="title">Anti‐TNF disease activity–guided dose tapering compared with anti‐TNF continuation</h4> <p>Three studies (all anti‐TNF agents, but again mostly etanercept and adalimumab) compared disease activity–guided anti‐TNF dose tapering with anti‐TNF continuation. Anti‐TNF disease activity–guided dose tapering may result in little or no difference in mean disease activity score and the proportion of participants switched to another biologic. Furthermore, anti‐TNF disease activity–guided dose tapering results in little or no difference in the proportion of participants with persistent remission. Next to this, tapering may result in a slight increase in the proportion of participants with minimal radiographic progression and probably causes a slight deterioration in function. It is uncertain whether anti‐TNF disease activity‐guided dose tapering influences the number of serious adverse events due to very low‐certainty evidence. No data were available on withdrawals due to adverse events. In the two studies that reported on cost‐effectiveness, costs were significantly lower, and decremental cost‐effectiveness ratios were found to be between EUR 53,000 and EUR 379,000 per QALY lost. </p> </section> </section> <section id="CD010455-sec-0101"> <h3 class="title" id="CD010455-sec-0101">Overall completeness and applicability of evidence</h3> <p>The number of controlled studies on this matter is increasing, although they are mostly limited to adalimumab and etanercept. Data were available on all three strategies, although discontinuation was studied most extensively. We considered the included studies to be quite comparable clinically and decided to accept some clinical heterogeneity in order to obtain more precision. One study was reported as abstract only (<a href="./references#CD010455-bbs2-0001" title="BejeranoC , OreiroN , Fernandez‐LopezC , Pinto‐TasendeJA , AtanesA , DeAspeB , et al. Clinical evaluation usefulness of standardized protocol strategies of dose reduction in patients with rheumatoid arthritis in clinical remission treated with biologic therapies. The OPTIBIO study [abstract]. Arthritis and Rheumatology2016;68:(Suppl 10). ">Bejerano 2016 (OPTIBIO)</a>). Excluding the results reported in this abstract did not change our conclusions. </p> <p>An important issue remains that the superiority design of the fixed‐dose reduction or discontinuation studies hampers interpretability and generalisability to clinical practice. With regard to the first issue, these studies do provide point estimates about between‐group differences in important outcomes between the strategies, but they do not compare these point estimates and their confidence intervals with a prespecified relevant non‐inferiority margin. Consequently, independent of whether superiority tests demonstrate a significant difference, the interpretation has to be made post hoc whether this (non‐)significant difference is relevant compared to a non‐inferiority claim, although this issue might become less important in meta‐analyses where sample sizes are large. Next to this, the preferred method of analysis for non‐inferiority trials is per protocol, while an intention‐to‐treat analysis is favoured for superiority trials. This hampers comparison of studies with different approaches. With regard to generalisability, it seems important to mention that for patients and clinicians alike, the outcome of fixed‐dose reduction or discontinuation is valuable to know. However, it would be much more valuable to know whether disease activity‐guided dose reduction and discontinuation is non‐inferior with regard to important outcomes, as this supports shared decision making with patients. </p> <p>The participants included in these studies vary from early RA with short treatment duration and no prior DMARD treatment to longstanding, established RA patients who have been treated for a long time with several other DMARDs, and also include patients with and without concomitant DMARD. This increases generalisability, although it also has been shown that no clinical patient‐, disease‐, or treatment‐related variable is clearly an effect modifier for the chance of successful dose reduction or discontinuation (<a href="./references#CD010455-bbs2-0094" title="TweehuysenL , van denEndeCH , BeerenFMM , BeenEMJ , van denHoogenFHJ , denBroederAA . Little evidence for usefulness of biomarkers for predicting successful dose reduction or discontinuation of a biologic agent in rheumatoid arthritis. Arthritis &amp; Rheumatology2017;69(2):301‐8. [PUBMED: 27696778] ">Tweehuysen 2017</a>). </p> <p>With regard to outcome measures, we noted that domains are often missing, such as functioning, radiographic damage progression, or cost (effectiveness). Also, when a domain is included as an outcome, there is marked heterogeneity in the way the outcome is assessed, leaving much room for improvement of outcome standardisation. </p> </section> <section id="CD010455-sec-0102"> <h3 class="title" id="CD010455-sec-0102">Quality of the evidence</h3> <section id="CD010455-sec-0103"> <h4 class="title">Anti‐TNF dose reduction compared with anti‐TNF continuation</h4> <p>Using the GRADE approach, we assessed the overall certainty of evidence as high for two of the seven 'Summary of findings' outcomes in the anti‐TNF dose reduction versus continuation comparison: mean disease activity and function. We assessed the certainty of the evidence for the proportion of participants with minimal radiographic progression as moderate because of imprecision. We assessed the certainty of the evidence for the remaining four main outcomes as low. For the proportion of participants with persistent remission, this was the result of heterogeneity (downgraded two times). For the proportion of participants that switched to another biologic, this was due to concern about risk of bias in the reporting study (downgraded two times). We downgraded the evidence on the number of serious adverse events and the number of withdrawals due to adverse events one level for risk of bias and one level for imprecision. </p> </section> <section id="CD010455-sec-0104"> <h4 class="title">Anti‐TNF discontinuation compared with anti‐TNF continuation</h4> <p>The overall certainty of the evidence was high for one of the seven 'Summary of findings' outcomes in the anti‐TNF discontinuation versus continuation comparison: proportion of participants with minimal radiographic progression. We assessed the certainty of the evidence for the outcomes mean disease activity and withdrawals due to adverse events as moderate. We performed a subanalysis for the outcome mean disease activity, since heterogeneity was present between the studies that could be explained by the study characteristics. We downgraded the evidence on mean disease activity for discontinuation without restarting or with restarting and with LOCF analysis one level because of imprecision. We downgraded the evidence for mean disease activity with restarting and without LOCF analysis one level due to concerns about risk of bias. We downgraded the evidence on withdrawals one level because of imprecision. We assessed the certainty of the evidence on the proportion of participants with persistent remission and function as low because of substantial heterogeneity (downgraded two levels). Lastly, we assessed the certainty of the evidence on the number of serious adverse events as very low because of (1) concerns about risk of bias, (2) moderate heterogeneity between effect estimates, and (3) imprecision. The included anti‐TNF discontinuation studies did not report the proportion of participants that switched to another biologic. </p> </section> <section id="CD010455-sec-0105"> <h4 class="title">Anti‐TNF disease activity–guided dose tapering compared with anti‐TNF continuation</h4> <p>The certainty of the evidence for the outcome proportion of participants with persistent remission was high in the anti‐TNF disease activity‐guided dose tapering versus continuation comparison. The data came from one study with a low risk of bias, and there were no other reasons to downgrade the certainty of the evidence. We assessed the certainty of the evidence on function as moderate because of imprecision. We assessed the certainty of the evidence on mean disease activity as low because of heterogeneity (downgraded two levels). We graded the certainty of the evidence on the proportion of participants that switched to another biologic as low because of imprecision (downgraded two levels). We graded the certainty of the evidence on the proportion of participants with minimal radiographic progression as low due to heterogeneity and imprecision. We assessed the certainty of the evidence for serious adverse events as very low because of substantial heterogeneity (downgraded two levels) and imprecision (downgraded two levels). The included studies for this comparison did not report on withdrawals due to adverse events. </p> </section> </section> <section id="CD010455-sec-0106"> <h3 class="title" id="CD010455-sec-0106">Potential biases in the review process</h3> <p>Two review authors independently reviewed all titles and abstracts, extracted data, and performed bias and quality assessment. Consequently, errors in extraction have been minimised. Risk of bias could not be completely assessed for some studies due to restricted information despite efforts to obtain additional information from study authors. Post‐hoc decisions had to be made regarding the presentation and pooling of outcomes (e.g. time of follow‐up, threshold values) which could have had implications on the results. The authors have tried to be as transparent as possible about choices that have been made, although they remain subjective. </p> </section> <section id="CD010455-sec-0107"> <h3 class="title" id="CD010455-sec-0107">Agreements and disagreements with other studies or reviews</h3> <p>A few other systematic reviews have examined anti‐TNF down‐titration, although the focus differed to some extent (<a href="./references#CD010455-bbs2-0065" title="GalvaoTF , ZimmermanIR , daMotaLMH , SilvaMT , PereiraMG . Withdrawal of biologic agents in rheumatoid arthritis: a systematic review and meta‐analysis. Clinical Rheumatology2016;35:1659‐68. ">Galvao 2016</a>; <a href="./references#CD010455-bbs2-0072" title="KuijperTM , Lamers‐KarnebeekFBG , JacobsJWG , HazesJMW , LuimeJJ . Flare rate in patients with rheumatoid arthritis in low disease activity or remission when tapering or stopping synthetic or biologic DMARD: a systematic review. Journal of Rheumatology2015;42(11):2012‐22. [PUBMED: 26428204] ">Kuijper 2015</a>; <a href="./references#CD010455-bbs2-0075" title="Navarro‐MillánI , SattuiSE , CurtisJR . Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis. Clinical Therapeutics2013;35(11):1850‐61. [PUBMED: 24156821] ">Navarro‐Millán 2013</a>; <a href="./references#CD010455-bbs2-0106" title="YoshidaK , SungY‐K , KavanaughA , BaeS‐C , WeinblattME , KishimotoM , et al. Biologic discontinuation studies: a systematic review of methods. Annals of the Rheumatic Diseases2014;73:595‐9. ">Yoshida 2014</a>). <a href="./references#CD010455-bbs2-0065" title="GalvaoTF , ZimmermanIR , daMotaLMH , SilvaMT , PereiraMG . Withdrawal of biologic agents in rheumatoid arthritis: a systematic review and meta‐analysis. Clinical Rheumatology2016;35:1659‐68. ">Galvao 2016</a> focused on discontinuation of biological DMARDs, and <a href="./references#CD010455-bbs2-0072" title="KuijperTM , Lamers‐KarnebeekFBG , JacobsJWG , HazesJMW , LuimeJJ . Flare rate in patients with rheumatoid arthritis in low disease activity or remission when tapering or stopping synthetic or biologic DMARD: a systematic review. Journal of Rheumatology2015;42(11):2012‐22. [PUBMED: 26428204] ">Kuijper 2015</a> on discontinuation of biologic and synthetic DMARDs. <a href="./references#CD010455-bbs2-0075" title="Navarro‐MillánI , SattuiSE , CurtisJR . Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis. Clinical Therapeutics2013;35(11):1850‐61. [PUBMED: 24156821] ">Navarro‐Millán 2013</a> investigated discontinuation of anti‐TNF agents specifically. The results of these reviews are comparable to the findings in our review. The systematic review by <a href="./references#CD010455-bbs2-0106" title="YoshidaK , SungY‐K , KavanaughA , BaeS‐C , WeinblattME , KishimotoM , et al. Biologic discontinuation studies: a systematic review of methods. Annals of the Rheumatic Diseases2014;73:595‐9. ">Yoshida 2014</a> looked into the design and failure definitions in anti‐TNF discontinuation studies. The review authors concluded that heterogeneity can be seen across studies in both study design and failure definition. This is consistent with the findings reported in our review. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010455-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/urn:x-wiley:14651858:media:CD010455:CD010455-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_t/tCD010455-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Flow chart of study selection." data-id="CD010455-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow chart of study selection.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/full#CD010455-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010455-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/urn:x-wiley:14651858:media:CD010455:CD010455-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_t/tCD010455-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010455-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/full#CD010455-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010455-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/urn:x-wiley:14651858:media:CD010455:CD010455-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_t/tCD010455-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010455-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/full#CD010455-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010455-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/urn:x-wiley:14651858:media:CD010455:CD010455-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_t/tCD010455-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐TNF dose reduction versus anti‐TNF continuation, Outcome 1 Mean disease activity score (DAS28)." data-id="CD010455-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Anti‐TNF dose reduction versus anti‐TNF continuation, Outcome 1 Mean disease activity score (DAS28). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/references#CD010455-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010455-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/urn:x-wiley:14651858:media:CD010455:CD010455-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_t/tCD010455-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐TNF dose reduction versus anti‐TNF continuation, Outcome 2 Proportion persistent remission (DAS28)." data-id="CD010455-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Anti‐TNF dose reduction versus anti‐TNF continuation, Outcome 2 Proportion persistent remission (DAS28). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/references#CD010455-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010455-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/urn:x-wiley:14651858:media:CD010455:CD010455-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_t/tCD010455-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐TNF dose reduction versus anti‐TNF continuation, Outcome 3 Proportion switched to another biologic." data-id="CD010455-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Anti‐TNF dose reduction versus anti‐TNF continuation, Outcome 3 Proportion switched to another biologic. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/references#CD010455-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010455-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/urn:x-wiley:14651858:media:CD010455:CD010455-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_t/tCD010455-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐TNF dose reduction versus anti‐TNF continuation, Outcome 4 Proportion radiographic progression (mSvdH &gt; 0.5)." data-id="CD010455-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Anti‐TNF dose reduction versus anti‐TNF continuation, Outcome 4 Proportion radiographic progression (mSvdH &gt; 0.5). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/references#CD010455-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010455-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/urn:x-wiley:14651858:media:CD010455:CD010455-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_t/tCD010455-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐TNF dose reduction versus anti‐TNF continuation, Outcome 5 Function (Health Assessment Questionnaire)." data-id="CD010455-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Anti‐TNF dose reduction versus anti‐TNF continuation, Outcome 5 Function (Health Assessment Questionnaire). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/references#CD010455-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010455-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/urn:x-wiley:14651858:media:CD010455:CD010455-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_t/tCD010455-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐TNF dose reduction versus anti‐TNF continuation, Outcome 6 Number of serious adverse events." data-id="CD010455-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Anti‐TNF dose reduction versus anti‐TNF continuation, Outcome 6 Number of serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/references#CD010455-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010455-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/urn:x-wiley:14651858:media:CD010455:CD010455-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_t/tCD010455-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐TNF dose reduction versus anti‐TNF continuation, Outcome 7 Withdrawals due to adverse events." data-id="CD010455-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Anti‐TNF dose reduction versus anti‐TNF continuation, Outcome 7 Withdrawals due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/references#CD010455-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010455-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/urn:x-wiley:14651858:media:CD010455:CD010455-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_t/tCD010455-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐TNF dose reduction versus anti‐TNF continuation, Outcome 8 Proportion of participants with a flare." data-id="CD010455-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Anti‐TNF dose reduction versus anti‐TNF continuation, Outcome 8 Proportion of participants with a flare. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/references#CD010455-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010455-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/urn:x-wiley:14651858:media:CD010455:CD010455-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_t/tCD010455-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐TNF dose reduction versus anti‐TNF continuation, Outcome 9 Quality of life." data-id="CD010455-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Anti‐TNF dose reduction versus anti‐TNF continuation, Outcome 9 Quality of life. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/references#CD010455-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010455-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/urn:x-wiley:14651858:media:CD010455:CD010455-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_t/tCD010455-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Anti‐TNF discontinuation versus anti‐TNF continuation, Outcome 1 Mean disease activity score (DAS28)." data-id="CD010455-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Anti‐TNF discontinuation versus anti‐TNF continuation, Outcome 1 Mean disease activity score (DAS28). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/references#CD010455-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010455-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/urn:x-wiley:14651858:media:CD010455:CD010455-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_t/tCD010455-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Anti‐TNF discontinuation versus anti‐TNF continuation, Outcome 2 Proportion persistent remission (DAS28)." data-id="CD010455-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Anti‐TNF discontinuation versus anti‐TNF continuation, Outcome 2 Proportion persistent remission (DAS28). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/references#CD010455-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010455-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/urn:x-wiley:14651858:media:CD010455:CD010455-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_t/tCD010455-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Anti‐TNF discontinuation versus anti‐TNF continuation, Outcome 3 Proportion radiographic progression (mSvdH &gt; 0.5)." data-id="CD010455-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Anti‐TNF discontinuation versus anti‐TNF continuation, Outcome 3 Proportion radiographic progression (mSvdH &gt; 0.5). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/references#CD010455-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010455-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/urn:x-wiley:14651858:media:CD010455:CD010455-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_t/tCD010455-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Anti‐TNF discontinuation versus anti‐TNF continuation, Outcome 4 Function (Health Assessment Questionnaire)." data-id="CD010455-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Anti‐TNF discontinuation versus anti‐TNF continuation, Outcome 4 Function (Health Assessment Questionnaire). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/references#CD010455-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010455-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/urn:x-wiley:14651858:media:CD010455:CD010455-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_t/tCD010455-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Anti‐TNF discontinuation versus anti‐TNF continuation, Outcome 5 Number of serious adverse events." data-id="CD010455-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Anti‐TNF discontinuation versus anti‐TNF continuation, Outcome 5 Number of serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/references#CD010455-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010455-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/urn:x-wiley:14651858:media:CD010455:CD010455-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_t/tCD010455-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Anti‐TNF discontinuation versus anti‐TNF continuation, Outcome 6 Withdrawals due to adverse events." data-id="CD010455-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Anti‐TNF discontinuation versus anti‐TNF continuation, Outcome 6 Withdrawals due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/references#CD010455-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010455-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/urn:x-wiley:14651858:media:CD010455:CD010455-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_t/tCD010455-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Anti‐TNF discontinuation versus anti‐TNF continuation, Outcome 7 Proportion flare." data-id="CD010455-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Anti‐TNF discontinuation versus anti‐TNF continuation, Outcome 7 Proportion flare. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/references#CD010455-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010455-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/urn:x-wiley:14651858:media:CD010455:CD010455-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_t/tCD010455-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Anti‐TNF discontinuation versus anti‐TNF continuation, Outcome 8 Quality of life." data-id="CD010455-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Anti‐TNF discontinuation versus anti‐TNF continuation, Outcome 8 Quality of life. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/references#CD010455-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010455-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/urn:x-wiley:14651858:media:CD010455:CD010455-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_t/tCD010455-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Anti‐TNF disease activity–guided dose tapering versus anti‐TNF continuation, Outcome 1 Mean disease activity score (DAS28)." data-id="CD010455-fig-0021" src="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Anti‐TNF disease activity–guided dose tapering versus anti‐TNF continuation, Outcome 1 Mean disease activity score (DAS28). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/references#CD010455-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010455-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/urn:x-wiley:14651858:media:CD010455:CD010455-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_t/tCD010455-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Anti‐TNF disease activity–guided dose tapering versus anti‐TNF continuation, Outcome 2 Proportion persistent remission (DAS28)." data-id="CD010455-fig-0022" src="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Anti‐TNF disease activity–guided dose tapering versus anti‐TNF continuation, Outcome 2 Proportion persistent remission (DAS28). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/references#CD010455-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010455-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/urn:x-wiley:14651858:media:CD010455:CD010455-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_t/tCD010455-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Anti‐TNF disease activity–guided dose tapering versus anti‐TNF continuation, Outcome 3 Proportion switched to another biologic." data-id="CD010455-fig-0023" src="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Anti‐TNF disease activity–guided dose tapering versus anti‐TNF continuation, Outcome 3 Proportion switched to another biologic. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/references#CD010455-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010455-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/urn:x-wiley:14651858:media:CD010455:CD010455-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_t/tCD010455-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Anti‐TNF disease activity–guided dose tapering versus anti‐TNF continuation, Outcome 4 Proportion radiographic progression (mSvdH &gt; 0.5 or &gt; 1.0)." data-id="CD010455-fig-0024" src="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Anti‐TNF disease activity–guided dose tapering versus anti‐TNF continuation, Outcome 4 Proportion radiographic progression (mSvdH &gt; 0.5 or &gt; 1.0). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/references#CD010455-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010455-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/urn:x-wiley:14651858:media:CD010455:CD010455-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_t/tCD010455-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Anti‐TNF disease activity–guided dose tapering versus anti‐TNF continuation, Outcome 5 Function (Health Assessment Questionnaire)." data-id="CD010455-fig-0025" src="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Anti‐TNF disease activity–guided dose tapering versus anti‐TNF continuation, Outcome 5 Function (Health Assessment Questionnaire). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/references#CD010455-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010455-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/urn:x-wiley:14651858:media:CD010455:CD010455-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_t/tCD010455-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Anti‐TNF disease activity–guided dose tapering versus anti‐TNF continuation, Outcome 6 Number of serious adverse events." data-id="CD010455-fig-0026" src="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Anti‐TNF disease activity–guided dose tapering versus anti‐TNF continuation, Outcome 6 Number of serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/references#CD010455-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010455-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/urn:x-wiley:14651858:media:CD010455:CD010455-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_t/tCD010455-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Anti‐TNF disease activity–guided dose tapering versus anti‐TNF continuation, Outcome 7 Proportion flare." data-id="CD010455-fig-0027" src="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Anti‐TNF disease activity–guided dose tapering versus anti‐TNF continuation, Outcome 7 Proportion flare. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/references#CD010455-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010455-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/urn:x-wiley:14651858:media:CD010455:CD010455-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_t/tCD010455-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Anti‐TNF disease activity–guided dose tapering versus anti‐TNF continuation, Outcome 8 Change in other medication." data-id="CD010455-fig-0028" src="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Anti‐TNF disease activity–guided dose tapering versus anti‐TNF continuation, Outcome 8 Change in other medication. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/references#CD010455-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/media/CDSR/CD010455/image_n/nCD010455-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010455-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Anti‐TNF dose reduction versus anti‐TNF continuation</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Anti‐TNF dose reduction compared to anti‐TNF continuation for rheumatoid arthritis in patients with low disease activity</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents<br/> <b>Setting:</b> clinical research centres<br/> <b>Intervention:</b> anti‐TNF dose reduction<br/> <b>Comparison:</b> anti‐TNF continuation </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>What happens</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with anti‐TNF continuation</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with anti‐TNF dose reduction</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease activity score</b><br/> Assessed with: DAS28<br/> Scale from 0.9 to 8; higher scores indicate worse disease activity<br/> Follow‐up: range 26 weeks to 52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean disease activity score was 2.34</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.06 higher<br/> (0.11 lower to 0.24 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>501<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: 1% higher (95% CI 2% lower to 3% higher)</p> <p>Relative percentage change: 2% higher (95% CI 5% lower to 10% higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐TNF dose reduction results in little or no difference in disease activity score (DAS28). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with persistent remission</b><br/> Assessed with: DAS28 &lt; 2.6 (remission)<br/> Follow‐up: 52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>653 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>659 per 1000<br/> (522 to 835) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.01<br/> (0.80 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>612<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: 1% higher (95% CI 13% lower to 18% higher)</p> <p>Relative percentage change: 1% higher (95% CI 20% lower to 28% higher)</p> <p>NNTB: not applicable (not statistically significant)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐TNF dose reduction may result in little or no difference in the proportion of participants with persistent remission (DAS28 &lt; 2.6). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants switched to another biologic</b> </p> <p>Mean follow‐up of 3.5 ± 1.5 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>44 per 1000<br/> (19 to 102) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.40<br/> (0.17 to 0.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>323<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: 7% lower (95% CI 9% lower to 1% lower)</p> <p>Relative percentage change: 60% (95% CI 83% lower to 7% lower)</p> <p>NNTB: 15 (95% CI 12 to 100)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐TNF dose reduction may slightly reduce the proportion of participants switched to another biologic. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with minimal radiographic progression</b><br/> Assessed with: mSvdH score &gt; 0.5<br/> Follow‐up: 52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>129 per 1000<br/> (80 to 206) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.22<br/> (0.76 to 1.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>553<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: 2% higher (95% CI 3% lower to 10% higher)</p> <p>Relative percentage change: 22% higher (95% CI 34% lower to 95% higher)</p> <p>NNTH: not applicable (not statistically significant)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐TNF dose reduction probably slightly increases the proportion of participants with minimal radiographic progression (mSvdH &gt; 0.5) . </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function</b><br/> Assessed with: Health Assessment Questionnaire<br/> Scale from 0 to 3; higher scores indicate worse function<br/> Follow‐up: range 26 weeks to 52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean function was 0.52</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.09 higher<br/> (0 to 0.19 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>501<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: 3% higher (95% CI 0% higher to 6% higher)</p> <p>Relative percentage change: 15% higher (95% CI 0% higher to 31% higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐TNF dose reduction does not result in an important deterioration in function.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of serious adverse events</b> </p> <p>Follow‐up: range 26 weeks to 52 weeks (mean follow‐up for <a href="./references#CD010455-bbs2-0008" title="BotsiosC , FurlanA , OstuniP , SfrisoP , TodescoS , PunziL . Effects of low‐dose etanercept in maintaining DAS‐remission previously achieved with standard‐dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2007;66(Suppl II):54. RaffeinerB , BotsiosC , OmettoF , BernardiL , StramareR , TodescoS , et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology2015;33:63‐8. [PUBMED: 25535985] ">Raffeiner 2015</a> 3.5 ± 1.5 years) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1000<br/> (34 to 94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.09<br/> (0.65 to 1.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1084<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: 0% (95% CI 2% lower to 4% higher)</p> <p>Relative percentage change: 9% higher (95% CI 35% lower to 82% higher)</p> <p>NNTH: not applicable (not statistically significant)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐TNF dose reduction may cause little or no difference in the number of serious adverse events.. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> </p> <p>Follow‐up: 52 weeks (mean follow‐up for <a href="./references#CD010455-bbs2-0008" title="BotsiosC , FurlanA , OstuniP , SfrisoP , TodescoS , PunziL . Effects of low‐dose etanercept in maintaining DAS‐remission previously achieved with standard‐dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2007;66(Suppl II):54. RaffeinerB , BotsiosC , OmettoF , BernardiL , StramareR , TodescoS , et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology2015;33:63‐8. [PUBMED: 25535985] ">Raffeiner 2015</a> 3.5 ± 1.5 years) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000<br/> (16 to 70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.07<br/> (0.51 to 2.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>937<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: 0% (95% CI 2% lower to 4% higher)</p> <p>Relative percentage change: 7% higher (95% CI 49% lower to 124% higher)</p> <p>NNTH: not applicable (not statistically significant)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐TNF dose reduction may cause little or no difference in the number of withdrawals due to adverse events . </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>DAS28:</b> disease activity score in 28 joints; <b>MD:</b> mean difference; <b>mSvdH:</b> modified Sharp van der Heijde; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome; <b>RCT:</b> randomised controlled trial: <b>RR:</b> risk ratio; <b>TNF:</b> tumour necrosis factor </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup>Downgraded two levels due to heterogeneity (I<sup>2</sup>=73%)<br/> <sup>2</sup>Downgraded two levels due to concerns about study risk of bias (high risk of selection bias, performance bias, detection bias and other bias).<br/> <sup>3</sup>Downgraded one level due to imprecision (insufficient sample size/low number of events).<br/> <sup>4</sup>Downgraded one level due to concerns about study risk of bias (mainly due to high risk of attrition bias in <a href="./references#CD010455-bbs2-0009" title="SmolenJS , NashP , DurezP , HallS , IlivanovaE , Irazoque‐PalazuelosF , et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet2013;381:918‐29. ">Smolen 2013 (PRESERVE)</a> and high risk of bias on several domains in <a href="./references#CD010455-bbs2-0008" title="BotsiosC , FurlanA , OstuniP , SfrisoP , TodescoS , PunziL . Effects of low‐dose etanercept in maintaining DAS‐remission previously achieved with standard‐dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2007;66(Suppl II):54. RaffeinerB , BotsiosC , OmettoF , BernardiL , StramareR , TodescoS , et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology2015;33:63‐8. [PUBMED: 25535985] ">Raffeiner 2015</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Anti‐TNF dose reduction versus anti‐TNF continuation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/full#CD010455-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010455-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Anti‐TNF discontinuation versus anti‐TNF continuation</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Anti‐TNF discontinuation compared to anti‐TNF continuation for rheumatoid arthritis in patients with low disease activity</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents<br/> <b>Setting:</b> clinical research centres<br/> <b>Intervention:</b> anti‐TNF discontinuation<br/> <b>Comparison:</b> anti‐TNF continuation </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>What happens</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with anti‐TNF continuation</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with anti‐TNF discontinuation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Disease activity score ‐</b> <br/> assessed with: DAS28<br/> Scale from: 0.9 to 8; higher scores indicate worse disease activity<br/> follow up: range 28 weeks to 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Discontinuation without restarting, or with restarting and LOCF analysis</b> </p> <p>Mean disease activity score was 2.82</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.96 higher<br/> (0.67 higher to 1.25 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>733<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absolute risk difference: 14% higher (95% CI 9% higher to 18% higher)</p> <p>Relative percentage change: 25% (95% CI 18% higher to 33% higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐TNF discontinuation probably increases the disease activity score slightly</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with persistent remission</b><br/> Assessed with: DAS28 &lt; 2.6 (remission)<br/> Follow‐up: range 28 weeks to 52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>RR values range from 0.16 to 0.77. Absolute risk differences range from 15% lower to 68% lower. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1188<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not pooled due to heterogeneity.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐TNF discontinuation may reduce the proportion of participants with persistent remission </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion participants that switched to another biologic due to loss of response</b> ‐ not measured </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies were found that evaluated the proportion of participants that switched to another biologic due to persistent loss of response. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion participants with minimal radiographic progression</b><br/> Assessed with: mSvdH &gt; 0.5<br/> Follow‐up: mean 52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>178 per 1000<br/> (116 to 273) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.69<br/> (1.10 to 2.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>549<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: 7% higher (95% CI 1% higher to 17% higher)</p> <p>Relative percentage change: 69% higher (95% CI 10% higher to 159% higher)</p> <p>NNTH: 15 (95% CI 6 to 100)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐TNF discontinuation increases the proportion participants with minimal radiographic progression &gt; 0.5 mSvdH point. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function</b><br/> Assessed with: Health Assessment Questionnaire<br/> Scale from 0 to 3; higher scores indicate worse functioning<br/> Follow‐up: range 28 weeks to 52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean function was 0.52</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.18 higher<br/> (0.05 higher to 0.31 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1498<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: 6% higher (95% CI 2% higher to 17% higher)</p> <p>Relative percentage change: 26% higher (95% CI 7% higher to 44% higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐TNF discontinuation may lead to a slight deterioration in function.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of serious adverse events</b> </p> <p>Follow‐up: range 28 weeks to 52 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>57 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000<br/> (47 to 116) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.29<br/> (0.82 to 2.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2095<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: 2% higher (95% CI 1% lower to 6% higher)</p> <p>Relative percentage change: 29% higher (95% CI 18% lower to 103% higher)</p> <p>NNTH: not applicable (not statistically significant)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It is uncertain whether anti‐TNF discontinuation influences the number of serious adverse events because the certainty of the evidence is very low and because of imprecision. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> </p> <p>Follow‐up: range 28 weeks to 52 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 1000<br/> (20 to 76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.46<br/> (0.75 to 2.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1116<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: 1% higher (95% CI 1% lower to 5% higher)</p> <p>Relative percentage change: 46% (95% CI 25% lower to 184% higher)</p> <p>NNTH: not applicable (not statistically significant)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐TNF discontinuation probably slightly increases the number of withdrawals due to adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>DAS28:</b> disease activity score in 28 joints; <b>LOCF:</b> last observation carried forward; <b>MD:</b> mean difference; <b>mSvdH:</b> modified Sharp van der Heijde; <b>NNTH:</b> number needed to treat for an additional harmful outcome; <b>RCT:</b> randomised controlled trial: <b>RR:</b> risk ratio; <b>TNF:</b> tumour necrosis factor </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level due to heterogeneity (I<sup>2</sup>=61% for disease activity score and I<sup>2</sup>=31% for number of serious adverse events).<br/> <sup>2</sup>Downgraded two levels due to heterogeneity (I<sup>2</sup>=80% for proportion of participants with remission and I<sup>2</sup>=79% for function).<br/> <sup>3</sup>Downgraded one level due to imprecision (low number of events).<br/> <sup>4</sup>Downgraded one level due to concerns about study risk of bias (high risk of selection bias, detection bias, attrition bias and other bias). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Anti‐TNF discontinuation versus anti‐TNF continuation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/full#CD010455-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010455-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Anti‐TNF disease activity–guided dose tapering versus anti‐TNF continuation</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Anti‐TNF disease activity–guided dose tapering compared to anti‐TNF continuation for rheumatoid arthritis in patients with low disease activity</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents<br/> <b>Setting:</b> clinical research centres<br/> <b>Intervention:</b> anti‐TNF disease activity–guided dose tapering<br/> <b>Comparison:</b> anti‐TNF continuation </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>What happens</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with anti‐TNF continuation</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with anti‐TNF disease activity–guided dose tapering</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease activity score</b><br/> Assessed with: DAS28<br/> Scale from 0.9 to 8; higher scores indicate worse disease activity<br/> Follow‐up: range 72 weeks to 78 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean disease activity score was 2.34</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.25 higher<br/> (0.17 lower to 0.67 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>357<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: 4% higher (95% CI 2% lower to 9% higher)</p> <p>Relative percentage change: 10% higher (95% CI 7% lower to 26% higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐TNF disease activity–guided dose tapering may result in little or no difference in disease activity score. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with persistent remission</b><br/> Assessed with: DAS28 &lt; 2.6 (remission)<br/> Follow‐up: 18 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>797 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>709 per 1000<br/> (597 to 844) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.89<br/> (0.75 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: 9% lower (95% CI 20% lower to 5% higher)</p> <p>Relative percentage change: 10% higher (95% CI 7% lower to 26% higher)</p> <p>NNTH: not applicable (not statistically significant)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐TNF disease activity–guided dose tapering results in little or no difference in the proportion of participants with persistent remission. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants switched to another biologic due to loss of response</b><br/> Follow‐up: 18 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>76 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47 per 1000<br/> (19 to 117) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.62<br/> (0.25 to 1.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>317<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: 3% lower (95% CI 6% lower to 4% higher)</p> <p>Relative percentage change: 38% higher (95% CI 75% lower to 54% higher)</p> <p>NNTH: not applicable (not statistically significant)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐TNF disease activity–guided dose tapering may result in little or no difference in the proportion of participants that switch to another biologic. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with minimal radiographic progression</b><br/> Assessed with: mSvdH score &gt; 0.5 or &gt; 1.0<br/> Follow‐up: mean 18 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>242 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>352 per 1000<br/> (187 to 662) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.45<br/> (0.77 to 2.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>312<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: 11% higher (95% CI 6% lower to 42% higher)</p> <p>Relative percentage change: 45% higher (95% CI 23% lower to 173% higher)</p> <p>NNTH: not applicable (not statistically significant)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐TNF disease activity–guided dose tapering may slightly increase the proportion of participants with minimal radiographic progression (mSvdH &gt; 0.5 or &gt; 1.0). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function</b><br/> Assessed with: Health Assessment Questionnaire<br/> Scale from 0 to 3; higher scores indicate worse function<br/> Follow‐up: mean 18 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean function was 0.4</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.2 higher<br/> (0.02 lower to 0.42 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: 7% higher (95% CI 1% lower to 14% higher)</p> <p>Relative percentage change: 33% higher (95% CI 3% lower to 70% higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐TNF disease activity–guided dose tapering probably leads to a slight deterioration of function. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of serious adverse events</b> </p> <p>Follow‐up: 18 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>129 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>160 per 1000<br/> (54 to 477) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.24<br/> (0.42 to 3.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>317<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: 3% higher (95% CI 8% lower to 35% higher)</p> <p>Relative percentage change: 24% higher (95% CI 58% lower to 270% higher)</p> <p>NNTH: not applicable (not statistically significant)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It is uncertain whether anti‐TNF disease activity‐guided dose tapering influences the number of serious adverse events because the certainty of the evidence is very low and because of imprecision. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> ‐ not measured </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies were found that evaluated the number of withdrawals due to adverse events.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>DAS28:</b> disease activity score in 28 joints; <b>MD:</b> mean difference; <b>mSvdH:</b> modified Sharp van der Heijde; <b>NNTH:</b> number needed to treat for an additional harmful outcome; <b>RCT:</b> randomised controlled trial: <b>RR:</b> risk ratio; <b>TNF:</b> tumour necrosis factor </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup>Downgraded two levels due to heterogeneity (I<sup>2</sup>=70% for disease activity score and I<sup>2</sup>=69% for number of serious adverse events).<br/> <sup>2</sup>Downgraded two levels due to imprecision (insufficient sample size/low number of events).<br/> <sup>3</sup>Downgraded one level due to heterogeneity (I<sup>2</sup>=59%).<br/> <sup>4</sup>Downgraded one level due to imprecision (insufficient sample size). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Anti‐TNF disease activity–guided dose tapering versus anti‐TNF continuation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/full#CD010455-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010455-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Anti‐TNF dose reduction versus anti‐TNF continuation</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mean disease activity score (DAS28) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>501</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.11, 0.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Proportion persistent remission (DAS28) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>612</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.80, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Proportion switched to another biologic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.17, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Proportion radiographic progression (mSvdH &gt; 0.5) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.76, 1.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Function (Health Assessment Questionnaire) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>501</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [‐0.00, 0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Number of serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1084</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.65, 1.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>937</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.51, 2.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Proportion of participants with a flare <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>501</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.04, 0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Anti‐TNF dose reduction versus anti‐TNF continuation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/references#CD010455-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010455-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Anti‐TNF discontinuation versus anti‐TNF continuation</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mean disease activity score (DAS28) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Discontinuation without restarting, or with restarting and LOCF analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>733</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.67, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Discontinuation with restarting without LOCF analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>692</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.14, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Proportion persistent remission (DAS28) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Proportion radiographic progression (mSvdH &gt; 0.5) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [1.10, 2.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Function (Health Assessment Questionnaire) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1498</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.05, 0.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Number of serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2095</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.82, 2.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.75, 2.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Proportion flare <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 DAS28 ≥ 3.2 and ΔDAS ≥ 0.6 (24 to 52 weeks' follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 DAS28 ≥ 3.2 OR ΔDAS ≥ 0.6 (follow‐up 52 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 DAS28 ≥ 2.6 OR ΔDAS &gt; 1.2 (follow‐up 28 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Proportion failure (follow‐up 48 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>733</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.13, ‐0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Anti‐TNF discontinuation versus anti‐TNF continuation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/references#CD010455-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010455-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Anti‐TNF disease activity–guided dose tapering versus anti‐TNF continuation</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mean disease activity score (DAS28) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [‐0.17, 0.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Proportion persistent remission (DAS28) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.75, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Proportion switched to another biologic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.25, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Proportion radiographic progression (mSvdH &gt; 0.5 or &gt; 1.0) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>312</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.77, 2.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Function (Health Assessment Questionnaire) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.02, 0.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Number of serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.42, 3.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Proportion flare <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 DAS28‐ESR &gt;2.6 with ∆DAS28‐ESR &gt; 0.6 after 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 ΔDAS28‐CRP &gt; 1.2 OR ΔDAS28‐CRP &gt; 0.6 and current DAS28‐CRP ≥ 3.2 for &gt; 3 months at 9 months' follow‐up </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 ΔDAS28‐CRP &gt; 1.2 OR ΔDAS28‐CRP &gt; 0.6 and current DAS28‐CRP ≥ 3.2 for &gt; 3 months at 18 months' follow‐up </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 ΔDAS28‐CRP &gt; 1.2 OR ΔDAS28‐CRP &gt; 0.6 and current DAS28‐CRP ≥ 3.2 for &lt; 3 months at 9 months' follow‐up </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 ΔDAS28‐CRP &gt; 1.2 OR ΔDAS28‐CRP &gt; 0.6 and current DAS28‐CRP ≥ 3.2 for &lt; 3 months at 18 months' follow‐up </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6 DAS28 &gt; 2.6, SDAI &gt; 5 or ACR/EULAR criteria not fulfilled (follow‐up 24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7 DAS28 &gt; 2.6, SDAI &gt; 5 or ACR/EULAR criteria not fulfilled (follow‐up 48 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.8 DAS28 &gt; 2.6, SDAI &gt; 5 or ACR/EULAR criteria not fulfilled (follow‐up 72 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.9 DAS28 &gt; 2.6, SDAI &gt; 5 or ACR/EULAR criteria not fulfilled (follow‐up 96 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Change in other medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Use of intramuscular or intra‐articular glucocorticoid injections at 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Use of oral glucocorticoids at 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 DMARDs reduction or discontinuation after 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 DMARD initiation or dose escalation after 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 Use of a DMARD at 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Anti‐TNF disease activity–guided dose tapering versus anti‐TNF continuation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010455.pub3/references#CD010455-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010455.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD010455-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD010455-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010455-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD010455-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD010455-note-0011">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010455\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010455\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010455\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010455\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010455\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010455\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010455\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010455\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010455\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010455\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010455\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010455\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010455\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010455\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010455\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010455\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010455\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010455\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=sogqpCtr&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010455.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010455.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010455.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010455.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010455.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714146109"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010455.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714146113"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010455.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d678d3e95937d',t:'MTc0MDcxNDE0Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 